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GABAB receptors are G-protein coupled receptors for the major inhibitory 
neurotransmitter in the mammalian central nervous system, γ-aminobutyric acid (GABA). The 
receptor is linked to a variety of disorders including epilepsy, pain, spasticity, drug addiction and 
cognitive impairment and is, therefore of major importance for drug discovery. The most 
abundant receptor isoforms GABABR1a and R1b differ by the presence in R1a of a pair of N-
terminal extracellular complement control protein modules (CCP1 and CCP2) which - in other 
proteins - are generally involved in mediating specific protein-protein recognition. The CCP1 
module contains disulphides but is natively disordered. 
In the current work, the yeast two-hybrid system was used to confirm an interaction of 
CCP1 of GABABR1a with the extracellular protein fibulin-2. Further work with the yeast two-
hybrid system extablished the novel interaction of the abundant extracellular matrix protein 
laminin, with GABABR1a CCP1, via its laminin globular (LG) domains. The laminin interaction 
was further characterised by surface plasmon resonance, demonstrating that several different 
domains are involved in the binding to the GABAB receptor CCPs. The primary binding site is 
located on laminin α5 LG4-5, but the E10 domains of the β1 chain and LG1-3 on α1 may also be 
involved. 
The pharmacological properties of the GABABR1a and R1b isoforms were studied by 
transient expression in Xenopus laevis oocytes. It was demonstrated that the agonist baclofen, as 
well as the antagonist CGP55845, appear to be more potent at GABABR1b compared to 
GABABR1a. Intriguingly, when recorded in the precence of laminin, GABABR1b/R2 expressing 
oocytes exhibited an increased baclofen-evoked response while the response in GABABR1a/R2 
was completely abolished. 
  In conclusion, the work demonstrates that laminin is a binding partner for GABABR1a 
CCPs. Such an interaction between the metabotropic GABA receptor and the extracellular 
matrix may lie behind the recently reported roles of GABA in neuronal migration and the laying 
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AD  activation domain 
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ATF4  activation transcription factor 4 
BMG   buffered minimal glycerol  
BMM   buffered minimal methanol  
BSA  bovine serum albumin 
C4BP   complement 4b binding protein   
CA1  Cornu Ammonis 1  
CA3  Cornu Ammonis 3  
cAMP  cyclic adenosine monophosphate    
CC  coiled-coil  
CCP   complement control protein    
CCP1  complement control protein module 1    
CCP2  complement control protein module 2    
cDNA  complementary deoxyribonucleic acid 
CNS  central nervous system 
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CREB  cAMP response element binding protein  
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LG   G-like domains  
LTP   long term potentiation    
MCS   multiple cloning site  
MD   minimal dextrose  
mGluR  metabotropic glutamate receptor   
MOPS  3-{N-morpholino] propanesulfonic acid 
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Mw   molecular weight 
NHERF  Na+/H+ exchange regulatory factor    
NHERF  Na+/H+ exchange regulatory factor  
NHS   N-hydroxysuccinimide  
NMR   nuclear magnetic resonance 
NTA   nitrilotriacetic acid  
OD  optical density 
PBP   periplasmic binding proteins  
PCR  polymerase chain reaction 
PDZ acronym of the first letter of the three proteinsfirst discovered to share the 
domain: PSD95, DlgA and zo-1 
PEG   polyethylene glycol 
PMSF   phenylmethanesulfonyl fluoride  
PNS   peripheral nervous system  
R1  receptor 1 
R2  receptor 2 
RNA  ribonucleic acid 
RU   resonance units  
SD   synthetic dropout  
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SOC   super optimal broth with catabolite repression  
SPR   surface plasmon resonance  
TAE   tris-acetate-EDTA buffer 
TBS   tris-buffered saline  
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TM   transmembrane  
tRNA  transfer ribonucleic acid 
UTR   untranslated region    
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YPD  yeast extract/peptone/dextrose  
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1 Chapter 1  Introduction 
 
1.1 G-protein coupled receptors 
The G-protein coupled receptors (GPCRs) are a large and diverse superfamily of 
membrane-bound receptor proteins, containing 1000-2000 members (Bockaert and Pin, 
1999). The GPCR are involved in recognition and transduction of signals from a wide 
range of ligands such as neurotransmitters, nucleotides, odorants, hormones and lipids. 
They regulate the sensory recognition of pain, cognition, muscle contraction, odours, 
inflammation, immunity and many other phenomena. The receptors are classified based 
on sequence homology and pharmacology into six families that all possess a seven-
transmembrane helix domain but differ in the length and function of their intra- and 
extracellular domains (Pin et al., 1999) as seen in Figure 1.  
Family 1 (or A) includes β-adrenergic receptors and rhodopsin. Members of this 
family have ligand-binding sites located within the seven-transmembrane domains. 
Family 2 (or B) includes receptors for the hormones secretin and glucagon. These 
receptors have ligand-binding sites in their extracellular domains. Family 3 (or C) 
includes both calcium-sensing receptors and metabotropic GABAB and glutamate 
receptors, all of which contain a large extracellular ligand-binding domain. Family 4 (or 
D) includes pheromone receptors (VNs) and has a long N-terminal domain. Family 5 (or 
E) includes cyclic AMP receptors (Parent and Devreotes, 1996); these control 
development of Dictyostelium discoideum, but have yet to be detected in vertebrates. 
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Family 6 (or F) includes the frizzled and smoothened receptors involved in embryonic 
development, intracellular polarity and cell localisation. The N-terminal cysteine-rich 

















Figure 1 Families of G protein -coupled receptors 
GPCRs are subdivided into six super families, dependent on sequence homology and their 
native ligands. Family 1 has a ligand-binding site located within the seven-transmembrane 
domain. Family 2 has a ligand-binding site in the extracellular domain. Family 3 contains a large 
extracellular Venus flytrap ligand-binding domain. Family 4 has an extended N-terminal ligand-
binding domain. Family 5 has an N terminal ligand binding site and an extended C terminal 
domain. Family 6 has an N-terminal cysteine-rich domain containing the ligand binding site. The 
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GPCRs are so named because of their ability to couple to and regulate the 
activity of intracellular heterotrimeric G-proteins. The nature of the interaction between 
G-proteins and GPCRs is not fully understood to date but is likely to vary amongst 
different GPCR families. A large body of work on rhodopsin, for example, suggests that 
activation of the receptor leads to a change in the orientation of transmembrane (TM) 
region III and TM region VI, which involves the disruption of a putative salt-bridge, and 
the possible exposure of key residues involved in G-protein binding and activation 
(Bourne, 1997; Gether, 2000; Wess, 1997).  Activation of the GPCR generates, in turn, a 
conformational change in the G-protein α-subunit (Gα) which leads to the exchange of 
GDP for GTP (Bourne, 1997; Bourne et al., 1991). The GTP-bound α-subunit then 
separates from the receptor and the β γ-subunits of the G-protein. Subsequently, both α-
subunit and β γ-subunits regulate various signalling pathways including activation and 
inhibition of adenylate cyclase and regulation of calcium and potassium channels 
(Figure 2) (Hamm, 1998). Recently, Gα-GDP has been reported to bind to G protein-
coupled inwardly-rectifying potassium channels (GIRKs), and specifically to GIRK1 
















Figure 2 An example of G-protein signalling 
Upon binding of ligand, the GPCR (shown in black) undergoes a conformational change and the 
Gα unit-bound GDP is exchanged for GTP. Gα binds to adenylyl cyclase and modulates cAMP 




Desensitisation reduces GPCR signalling even in the presence of agonist 
stimulation. This is an important physiological regulatory mechanism that protects 
against receptor overstimulation (Kristiansen, 2004; Tilakaratne and Sexton, 2005). In 
the absence of this mechanism, prolonged stimulation of a GPCR could promote, for 
example, excessive cell growth, which is a feature of many cancers. The regulation of 
signalling can operate directly at the receptor, or further downstream. Phosphorylation of 
the C-terminus, or the third intracellular loop, of receptors is mediated by GPCR 
regulatory kinases (GRKs) (Carman and Benovic, 1998) to phosphorylated sites of the 
receptor molecules. In general arrestins bind to the third intracellular loop or the C-



























with G-proteins that bind to the same area of the receptor, and they thereby desensitise 
G-protein-mediated signalling (Reiter and Lefkowitz, 2006).  Binding of arrestins also 
targets the receptor for internalisation by attracting clathrin (Carman and Benovic, 1998; 
Lefkowitz, 1998). The receptor is later dephosphorylated and recycled to the cell surface 
(Ferguson et al., 1998). It has been suggested that arrestins are not only involved in the 
blocking of G-protein-mediated signalling but also the activation of other pathways 
involving recruitment of the tyrosine kinase Src, and subsequently activation of MAP 
kinases ( Luttrell et al., 1996; Luttrell et al., 1999). 
 
1.1.2 Protein-protein interactions 
GPCRs were previously though to function as monomers and bind to trimeric G-
protein with a stochiometry of 1:1. Lately, many GPCRs have been shown to dimerise, 
which may have an important role in receptor signalling (Bouvier, 2001; Marshall, 
2001). GPCR dimerisation can occur between two identical receptor subunits forming a 
homodimer, as occurs for example in the case of β2-adrenergic receptors (Hebert et al., 
1996). Heterodimerisation between two different receptor protein subunits from the 
same subfamily can also occur - the GABAB receptors R1 and R2 (Jones et al., 1998; 
Kaupmann et al., 1998; White et al., 1998) provide an example.  
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1.1.2.1 Dimerisation and cross-talk 
Many members of the GPCR family exist as either homo- or heterodimers 
(Franco et al., 2007; Marshall, 2001). Dimerisation may involve one or more of the 
receptor’s extracellular, transmembrane and intracellular domains, and may occur via 
disulfide bridges and/or non-covalent interactions (Pin et al., 2003). The GABAB 
receptor (discussed further in section 1.2) was one of the earliest identified heterodimers, 
containing one GABABR1 subunit and one GABABR2 subunit (Jones et al., 1998; 
Kaupmann et al., 1998; White et al., 1998). It was initially thought that the receptor 
dimerises through interactions of the C-terminal tails of the subunits. However, it has 
been shown that isoform GABABR1e, which is naturally truncated and lacking the C-
terminal domain, can nonetheless form heterodimers with GABABR2 (Schwarz et al., 
2000) although the receptor remains inactive. Dimerisation of GPCRs is often essential 
for receptor trafficking and signalling, where one subunit might act as a chaperone for 
the other subunit, as is the case for the GABAB receptor (Margeta-Mitrovic et al., 2000) 
(discussed further in section 1.2.1).  
There are an increasing number of studies suggesting cross-talk between 
different GPCR signalling pathways.  The interaction between the dopamine D5 receptor 
and the GABAA γ2 subunit for example, inhibits signalling of both receptors (Liu et al., 
2000). Interestingly, the GABABR1 subunit can heterodimerise with GABAA subunit 
γ2S to form cell surface-expressed receptors. The γ2S subunit does however also bind to 
the GABABR1/R2 heterodimer, resulting in an enhanced internalisation; this suggests 
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the two receptor classes are putatively involved in regulating each other 
(Balusuramanian et al 2004). 
 
1.1.2.2 Intracellular interactions 
 A multitude of studies suggest that GPCRs interact with a range of binding 
partners besides G-proteins (Bockaert et al., 2004; Hall et al., 1998; Heuss and Gerber, 
2000; Milligan and White, 2001). For example, GPCRs have been observed to interact 
with a family of proteins containing PDZ domains, which are amongs the most common 
protein-protein interaction domains. These domains generally bind stretches of three-
four amino acid residues within the C-terminal sequences of partner proteins, although 
the target sequence varies greatly. One example is the β2-adreneric receptor that interacts 
with the first PDZ-domain of the Na+/H+-exchange regulatory factor (NHERF) (Hall et 
al., 1998) in an agonist-dependent manner. It has been suggested that this binding is 
essential for β2-adrenergic regulation of Na+/H+-exchange in vivo (Hall et al., 1998).  
Binding of arrestins to GPCRs were long thought to be involved only in 
internalization of the receptor (discussed previously in section 1.1.1) (Pierce and 
Lefkowitz, 2001). β-arrestins were later shown to link receptors to various signalling 
cascades apart from G-protein-dependent signalling, such as Src family kinases (Luttrell 
and Lefkowitz, 2002) as illustrated in Figure 3. It has recently been shown that other 
parameters such as agonist concentration and receptor clustering can selectively activate 
G-protein-dependent receptor signalling or β-arrestin-regulated receptor signalling 
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(Violin and Lefkowitz, 2007), where agonists can selectively activate one signalling 






















Figure 3 Receptor signalling via two distinctly different pathways  
The receptor (shown in orange and black) can be independently regulated by either G-protein-
dependent receptor signalling, stimulating cyclic AMP and calcium, or β-arrestin-regulated 
receptor signalling, where β-arrestin binds to receptors phosphorylated by GRKs and thereby 
terminating G protein-coupled signalling (indicated by red symbol), and stimulating protein 
kinases Akt and Src. 
 
 
Furthermore, binding of calmodulin to the serotonin receptor has been shown to be 
essential for β-arrestin binding and cell signalling (Labasque et al., 2008). Examples of 
other GPCR-interacting proteins include the Homer/Vesl proteins containing 
Enabled/VASP homology (EVH) domains that bind polyproline regions and the 
β arrestinG-protein
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metabotropic glutamate receptor (mGluR) group-1 proteins mGluR1a and mGluR5 
contain a C-terminal sequence which interacts with EVH domains in all Homer isoforms 
(Ciruela et al., 2000). This interaction controls intracellular calcium release by 
regulation of the interaction of mGluR with the endoplasmic reticulum-based inositol 
triphosphate (IP3) receptor (Tu et al., 1998). 
The GABABR1 subunit has been shown to interact via its C-terminus with the 
activation transcription factor ATF4 (also known as cAMP response element binding 
protein, CREB2) (Nehring et al., 2000; Vernon et al., 2001; White et al., 2000) as well 
as members of the 14-3-3 family; this latter interaction appears to interfere with the 
dimerisation between GABABR1 and GABABR2. The GABABR2 subunit interacts with 
the transcription factor CHOP (Sauter et al., 2005) and the PDZ domain-containing 
protein MUPP1 (Ige and Onadeko, 2001). 
 
1.1.2.3 Extracellular interactions 
The literature on extracellular binding partners for GPCR is much less extensive. 
Interactions on the extracellular surface are believed to play important roles in GPCR 
biology connected with pharmacology, localisation and signalling. The receptor’s 
ligand-binding site is often located either in the large extracellular N-terminal domain or 
the extracellular loops of the seven-transmembrane regions (Bockaert and Pin, 1999). 
The existence of protein-protein interaction motifs on the extracellular domains of 
GPCRs suggests roles such as receptor clustering, transmembrane signalling and 
localisation (Stacey et al., 2000). The extracellular matrix (ECM) protein neuronal 
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activity-regulated pentraxin (Narp) has been reported to aggregate α-amino-3-hydroxyl-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors in excitatory synapses by a direct 
or indirect interaction to AMPA-receptor subunits (O'Brien et al., 1999).  
Germane to this thesis, the family-3 GPCR GABABR1a subunit (but not the 
GABABR1b subunit) contains a tandem-pair of protein-protein interaction domains 
known as complement control protein (CCP) modules (Blein et al., 2004; Martin et al., 
2001; Tiao et al., 2008) thought to be involved in binding to other proteins, which will 
be discussed further in section 1.2.2.1.  The ECM proteins tenascin-R and tenascin-C 
contains the HNK-1 carbohydrate and have been shown to interact and inhibit the 
activation of GABAB receptors (Saghatelyan et al., 2003). These modulator interactions 
have been further probed as alternative targets in drug discovery as discussed in section 
1.2.5 
 
1.2 The Gamma-aminobutyric Acid Type B (GABAB) 
receptor 
Gamma (γ) aminobutyric acid (GABA) is the major inhibitory neurotransmitter in 
the mammalian central nervous system (CNS) (Bettler and Tiao, 2006; Chebib and 
Johnston, 1999). It was discovered in the 1950s and is now known to inhibit mammalian 
neurons from firing action potentials. There are several other amino acid 
neurotransmitters besides GABA, namely glycine, glutamate and aspartate. GABA is 
synthesised from glutamate by the enzyme glutamic acid decarboxylase. There are three 
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receptors for GABA; these are the GABAA, GABAB and GABAC receptors. GABAA/C 
receptors are responsible for fast (synaptic) inhibition and are generally classified as 
ionotropic voltage-gated receptors. GABAB receptors, on the other hand, are involved in 
slow, more prolonged (synaptic) inhibition and are classed as metabotropic GPCRs.   
The GABAB receptor was identified in the 1980s (Bowery et al., 1979; Bowery 
et al., 1980; Bowery and Hudson, 1979; Hill and Bowery, 1981) Although the receptor 
was studied intensively with regards to its pharmacology, very little could be established 
about its molecular characteristics. In 1997 the GABAB receptor subunit R1 was 
identified (Kaupmann et al., 1997) and sequenced, and two splice variants - GABABR1a 
and GABABR1b - were isolated. The cloned receptor did not couple as efficiently to 
predicted signalling pathways as endogenous receptors, despite binding to agonists. 
Interestingly, agonist-binding affinities were found to be 100-fold lower than for native 
receptors (Kaupmann et al., 1997; Kaupmann et al., 1998) and the R1 subunit was 
detained in the endoplasmic reticulum instead of being expressed at the plasma 
membrane (Couve et al., 1998; White et al., 1998). The finding of a second subunit, 
GABABR2, was subsequently reported by several groups in 1998 (Jones et al., 1998; 
Kaupmann et al., 1998; Kuner et al., 1999; Martin et al., 1999; Ng et al., 1999; White et 
al., 1998).  
 
1.2.1 Receptor topology    
Like all the GPCRs, the GABAB receptor subunits has seven helical 
transmembrane stretches of 20-25 residues each, giving rise to three intracellular and 
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three extracellular loops. The ligand-binding properties of the GABAB receptor and 
other members of family 3 are quite different to other GPCR families due to its ‘Venus-
flytrap-like’ ligand-binding site. The large N-terminal extracellular domains of the 
GABAB receptor subunits R1 and R2 (as well as other metabotropic receptors) share 
sequence similarities with periplasmic binding proteins (Pbp) of bacteria (O'Hara et al., 
1993) each is comprised of two lobes linked by a hinge region (Figure 4). A number of 
studies indicate that upon binding of the ligand to the extracellular globular domains of 
the GABABR1 subunit, the two lobes close like a Venus flytrap (O'Hara et al., 1993; 
Quiocho, 1990) (Bockaert and Pin, 1999; Galvez et al., 1999).  Despite the likely 
presence of a putative Venus flytrap domain in the GABABR2 subunit, residues involved 
in GABA binding are lacking (Kniazeff et al., 2002). Heterodimerisation (see section 
1.1.2.1), probably though an interaction of the coiled-coil C-terminal domains of the R1 
and R2 subunits, masks an arginine-rich endoplasmic reticulum-retention signal at the 
C-terminus of the R1 subunit, which otherwise restricts surface expression (Margeta-
Mitrovic et al., 2000). It was later shown (Schwarz et al., 2000) that the two subunits can 
dimerise even in the absence of the C-terminal domains and that further sites for 
dimerisation must therefore be located elsewhere. The seven transmembrane helices of 
GABABR2 are thought to be involved in receptor activation, following ligand binding to 
GABABR1, through a conformational change that activates intracellular G-protein 
signalling (Galvez et al., 2001; Robbins et al., 2001) (shown in pink and purple in Figure 
4). The Gα subunit binds to cyclic AMP and inhibits adenylate cyclase, while the Gβ/γ 













Figure 4 Schematic overview of the GABAB receptor subtypes and composition  
GABAB receptor subunit R1 is illustrated in orange and receptor subunit R2 in black. The ligand 
binding site lies within the two large lobes of the N-terminal extracellular domain of R1. Ligand 
binding to R1 results in a conformational change in the transmembrane domain of R2 which 
separates the α-subunit of the G-protein which binds to cyclic AMP and inhibits adenylate 
cyclase. The β- and γ-subunits of the G-protein regulate K+ and Ca2+ channels. 
 
1.2.2 Receptor isoforms 
 Native studies of GABAB receptors indicate pharmacologically and 
functionally distinct receptor subtypes (Dutar abd Nicoll 1988, Bonanno and Raiteri 
1993). However, on a molecular level only two subtypes have been found and the 
pharmacological diversity observed in native studies has not been reproduced using 
recombinantly expressed receptors molecules (Bettler et al., 2004; Marshall et al., 1999). 
The limited molecular diversity originates primarily from the existence of two isoforms 
of the GABABR1 subunit (Figure 5), R1a and R1b (Kaupmann et al., 1997). The 

























The R1a and R1b isoforms are structurally identical with the exception of the 143 amino 
acid residues that form two CCP modules (or ‘Sushi domains’), CCP1 and CCP2, 
present at the extracellular N terminus of R1a (Bettler et al., 1998; Hawrot et al., 1998). 
CREB has been shown to be involved in transcriptional regulation of isoform levels in 
vivo by binding to unique regions of the promoter (Steiger et al., 2004). In addition, 
there exists a human R1c splice variant that is the result of a 62-amino acid residue 
deletion of the second CCP module at the N terminus of GABABR1 (Martin et al., 
2001). GABABR1e is present in both humans and rat and is a truncated, soluble form of 
R1a lacking exon 11 encoding the transmembrane domain (Schwarz et al., 2000). The 
secreted isoform GABABR1j has recently been reported, which is identical to 
GABABR1a up to and including exon 4 (i.e. CCP1 and 2) but with a soluble C terminus 
lacking sequence homology to known proteins (Tiao et al., 2008). All GABABR1 
isoforms are illustrated in Figure 5. Three splice variants of the GABABR2 subunit has 
been reported (Clark et al., 2000; Ng et al., 1999), however more recent analysis of the 
gene suggests these are cloning artefacts and in fact only one native form of R2 exists 




























Figure 5 GABAB R1 isoforms  
There are a large number of isoforms of the R1 subunit of the GABAB receptor, including four 
found in humans. R1a and R1b are the most abundant. CCP modules, transmembrane (TM) 
domains and coiled-coil (CC) domains are labelled. Scale is indicated at the top of the image. 
Isoform 1d, 1e, 1g and 1j have unique C- terminal tails (shown in black). R1f has a 21-amino 
acid deletion in the extracellular domain and an insertion in the transmembrane domain. Several 
of the truncated forms have insertions after exon 4, shifting the reading frame and thereby 
incorporating stop codons and truncations (Holter et al., 2005; Martin et al., 2001; Schwarz et al., 
2000; Wei et al., 2001). 
 
 
1.2.2.1 Complement control protein modules 
Many proteins, particularly extracellular ones, are composed from arrays of 
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sequences (Kirkitadze and Barlow 2001). The consensus sequence of each module-type 
normally defines a characteristic three-dimensional structure (Campbell and Downing, 
1998). Databases of primary sequences reveal that some types of modules occur 
repeatedly in a range of different proteins, and in diverse combinations with other 
module-types. Thus, although the number of module-types is limited to hundreds, exon 
duplication and shuffling have created thousands of functionally different multiple-
module proteins.  
The CCP module is the predominant module-type in proteins involved in 
regulating complement activation, such as complement 4b-binding protein (C4BP) and 
factor H (DiScipio, 1992). CCP modules also occur widely in other types of proteins 
(see section 1.1.2.3), for example GABABR1a, the brain-specific seizure-related gene 
Sez-6 (Shimizu-Nishikawa et al., 1995) and Hikaru genki (hig), which has been 
suggested to have a neural-specific role in the development of CNS functions involved 
in locomotor activity (Hoshino et al., 1993). It has been shown that when CCP modules 
occur near the N terminus of cell-surface expressed proteins, they are often involved in 
ligand binding and interactions with other proteins (Hawrot et al., 1998; Hoshino et al., 
1993). 
A CCP module consists of approximately 60 amino acid residuess (Kristensen 
and Tack, 1986; Lehtinen et al., 2004). Many atomic-resolution structures of CCP 
modules have been solved (Grace et al., 2004; Uhrinova et al., 2003);(Blein et al., 2004). 
In all of these structures, five extended regions run parallel and antiparallel with the long 
axis of the prolate module causing N- and C-termini to lie at opposite ends. For some or 
all of their lengths these extended regions form β-strands that contribute to antiparallel 
 33 
β-sheets, which wrap around a hydrophobic core. The four conserved cysteine residues 
form two disulfide bridges that stabilise the globular fold (Figure 6). These cysteines are 
disulfide-linked, Cys-I–Cys-III and Cys-II–Cys-IV (Barlow et al., 1991; Janatova et al., 













Figure 6 Structure of GABABR1a CCP2 
The CCP module structure has five extended regions that run parallel and antiparallel with the 
long axis module causing N- and C-termini to lie at opposite ends. β-strands contribute to 
antiparallel β-sheets, which wrap around a hydrophobic core. Four conserved cysteine residues 
form two disulfide bridges that stabilise the globular fold β-strands (β-strands indicated in brown 
and labeled B-H). The two disulphide bridges are shown in ball-and-stick representation. 
Structure from (Blein et al., 2004). 
 
A recombinant version of the GABABR1a N-terminus (residues 17-159 in the 
GABABR1a rat sequence, numbering includes the protein signal sequence of 
GABABR1a (Hawrot et al., 1998)) was expressed in Pichia pastoris. Figure 7 shows the 






CLUSTAL W (1.83) multiple sequence alignment 
 
CCP1   CQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGEREVVGPKVRKCLANGSW 58 
CCP2 RICSKSYLTLENGKVF--LTGGDLPALD----GARVEFRCDPDFHLVGSSRSVCSQ-GQW 53 
       *.  : . *.*  :  ** .:: *::    . .:*: *  : .:**..   *   *.* 
 
CCP1    TDMDTPSRC-- 67 
CCP2    S-TPKP-HCQV 62 
        :   .* :*   
 
Figure 7 Sequence alignment of GABABR1a CCP1 and CCP2 




The structures of CCP1 and CCP2 were extensively studied and shown to have 
strikingly different characteristics (Blein et al., 2004). Circular dichroism (CD) 
spectroscopy studies implied that the second CCP module (CCP2) remains stable at 
relative high temperatures and denaturing conditions. CCP1 on the other hand loses 
secondary structure under similarly harsh conditions. CCP2 is well structured with 
disulfide bridges and hydrophobic side chains protected at its core, while CCP1, despite 
possessing two disulphides, has a poorly structured hydrophobic core. An isotopically 
labelled version of GABABR1a CCP12 was used for determination of 3-D structure 
based on nuclear magnetic resonance (NMR) spectroscopy. The second of the two 
putative CCP modules present in this sequence was found to have a structure 
characteristic of other CCP modules. On the other hand, CCP1 appeared to be natively 
unfolded (Blein et al., 2004). Within the module-pair, CCP1 appears to be somewhat 
stabilised by the presence of CCP2 (Blein et al., 2004) compared to the isolated CCP1. 
As mentioned above, in the instances where they occur toward the N-terminal 
end of a protein, CCP modules often participate in protein-protein interactions. It is 
therefore possible that the CCP domains of the GABAB receptor interact with auxiliary 
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proteins and this may affect the localisation of the R1a isoform, by influencing either its 
transport or retention or modulate its function. That the two CCP modules of the 
GABAB receptor have striking structural differences is therefore of potential interest. 
The open, disordered fold of CCP1 suggests the possibility that CCP1 participates in 
interactions with multiple protein-binding partners. This would explain some of the 
functional diversity observed in studies with native GABAB receptors.  
 
1.2.3 Distribution and localisation 
The GABABR1 and R2 subunits are widely expressed in the mammalian central 
nervous system. The expression pattern for the two subunits generally overlap, which is 
to be expected with the necessity for co-expression. Interestingly though, this is not 
always the case (Calver et al., 2000), which suggests the possibility of a different 
molecular nature of the receptor subunits in these tissues, as discussed in section 1.1.2.1. 
The highest expression levels of the receptor are found in the cerebellum and 
hippocampus but it is also present in the thalamus, cortex and brain stem (Clark et al., 
2000; Mohler et al., 2001). Furthermore, GABAB receptors are found in a wide range of 
tissue including the peripheral nervous system and non-neural tissue such as smooth 
muscle, gut and pancreatic islets (Bowery, 1993; Ong and Kerr, 1990). 
           GABAB receptors are located both pre-and post-synaptically in the brain. Pre-
synaptic receptors can be auto- or hetero-receptors that control the release of GABA, 
and other neurotransmitters, respectively, by inhibition of calcium ion channels. Post-
synaptic receptors cause hyperpolarisation of the plasma membrane by gating inward 
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rectifying potassium (KIR) type channels (as discussed in the previous section). 
GABABR1a is primarily located at pre-synaptic sites, while GABABR1b is located at 
post-synaptic sites (Fritschy et al., 2004; Vigot et al., 2006). 
There had been no solid experimental evidence supporting functional differences 
between isofoms until recently, when support for differential functions of the two 
isoforms, GABABR1a and R1b, in the hippocampus was reported (Vigot et al., 2006). 
By knocking out one isoform at a time, the expression and function of each individual 
isoform could be studied in vivo. GABABR1a appears to inhibit glutamate release at the 
connection between CA3 and CA1 regions of the hippocampus by forming 
heteroreceptors, while GABABR1b mediates postsynaptic inhibition. GABABR1a is 
selectively expressed in distal axons of CA3 neurons, indicating the putative 
involvement of CCP modules in retaining the heteroreceptor at this specific location 
(Vigot et al., 2006). In addition, separate physiological roles have been suggested for the 
GABABR1a and R1b isoforms at layer 5 of pyramidal neurons in the neocortex. 
GABABR1b appears to be involved in the blocking of Ca2+ currents in dendrites due to 
postsynaptic inhibition, whereas GABABR1a is involved in presynaptic inhibition of 
GABA release (Perez-Garci et al., 2006). Interestingly, differences in expression levels 
of the GABABR1 isoforms during development and adult life in rat and human have 
been observed (Martin et al., 2001). GABABR1a has been shown to be predominantly 
expressed during human and rat early development, with levels dropping rapidly after 
postnatal day five to moderate levels in adult brain. In contrast, GABABR1b is 
undetectable at birth and expression levels increase after postnatal day five so that this is 
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the dominant isoform expressed in adult brain. GABABR1c is expressed solely in foetal 
brain and at similar levels to GABABR1a (Fritschy et al., 1999; Martin et al., 2001).  
The fact that the isoforms that are more abundant during development, R1a and 
R1c, both contain CCP modules while the CCP-lacking isoform R1b is dominant in 
adult brain is intriguing. CCP modules have been found in other GPCRs (see section 
1.2.2.1). The CCP module of neurocan was reported to interact with the L1 adhesion 
molecule of the immunoglobulin super family, which is linked to axonal outgrowth and 
neuronal cell migration, and ultimately to memory and learning (Oleszewski et al., 
2000). This evidence suggesting a role of CCP modules in the developing brain forms 
the basis of an intriguing area of research. It has been reported that the CCP modules of  
GABABR1a are involved in an interaction with the extracellular matrix protein fibulin 
(Ginham et al., 2002), which was further confirmed in our lab (Blein et al., 2004) but the 
functional relevance of this interaction, as well as others that have been mooted, is yet to 
be explored.  
 
1.2.4 Pharmacological differences between GABAB receptor 
isoforms 
A few studies have indicated distinct pharmacological properties for each of the 
two isoforms (Ng et al., 2001; Parker et al., 2004).  Ng et al reported that gabapentin 
acts as an isoform-selective agonist of R1a; this would have provided the first tool 
capable of distinguishing the isoforms pharmaceutically. Subsequntly, it was suggested 
that gabapentin selectively activates postsynaptic R1a/R2 receptors but not presynaptic 
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receptors (Ng et al., 2001). Confusingly, another report claimed that gabapentin 
selectively activates presynaptic heteroreceptors (Parker et al., 2004). These 
contradictory findings have not been reproduced by others (Jensen et al., 2002; Lanneau 
et al., 2001; Shimizu et al., 2004), however. These claims and counter-claims meant 
further investigation. 
Turning to the intracellular side, selective activation pathways mediated through 
a preference for G-protein isoforms has been reported for GABABR1a and R1b. While 
R1a selectively signals via G0αA, R1b signals equally via G0αA and Giα2 (Leaney and 
Tinker, 2000). The same paper suggested that R1b (but not R1a) was able to activate 
KIRs directly, i.e. in absence of the R2 subunit that is normally needed for G protein 
signalling. This work therefore appears to show a distinct difference in signalling 
between the two isoforms. 
 
1.2.5 Relevance to disease and possible therapies 
The human gene for GABABR1 is located on chromosome 6p21.3, which is a 
genetic locus for a range of neurological disorders including schizophrenia, dyslexia and 
juvenile myoclonic epilepsy. On the other hand, the human gene for GABABR2 is 
located on chromosome 9q22.1, which is linked to hereditary sensory neurophathy type 
1. The GABAB receptor has long been considered a promising drug target for disorders 
such as epilepsy, chronic pain, spasticity, drug addiction and cognitive impairment 
(Bowery, 2006; Marshall et al., 1999). 
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A number of selective, high- and low-affinity GABAB receptor antagonists have 
aided pharmacological and physiological studies of this receptor. The earliest known 
antagonists were the low-affinity binders saclofen, 2-hydroxy saclofen and phaclofen 
(Kerr et al., 1988; Kerr et al., 1987). Further development of high-affinity antagonists 
resulted in CGP35348 and the widely used CGP55845 followed by very high-affinity 
antagonists, including some radio-labelled ones, that were important in work leading to 
the initial expression cloning of the GABAB receptor (Davies et al., 1993; Kaupmann et 
al., 1997). Baclofen is the most commonly employed GABAB receptor agonist in 
humans. It is used for treatment of spasticity by decreasing spinal reflex transmission 
(Bowery, 1993) and has also been shown to decrease cravings for addictive substances 
like alcohol, cocaine and heroin. Despite the potential benefits of Baclofen, it is rapidly 
tolerated and can give numerous side-effects such as muscle relaxation, sedation and 









Figure 8 GABABreceptor agonist and antagonist structures 
Stuctures from Tocris Bioscience 
 
Baclofen Saclofen 2-hydroxy saclofen
Phaclofen CGP35348             CGP55845
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An interesting alternative proposal for treatment is the use of allosteric modulators. 
These do not bind to the receptor at the ligand-binding site, but increase or decrease the 
inhibitory effect in the presence of an agonist (Bridges and Lindsley, 2008; Ross, 2007). 
One example of a target for drug design is the modulator Tenascin-R which upon 
binding to the GABAB receptor inhibits binding of GABA and thereby receptor-
activated K+ currents (Saghatelyan et al., 2003). Tenascin-R carries the HNK-1; a 
carbohydrate expressed by neuronal adhesion molecules and thought to be involved in 
induction of long term potentiation (LTP). When binding is disrupted by anti-HNK-1 
antibody, receptor remains active (inhibitory function) and K+ currents are restored 
(Saghatelyan et al., 2000; Saghatelyan et al., 2003). Furthermore, the positive modulator 
GS39783 has been reported to be efficient in treating anxiety without the undesired side 
effects of baclofen (Cryan et al., 2004). 
 
1.3 The extracellular matrix 
All cells in the human body are surrounded by a network of secreted 
macromolecules that make up the extracellular matrix (ECM). The ECM varies between 
different tissues, from a thick layer of matrix in epithelial tissue to thin sheets of 
extracellular protein in basement membrane, and plays an important role in complex 
communications between cells at various locations of the body. The basement 
membrane has a major impact on cell phenotypes as well as tissue compartmentalisation 
from development onwards. During development cells migrate by attaching to the 
basement membrane; it is furthermore involved in wound healing and nerve 
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regeneration. (Engvall, 1995; Timpl and Brown, 1996). The proteins of the ECM are 
continually produced to replace others that have been internalised during cell signalling 
or disturbed by cells migrating through the matrix. The major components of the 
basement membrane are laminin and collagen IV; both proteins form a large network by 
self-assembly. They also interact with each other and various other ECM proteins such 
as nidogen, fibulin and proteoglycans (Timpl and Brown, 1996). The apparent 
complexity of the basement membrane continues to expand (Erickson and Couchman, 
2000), with the discovery of new protein members and isoforms such as endactin-
2/nidogen-2 (Kimura et al., 1998; Kohfeldt et al., 1998) and argin (Nitkin et al., 1987). 
The structure of the ECM is tissue-specific consistent with its many functions, from 
barriers against tumour cells to substrates for cell attachment.  The basement membrane 
is attached to cells by interactions with integrin receptors, primarily to laminin and 
collagen IV. The interactions between ECM components and cell surface receptors 
transmit signals across the cell membrane and thereby alter cell behaviour, as well as 
developmental fate. Intracellular signalling pathways connected with the ECM are 
highly conserved and a breakdown of the ECM can lead to uncontrolled cell growth and 
tissue death (Timpl and Brown, 1996).The ECM has been extensively studied in tissues 
other than the brain (Ekblom, 1995). The existence of ECM in the brain was earlier 
under debate but is now accepted and widely studied. A schematic overview of the 
extracellular matrix illustrates the complexity of the protein network (Figure 9). Many 
proteins are large, consisting of several chains and domains and are involved in specific 
















Figure 9 The complex network of the extracellular matrix 
The extracellular matrix is built up of a mixture of proteins. Laminin (grey crucifix) and collagen 
type IV (thin grey rods) are crosslinked together by entactin (yellow) and perlecan (pink). Picture  




1.3.1.1 Isoforms    
The laminins are a major family of glycoproteins making up an important part of 
the ECM. Laminin-1, the first-described and most extensively studied member of this 
family, was isolated from mouse Engelbreht-Holm Swarm (EHS) tumour in 1979 
(Timpl et al., 1979). The number of laminins identified in mammals has increased in 
recent years; to date, 15 isoforms have been recognised (Table 1), many with a unique 




Table 1. Overview of the 15 laminin isoforms 
Isoform New nomenclature* Chain composition 
Laminin-1   111 α1β1γ1 
Laminin-2 211 α2β1γ1 
Laminin-3 121 α1β2γ1 
Laminin-4 221 α2β2γ1 
Laminin-5 332 α3β3γ2 
Laminin-6 311 α3β1γ1 
Laminin-7 321 α3β2γ1 
Laminin-8 411 α4β1γ1 
Laminin-9 421 α4β2γ1 
Laminin-10 511 α5β1γ1 
Laminin-11 521 α5β2γ1 
Laminin-12 213 α2β1γ3 
Laminin-13 522 α5β2γ2 
Laminin-14 423 α4β2γ3 
Laminin-15 523 α5β2γ3 
*discussed further in section 1.3.1.2 
 
Laminin consists of one α-chain, one β-chain and one γ-chain. There are five 
types of α-, three types of β- and three types of γ-chains, resulting in many possible 
combinations (Beck et al., 1990). Each chain is encoded by a different gene; α by the 
LAMA family, β by the LAMB family and γ by the LAMC family. Some laminin chains 
have been shown to be alternatively spliced; examples are the human α3 chain that is 
modified in the IIIa domain (see below) (Galliano et al., 1995; Ryan et al., 1994), γ2 that 
displays two variants with differences at the 3’-end (Airenne et al., 1996) and human β2 
where alternative splicing occur at the 5’-untranslated region (UTR) of the mRNA 
transcript (Kallunki et al., 1992; Durkin et al., 1996). Other modifications include the 
proteolytic cleavage of polypeptide chains within already assembled laminins 
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(Colognato and Yurchenco, 2000); the cleaved fragment may remain bound to the main 
laminin protein. 
 
1.3.1.2 Structure  
The α-, β- and γ-chains of laminin form a large cruciform trimer with a 
molecular weight of approximately 800 kilodaltons (kDa). Coiled-coil regions, stabilised 
by inter-disulphide bonds, holds the three chains (as seen in Figure 10) (Engel, 1992; 









Figure 10 Electron microscopical visualisation and schematic structure of the Laminin 
heterotrimer  
The cruciform trimer of laminin consists of one α- (red), one β- (blue), and one γ (green) chain . 
Images (Aumailley et al., 2005; Engel, 1992). The C-terminus of the γ-chain contains five laminin 
globular (LG) domains, seen in green.   
 
The laminin polypeptides consist of several types of structurally and sometimes 
functionally independent domains originally designated by the roman numerals I to IV 
(Figure 11) (Beck et al., 1990; Sasaki et al., 1988). These domains include epidermal 
 
 45 
growth factor (EGF)-like repeats, coiled-coil domains (CC) and globular-like domains 
(LG) (Beck et al., 1990). A new nomenclature was proposed (Aumailley et al., 2005) to 
simplify the naming of laminin domains, where instead of βIV or γIV for example, the 
domains are named laminin N-terminal domain (LN), laminin epidermal growth factor 
domain (LE), laminin domain 4 α- and γ-chain (L4), laminin domain 4 β-chain (LF), 
laminin coiled coil domain (LCC) and laminin globular-like domain (LG) (Aumailley et 
al., 2005; Scheele et al., 2007). However, both nomenclatures are still being used at 
























































Figure 11 Schematic overview of domains making up laminin α-, β-, and γ-chains  
Figure A names laminin domains using the ‘old’ nomenclature (I,II,III,IV,V,VI), figure (Colognato 
and Yurchenco, 2000) while figure B names rodlike EGF-like tandems (LEa, LEb, LEc) and 
globular domains (LN, L4a, L4b, L4, LF) according to the new proposed nomenclature , figure 
(Tzu and Marinkovich, 2008).  
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The three-dimensional structure of the α2 LG4-5 domains (Hohenester et al., 
1999; Tisi et al., 2000) has been determined. Furthermore, a protein corresponding to the 
α1 LG4-5 was recently crystallised (Harrison et al., 2007), as was LG4 of α3 (Kato-
Takagaki et al., 2007); also known is the structure of the nidogen-binding γ1 EGFs 
(Stetefeld et al., 1996). Most recently determined is the crystal structure of α2 LG1-3 
(Carafoli et al., 2009). 
 
1.3.1.3 Expression and localisation  
In non-neuronal tissue, laminins are primarily expressed in the basement 
membrane, where they assembly into a tightly structured network. In contrast, laminins 
expressed in the developing CNS form looser structures and are associated with 
neuronal cells, glia cells and axons (Colognato et al., 2005). In the peripheral nervous 
system (PNS), laminins are present in the basement membrane surrounding Schwann 
cells (Hagg et al., 1997; Miner, 2008). In higher vertebrates laminin is expressed in the 
CNS during development and to lesser extent in adult CNS (Colognato et al., 2005). It is 
continuously expressed in adult PNS (Engvall et al., 1990; Miner, 2008; Montell and 
Goodman, 1989). Laminin-10 (containing the chains α5, β1 and γ1) is a major isoform 
in mouse hippocampus (Indyk et al., 2003) and is crucial for brain development 
(Colognato and Yurchenco, 2000; Miner et al., 1998). Expression of laminin chains α1, 
α2, α4, α5, β1, β2, γ1 and γ3 is found in both developing and adult CNS in mammals. It 
is however not entirely clear which laminin isofoms are expressed where, as identical 
chains are shared between different laminin isofoms (Colognato et al., 2005). 
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Interestingly, the α1-containin laminin-1 is involved in the clustering of acetylcholine 
receptors in the brain (Siguyama 1997). However, the α5-containing laminin-10, which 
is the major laminin isoform in the hippocampus (Indyk et al., 2003), appears not to be 
involved.  
 
1.3.1.4 Relevance of laminin to disease 
Congenital muscular dysfunction, resulting from a mutation in LAMA2, 
associates with defects in the peripheral and central nervous system, such as epileptic 
seizures and reduced myelination, supporting the necessity for laminin in the 
mammalian nervous system (Mercuri et al., 1996; Sunada et al., 1995). Laminin, γ1 in 
particular, but also α1 and α5, have been implicated as important for kidney 
development (Scheele et al., 2007). They have been shown to be particularly important 
for the capillaries that filter waste from the blood to produce urine. Laminins are also 
linked to the growth of cancers; it is reported that the state of the basement membrane 
yields an indication of the severity of cancers, e.g. a disrupted basement membrane is an 
indication of more malignant tumours (Scheele et al., 2007). Mammary carcinomas, in 
contrast, have very low if any expression of laminin chains. The α1 chain is commonly 




1.3.2 The fibulin family 
 
1.3.2.1  Structure 
Fibulin proteins consist predominantly of a series of calcium-binding epidermal growth 
factor (EGF)-like modules, followed by a carboxy-terminal fibulin-type module, as 
illustrated in Figure 12 (Kobayashi et al., 2007; Timpl et al., 2003). The composition of 
each fibulin will be further discussed in the next section.  
 
1.3.2.2 Isoforms 
Fibulins are a family of seven extracellular matrix proteins, fibulin-1 to fibulin-7. 
Fibulin-1 and -2 are structurally similar and fall into the same subgroup. Fibulin-3, -4 
and -5 are also subgrouped on the basis that they are much smaller in size. Alternative 
splicing of fibulin-1 results in four alternative proteins designed fibulin-1A-1D. Fibulin-
2 forms a homodimer where two subunits, arranged in an anti-parallel manner, are 
linked by a disulphide bond (Timpl et al., 2003). Fibulin-3, -4 and -5 are structurally 
closely related, as seen in Figure 12. Fibulin-6, which is also referred to as hemicentin, 
contains 48 immunoglobulin domains (Argraves et al., 2003; Vogel and Hedgecock, 
2001) .Fibulin-7 is the newest addition to the fibulin family and is reportedly the only of 






















Figure 12  Illustration of the modular structure of the fibulin proteins  
The fibulin family consists of seven proteins. Each is built up predominantly from a string of EGF 
like domains that are linked to the C-terminal domain- further details in the figure; Fibulin-1 has 
four splice variants, 1A-1D, which varies at the C-terminus (Not all 48 immunoglobulin c-2 
domains are illustrated due to space constaints). Figure based on (Argraves et al., 2003) 
 
 
1.3.2.3 Distribution and localisation 
Fibulins are expressed in the ECM. Fibulin-1, for example, is widely expressed 
within the matrix fibre and basement membranes of most organs. The other fibulin 
proteins have a more restricted distribution, with fibulin-2 expressed in fibroblasts and 
basement membranes and fibulin-3, -4 and -5 mainly expressed in larger blood vessels 
and some basement membranes (Timpl et al., 2003). Fibulin-6 is expressed in skin 
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Expression of fibulin-1 has an onset in early development and it is expressed at very 
high levels (10-50 µg/ml) in human serum. This is approximately 1000-fold higher 
concentration than other fibulins and ECM proteins. Fibulin-2 has a slightly later onset, 
but is still expressed at high levels during organ development. Interestingly, both fibulin-
1 and -2 are expressed in the brain, suggesting a neuronal function for fibulins 
(Kobayashi et al., 2007; Timpl et al., 2003). 
 
1.3.2.4  Relevance of fibulin to disease 
Fibulins are known to regulate cell-growth, migration and morphology. Tumour 
suppressive and oncogenic roles have been reported for several members of the fibulin 
family. Fibulin-1D (Figure 12) is reported to be involved in breast cancers by 
suppressing the invasiveness of tumour cells (Argraves et al., 2003; Greene et al., 2003). 
Fibulin-1C is up-regulated in ovarian cancer. A number of ECM proteins like fibronectin 
and tenascin have also been found to be up-regulated in breast cancers (Loridon-Rosa et 
al., 1990; Mackie et al., 1987). Down-regulation of fibulin-2 has been reported in breast 
cancer tissue, which may aid cell migration and invasion in breast cancer (Yi et al 2007). 
Fibulin-4 is positive regulator and fibulin-5 is a dual positive and negative regulator of 
cell-growth (Gallagher et al., 2005). Fibulin-4 has further been reported to be up-
regulated in colon cancer (Gallagher et al., 2001). Fibulin-3 and fibulin-6 are not known 
to have a role in cancer to date (Gallagher et al., 2005) Yi 2007).  
Fibulins have furthermore been linked to inherited eye disorders. A mutation in the 
fibulin-3 gene has been linked to Malattia Leventinese (ML) macular dystrophy (Argraves 
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et al., 2003; Stone et al., 1999), whereas mutations in the fibulin-6 gene may predispose 
for age-related macular degeneration (AMD) in a small subset of the population, 
however it has little effect in the overall population (Fisher et al., 2007; Schultz et al., 
2003). 
 
1.4 Aims of study 
The GABAB receptor isoform R1a has been shown to be expressed selectively 
within heteroreceptors at presynaptic sites as discussed previously. This would support 
the idea that the CCP modules present in R1a may be involved in localising these 
receptors to presynaptic sites. This may occur through interaction with extracellular 
proteins in an analogous fashion to the clustering of acetylcholine receptors via 
interactions with agrin and laminin (Sugiyama et al., 1997) (section 1.3.1.3). 
Interestingly, GABABR1a is the predominant isoform during CNS development. 
Similarly laminin and fibulin are also primarily expressed in the CNS during 
development. These observations are consistent with a functional role for these 
interactions in regulation of the developing brain.  It has been shown that the CCP 
modules of R1a bind to the extracellular matrix protein fibulin-2 (Blein et al., 2004). It 
was speculated that the CCP modules are also involved in binding to other extracellular 
proteins. Thus the ECM interaction mediated by these modules requires further 
investigation.   
These intriguing but tentative observations of interactions between the GABAB 
receptor and the ECM provided a starting point for the current project. In order to 
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establish a firmer basis for further study of this phenomenon it was necessary to validate 
or otherwise the preliminary work. Thus the first aim was to re-examine the interaction 
between the GABABR1aCCP modules and fibulin-2, with an emphasis on establishing 
which modules/domains are involved. It was also of interest to investigate a potential 
interaction with fibulin-3 that shares with fibulin-2 a unique C-terminal fibulin-like 
module. Given the predominance of laminins in the ECM and the large number of 
proteins reported to interact with the laminin family, the protein-protein interaction 
studies devised for fibulins could also be applied to laminins and laminin domains – this 
constitutes the next aim. All of these studies, which utilise yeast two-hybrid and surface 
plasmon resonance approaches, will be described in Chapters 2 and 3.  
 Having fleshed out the interaction data, the next aim was to investigate their 
functional implications. An important objective, given controversies in this area, was to 
investigate any pharmacological differences between GABABR1a and GABABR1b. This 
was accomplished using oocyte-expressed isoforms and a two-electrode voltage clamp 
technique. The intention was then to employ a similar approach in order to facilitate an 
investigation of whether the pharmacological responses (e.g. to the agonist, baclofen) of 
the isoforms GABABR1a and GABABR1b is influenced by the presence of extracellular 
















2 Chapter 2 Yeast two-hybrid binding study 
 
 
2.1 Aims  
The first aim was to establish the yeast two-hybrid (Y2H) system as a means by 
which to further investigate protein-protein interactions mediated by the CCP modules 
of GABABR1a. The second aim was to validate or otherwise the previously proposed 
interaction between the GABABR1aCCP1 and the C-terminal module of the 
extracellular protein fibulin-2, and to investigate a potential interaction with the 
equivalent module of fibulin-3. The third aim was to characterise the putative interaction 
between the CCP modules of GABABR1a and the extracellular matrix protein laminin, 
with an emphasis on establishing which laminin domains are involved. 
 
2.2 Context   
As outlined in the previous chapter, controversy persists as to whether 
pharmacological differences between the GABAB receptor isofoms are detectable when 
working in vitro or in X. laevis oocytes. But the situation must in any case be more 
sophisticated within the mammalian central nervous system wherein receptors operate in 
the presence of other, potentially interacting, proteins that are absent from 
experimentally more tractable model systems. To reiterate, the difference between 
isoforms GABABR1a and R1b lies in the presence of two, tandemly arranged, CCP 
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modules on the N-terminal ectodomain of GABABR1a. There is a considerable amount 
of literature indicating that CCP modules (in general) participate in protein:protein 
interactions indicating that the CCP modules of GABABR1a might also have such a role.  
To pursue this line of enquiry, it is necessary to identify and characterise the putative 
binding partners for these modules. In the current work, which builds on previous 
published and unpublished observations, the CCP modules of GABABR1a were 
therefore studied to characterize their ability to bind ECM proteins. Fibulin domains 
were selected for study on the basis of previous report of interaction between 
GABABR1a modules and fibulin 2 (Ginham 2002). The laminin globular (LG) domains 
were selected for study in this project because laminin is one of the most abundant ECM 
protein; moreover there is precedent for CCP module-LG domain interactions in the 
literature – specifically, the LG domains of protein S interact with CCP modules of C4b 
binding protein (C4BP) (Fernandez and Griffin, 1994; Hardig and Dahlback, 1996; 
Hardig et al., 1993; Hillarp and Dahlback, 1990) 
 
2.3 Materials and Methods 
 
2.3.1 Yeast two-hybrid background and theory 
Identification of a protein’s interaction partners affords valuable insight into its 
biological roles and mechanisms of action. With this in mind, Fields and Song (1989) 
invented the yeast two-hybrid (Y2H) system as a means of detecting protein-protein 
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interactions (Fields and Song, 1989). The system has since been modified to additionally 
detect protein-RNA and protein-ligand interactions (Coates and Hall, 2003). The Y2H 
system has been extensively used to study intracellular protein interactions including 
those involving the GABAB receptor (Durfee et al., 1993; White et al., 2002), but has 
also been applied successfully to the detection of extracellular protein-protein 
interactions (Overall et al., 2002; Oxford et al., 2004; Veroni et al., 2007). The Y2H 
system exploits a transcription factor - generally Gal4 or LexA. A schematic diagram 
summarizing the Gal4-based Y2H system is presented in Figure 13. The system relies on 
the utilization of two components: the Gal4 DNA-binding domain fused to protein ‘bait’ 
and the Gal4 transcription activation domain fused with protein ‘prey’. When both 
fusion proteins are co-expressed, and provided the ‘bait’ and the ‘prey’ interact, a 
functional transcription factor is reconstituted from the resulting juxtaposition of the 
activation and DNA-binding domains. This activates transcription of reporter genes, 
typically His3, Ade2, lacZ and Mel1. The first two of these are yeast biosynthetic 
markers and their inclusion ensures selection can be carried out for organisms able to 
grow on media lacking histidine and adenine. The latter two reporter genes enable 





Figure 13 The principle of the Gal4 Y2H  
The bait protein is expressed as a fusion with the DNA-binding domain of the Gal4 transcription 
factor, the prey protein is expressed as a fusion with the Gal4 transcription-activating domain. 
Upon interaction of the bait and prey, mediated by their fusion partners, transcription is initiated 
leading to expression of reporter genes used to detect the interaction. 
 
 
The Y2H system was originally designed to confirm binding between two known 
proteins that had already been suggested to interact on the basis of evidence from other 
methods. The system has additionally been employed to delineate the specific domains 
involved in such an interaction (Legrain and Selig, 2000; Stokes et al., 2007). 
Identifications of novel protein-binding partners using the Y2H system have been 
achieved by screening a cDNA library (Legrain and Selig, 2000). The ‘Matchmaker 
Gal4 Two-Hybrid System 3’ (Clonetech) was chosen for the current work on the 
grounds that  this system enables detection of relatively weak or brief interactions 
between proteins – it has a detection limit in the region of KD ~70 µM (Yang et al., 
1995). The assay is carried out in a eukaryotic system in vivo, which increases the 
chance of correct conformation and folding of proteins, thus optimizing sensitivity and 
maximising the possibility of detecting an interaction. In the current study, this system 
was applied to investigate the interaction between GABABR1aCCP1 and C-terminal 
fragments of the ECM proteins fibulin-2, fibulin-3 and laminin α5. 
Gal4 upstream 
activating sequence 












2.3.2.1 Stock solutions and media 
The following solutions were prepared in double-deionised water: 
50% (w/v) polyethylene glycol (PEG) 3350 
10 x tris/ethylenediaminetetraacetic acid (TE) buffer (0.1 M Tris-HCl, 10 mM EDTA, 
pH 7.5, autoclaved) 
10 x LiAc (1 M lithium acetate, adjusted to pH 7.5 with dilute acetic acid, autoclaved) 
Yeast extract/peptone/dextrose/adenine (YPDA) medium (to 1 L of yeast 
extract/peptone/dextrose (YPD) medium (Clontech), 15 ml of filter-sterilized 0.2 % 
(w/v) adenine hemisulfate was added, producing a final concentration of 0.003 % (w/v)) 
Polyethylene glycol (PEG)/LiAc solution (8 ml of 50% PEG (w/v), 1 ml of 10 x TE, 1 
ml of 10 x LiAc) 
10 x BU salts (70 g Na2HPO4H2, and 30 g NaH2PO4 were dissolved in one litre of water, 
adjusted to pH 7, and autoclaved)  
Z-buffer/x-gal solution (To 15 ml Z-buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 
mM KCl, 0.1 mM MgSO4 , pH 7.0) was added 60 µL of β-mercaptoethanol, 300 µl of a 
20 mg/ml β X-gal stock solution (5-bromo-4-chloro-3-indolyl-β-D-galactopyranosode 
dissolved in N,N-dimethylformamide) which gives a final concentration of ~0.4 mg/ml). 
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2.3.2.2 Synthetic dropout (SD) base media plates 
Agar plates were made up from the following constituents: yeast nitrogen base without 
amino acids (6.7 g); 20 g agar; 850 ml H2O; and 100 ml 10x ‘drop-out’ solution (see 
below). Plates were autoclaved, allowed to cool to 55°C, then dextrose to 2% (w/v) and 
adenine to 0.2% (w/v) were added  
 
Drop-out solutions: Three - ‘low’ ‘medium’ or ‘high’ - drop-out solutions contained a 
mixture of  amino acids and nucleosides (adenine hemisulphate salt, L-arginine HCL, L-
histidine HCL monohydrate, L-isoleucine, L-leucine, L-lysine HCL, L-methionine, L-
phenylalanine, L-threonine, L-tryphtophan, L-tyrosine, L-uracil, L-valine, their 
concentrations are proprietary to Clontech). These were added to the Minimal SD Bases 
to make a defined medium lacking the specified nutrients as shown below: 
 
“Low”:  minus leucine and tryptophan.  
“Medium”:  minus leucine, tryptophan and histidine 
“High”:   minus leucine, tryptophan, histidine and adenine 
 
SD/Gal/ /Drop-out plates: Minimal SD base media plates were prepared as above, 
except the volume of water was reduced to 725 ml. Plates were autoclaved, and the 
following were added once the temperature had cooled to 55°C: 2% w/v dextrose; 0.2% 
w/v adenine, 1x BU salts see above), pH 7, 20 mg/l x-gal (see z-buffer/x-gal solution 
above) 
 61 
2.3.2.3 Plasmid DNA preparation 
Note: Buffers P1, P2, N3 and PE were all supplied as part of the Qiagen kit and their 
formulations are proprietary. 
Re-suspension buffer: buffer P1, with addition of 140 µl of the Qiagen-provided RNase 
A solution 
Lysis buffer: buffer P2 
Neutralization buffer: buffer N3  
Wash buffer: buffer PE, with addition of 100% ethanol (according to manufacturer’s 
protocol) 
 
2.3.2.4 Protein expression and purification 
The following soulutions were pepared: 
Buffered minimal glycerol medium (BMG): 100 mM potassium phosphate (pH 6); 
1.34% (w/v) yeast nitrogen base (YNB; with (NH4)2SO4 and without amino acids), 1% 
(v/v) glycerol, 0.00004% (w/v) biotin) 
 
Buffered minimal methanol medium (BMM): 100 mM potassium phosphate (pH 6); 
1.34% (w/v) YNB (with (NH4)2SO4 and without amino acids), 0.5% (v/v) methanol, 
0.00004% (w/v) biotin 
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For digest with Endo Hf:: 5 ml of protein-containing supernatant (~0.25-0.3 mg/ml), 
7.5 ųl of Endo Hf  (7500 U), 5 ųl of protease-inhibitor cocktail (Sigma), 10 ųl of 0.5M 
EDTA; Incubate for approximately 6 hours at 37 °C 
 
ConA Buffers: 
Binding buffer: 20 mM Tris-HCl pH 7.4 (16.8 ml 1 M Tris-HCl + 3.2 ml 1 M Tris Base) 
+ 0.5 M NaCl  
Elution buffer: 20 mM Tris-HCl pH 7.4 + 0.5 M NaCl + 0.5 M Methyl α-D-
glucopyranoside 
 
Cation-exchange chromatography buffers: 
Binding buffer for CCP1 and CCP1-2: 12.5 mM NaAc pH 5.3 
Binding buffer for CCP2: 50 mM NaAc pH 4.6 
Elution buffer for CCP1 and CCP1-2: 12.5 mM NaAc pH 5.3 + 1 M NaCl 
Elution buffer for CCP2: 50 mM NaAc pH 4.6 + 1 M NaCl 
 
2.3.3 Methods 
In the present study we set out to investigate the potential interactions of 
GABABR1a with fragments of ECM proteins using the Y2H system. A previously 
published study (Blein et al., 2004) used a recombinantly expressed fibulin-2 C-terminal 
fragment to pull down GABABR1a from solubilized rat synaptic plasma membranes, 
supporting an unpublished earlier observation (Dr. Julia White, GlaxoSmithKline, 
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personal communication).  Thus the present study aimed to provide independent 
evidence for this putative interaction between GABABR1-CCP12 and fibulin using the 
Y2H system. Furthermore, it was hypothesized that the abundant ECM protein laminin 
might be an additional potential binding partner for GABABR1a (as discussed in section 
1.4) providing another target for the current Y2H-based investigation. 
 
2.3.3.1 Generation of constructs for Y2H  
For the bait, the cDNA for rat GABABRCCP1 (residues 17-98) was incorporated 
into the vector pGBKT7 DNA-BD (Clontech) by digesting a pET15b plasmid 
(Novagen) containing GABABR1aCCP1 (previously cloned by Dr Blein, Barlow group) 
and inserting the GABABR1aCCP1 fragment into a previously digested pGBKT7 DNA-
BD vector. For the prey, the C-terminal fragment of fibulin-2 (FTM2) (residues 1068-
1184) and the C-terminal fragment of fibulin-3 (FTM3) (residues 377-493), were 
inserted separately into the vector pGADT7 AD (Clontech) by digesting the pET41 
plasmids (Novagen) containing FTM2 or FTM3 (previously cloned by Dr Blein), 
respectively, and inserting the fibulin fragments into separate, previously digested, 
pGADT7 vectors.  The prey construct for laminin 5 laminin globular domains 1-5 
(LAMA5 LG1-5) (residues 2733-3695) was created by amplifying the LAMA5 LG 1-5 
from a cDNA library and blunt-end ligating the fragment into a pCR4blunt TOPO vector 
(Invitrogen). The TOPO vector was thereafter digested and the laminin fragment was 
inserted into a previously digested pGADT7 vector. Plasmid maps of the vectors 












Figure 14 Plasmid maps of the two vectors pGBKT7 and pGADT7 used for Y2H studies  
A bait gene is expressed in pGBKT7 as a fusion to a Gal4 DNA-binding domain. The prey is 
expressed in pGADT7 as a fusion with the Gal4 transcriptional activating domain. 
 
2.3.3.1.1 Primer design 
The sequences of the genes under investigation were retrieved using 
www.ensemble.org. Primer sequences were designed, taking into account predicted 
secondary structure using Sigma-Genosys primer design (http://orders.sigma-
genosys.eu.com). Finally the primer sequences were analysed using the Basic Local 
Alignment Search Tool (BLAST) to check for specificity to the genes of interest. 
Primers were synthesized commercially by Sigma-Genosys and re-suspended in 
ultrapure water for use at a concentration of 10 µM (for primer sequences see Appendix 
A.I). 
2.3.3.1.2 Polymerase chain reaction 
Conditions for the PCR were optimized by varying annealing temperatures from 
50°C to 68°C. The following conditions, resulting in a single strong band of the correct 
size, were chosen for amplification of the genes; 
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An aliquot of 1 µl 10 mM dNTP (containing the four deoxyribonucleotides: dATP, 
dCTP, dGTP and dTTP) was mixed with 1 µl of 1:100 diluted plasmid DNA 
(approximately 200 ng), 1 µl forward-primer (10 µM), 1 µl reverse-primer (10 µM), 0.5 
µl (2.5 U) Herculase hot-start polymerase, 5 µl Herculase 10x reaction buffer 
(Stratagene, Ca, USA) and 40.5 µl ultrapure water. 
 
The PCR was carried out according to the following scheme: 
95 ºC 2 min 
95 ºC 30 seconds 
65 ºC* 30 seconds      30 cycles 
72 ºC 1 min 
72 ºC 10 min  
4 ºC hold 
*or varied according to optimization  
 
For the PCR, used to amplify the gene from the cDNA library, the following solutions 
were employed: 
 
An aliquot of 1 µl 10 mM dNTP (containing the four deoxyribonucleotides: dATP, 
dCTP, dGTP and dTTP) was mixed with 1 µl (1 ng) Quick-clone cDNA universal 
human library (Clontech, UK), 1 µl forward-primer (10 µM), 1 µl reverse-primer (10 
µM), 0.5 µl (2.5 U) Herculase hot-start polymerase, 5 µl Herculase 10x reaction buffer 
(Stratagene), 1.5 µl DMSO and 39 µl ultrapure water. 
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The PCR was carried out according to the following scheme: 
95 ºC 2 min 
95 ºC 30 seconds 
60 ºC* 30 seconds      10 cycles      *decrease 0.5 ºC per cycle until 55 ºC 
72 ºC 3 min 
95 ºC 30 seconds 
55 ºC 30 seconds      25 cycles       
72 ºC 3 min 
72 ºC 10 min 
4 ºC hold 
 
2.3.3.1.3 Restriction digests 
The pGBKT7 and pGADT7 cloning vectors were digested with the restriction 
enzymes NdeI/BamH1 and NdeI/XhoI respectively. The pET15b plasmid already 
containing GABABR1a-CCP1 was digested with the restriction enzymes NdeI/BamH1, 
and the pET41 plasmids already containing FTM2 or FTM3 were digested with the 
restriction enzymes NdeI/XhoI. The pCR4blunt TOPO vector containing the amplified 
LAMA5 LG1-5 was digested with EcoR1, The pGADT7 vector was similarly digested 
with EcoR1.  
For the digest reactions the following procedure was adopted:  
 
Sample of 1 µg of DNA (plasmid DNA) were added to 1.5-ml Eppendorf tubes 
containing restriction-digest mix, which was made up of the following: 1 µl (20 U) Nde1 
and 1 µl (20 U) BamH1, 2 µl BamH1-buffer, 2 µl 10 x bovine serum albumin (BSA) and 
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11 µl ultrapure water (CCP1 construct) or 1 µl (20 U) Nde1 and 1 µl (20 U) Xho1, 2 µl 
10 x BSA, 2 µl buffer 4, and 11 µl ultrapure water (FTM2 and FTM3 constructs)/ 1 µl 
(20 U) EcoR1, 2 µl EcoR1-buffer, and 14 µl ultrapure water (LAMA5 LG1-5 construct) 
(all New England Biolabs). The DNA-digest mixtures were incubated at 37°C for 60 
minutes. The digested DNA products were analysed by SDS-PAGE and gel-purified 
using a kit from Qiagen. 
 
2.3.3.1.4 Ligation 
For ligation reactions the following procedure was used: 
 
An aliquot containing approximately 10 ng of PCR-product DNA was added to a 
ligation reaction volume including 1 µl (2000 U) ‘Quick T4 DNA ligase’, 10 µl 2x 
Quick ligation reaction buffer (132 mM Tris-HCl, 20 mM MgCl2, 2 mM dithiothreitol, 2 
mM ATP, 15% polyethylene glycol (PEG 6000), pH 7.6) (all from New England 
Biolabs), 50 ng restriction-digested and gel-purified vector. The reaction was incubated 
at room temperature for 10 minutes together with a negative control reaction (containing 
water instead of DNA insert). 
 
2.3.3.1.5 Transformation   
For transformations E. coli Top10 competent cells (Invitrogen CA, USA) were 
used. The following procedure was applied: 
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Top10 competent cells were transformed with products of ligation by heat shock. An 
aliquot of 50 µl of Top10 cells were removed from a -80 °C freezer and thawed on ice 
before a 5 µl aliquot of ligation mix was added and gently mixed. The mixture was left 
on ice for 30 minutes before the heat-shock step. The cell-ligation mix was incubated in 
a water bath at 42°C for 45 seconds and then placed on ice for two minutes. The cell 
mixture was resuspended in 1.0 ml of super optimal broth with catabolite repression 
(SOC) medium (Invitrogen) and incubated at 37°C with shaking at 200 rpm for 60 
minutes. Subsequently, 50-200 µl of the mix was plated on Luria-Bertani (LB) agar 
plates containing 50 µg/ml ampicillin and incubated at 37°C overnight. 
 
2.3.3.2 Yeast two-hybrid assay 
2.3.3.2.1 Preparation of plasmid DNA 
Colonies were picked from the selective plates and inoculated into 5.0 ml of LB 
medium containing 50 µg/ml ampicillin and incubated at 37°C with shaking overnight. 
Cells were pelleted by centrifugation at 13000 rpm for 60 seconds in a bench-top 
centrifuge (Eppendorf, Hamburg, Germany). Recombinant plasmids were purified from 
cell pellets by alkaline lysis using the Qiaprep miniprep kit (Qiagen, UK). Following re-
suspension of the cell pellet in buffer P1, cells were lysed by addition of buffer P2 for up 
to five minutes and then neutralized by buffer N3 and gentle mixing. The suspension 
was centrifuged for 10 minutes in the bench-top centrifuge to pellet the precipitate and 
the supernatant was transferred to a Qiaprep silica-gel membrane column. The column 
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was centrifuged at 13000 rpm for 60 seconds in the bench-top centrifuge and the flow-
through was discarded.  The DNA-containing membrane was washed with buffer PE, 
the flow-through discarded and the centrifugation step was repeated. Finally, the 
membrane column was transferred to a clean Eppendorf microfuge tube and the purified 
plasmid DNA was eluted with 50 µl double-distilled water by centrifugation at 13000 
rpm for 60 seconds. Plasmid DNA was analysed by analytical restriction-enzyme digests 
and PCR to confirm correct insertion of the gene, followed by DNA sequencing to 
confirm a correct reading frame. 
 
2.3.3.2.2 Yeast transformation 
Preparation of competent cells was undertaken using the following procedure: 
 
A 1-ml aliquot of YPDA media was inoculated with a fresh colony of Saccharomyses 
cerevisiae strain Y190 (one-three weeks old) and thoroughly resuspended by vortexing. 
The inoculated media were transferred to a 1-liter flask containing 50 ml of YPDA 
media. The culture was incubated at 30 ºC overnight until OD600 > 1.5, whereupon 30-40 
ml of the culture was transferred to a 2-liter flask containing 300 ml YPDA media and 
diluted in order to achieve an OD600 of 0.2-0.3. The culture was further incubated at 30 
ºC for 2-3 hours until OD600 reached 0.4-0.6 and cells where then pelleted at 1000 x g for 
five minutes at room temperature. The supernatant was discarded and the cell pellet was 
re-suspended in a total volume of 25-50 ml sterile H2O by vortexing, then centrifuged 
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again. The cell pellet was finally re-suspended in a volume of 1.5 ml freshly prepared 1 
x TE/LiAc buffer. 
 
The following protocol was used for transforming yeast cells: 
1. Prepare 10 ml of PEG/LiAc buffer 
2. Mix solutions containing 0.1 µg of pGBKT7-BD/Bait, 0.1 µg of pGADT7-
AD/prey and 0.1 mg of herring-testes carrier DNA in 1.5-ml Eppendorf tubes 
3. Add 0.1 ml of yeast competent cells to each tube. Mix by vortexing 
4. Add 0.6 ml of sterile PEG/LiAc solution to each tube, vortex at high speed 
5. Incubate at 30 º C for 30 minutes with shaking 
6. Heat shock for 15 minutes in a 42º C water bath 
7. Chill on ice for 1-2 minutes 
8. Spin for one minutes at 7000 rpm in table-top centrifuge (Eppendorf) 
9. Remove supernatant 
10. Re-suspend in 0.5 ml of H2O 
11. Plate 100 µl (50-150 µl) of cells on selective media 
 
2.3.3.2.3 Colony-lift filter assay 
Colonies were screened using a colony-lift filter assay. Colonies were lifted from plates 
onto Hybond-C nitrocellulose membranes (Amersham Biosciences, Uppsala, Sweden). 
Colonies containing the interacting proteins should produce galactosidase (Mel1 or LacZ 
selection) which produces a blue colour  in the presence of X-gal. The galactosidase 
assay was carried out according to the Clontech Matchmakers protocol with some 
alterations (0.4 mg/ml β X-gal instead of 0.32 mg/ml was used, and the filter was 
submerged in liquid nitrogen twice and allowed to thaw in between). The membranes 
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were incubated for up to eight-ten hours. Positive and negative controls were performed 
in parallel. 
 
The following protocol was used for colony-lift filter assay: 
1. Pre-soak Whatman filters in a petri dish containing 2.5-3 ml of z-buffer/X-gal 
solution 
2. Using forceps, place a Hybond-C nitrocellulose membrane over the surface of a 
plate of colonies to be assayed. Gently rub the filter with the forceps to help colonies 
cling to the filter 
3. Mark filter and plate with holes to identify orientation of filter with respect to agar 
4. Carefully lift filter off agar plate with forceps and transfer to pool of liquid 
nitrogen for 10 seconds 
5. Remove filter and let thaw. Repeat procedure 
6. Place filter, colony side up, on pre-soaked Whatman filter 
7. Incubate at 30 ºC until blue (positive) colonies appear 
 
 
2.3.3.2.4 Average intensity assay 
A representative selection of colonies was picked from a plate (five-ten colonies) 
and the mixed pool of colonies was streaked onto a Whatman filter and incubated for 
two days at 30 C. The same procedure was carried out for the negative and positive 
controls. A galactosidase assay was performed using the pool of colonies (an identical 
procedure as for colony-lift assay, except that the Whatman filter bearing the pool of 
colonies was transferred to liquid nitrogen and then placed on Whatman filter pre-
soaked in z-buffer/X-gal solution), to get an average intensity of colour arising from the 
 72 
putative interaction in the overall population. This made it easier to compare the 
intensities of colour arising from the interactions between GABABR1a-CCP1 and 
FTM2, GABABR1a-CCP1 and FTM3, and GABABR1a-CCP1 and LAMA5 LG1-5 with 
the positive and negative controls.  
 
For average intensity assay the following protocol was observed: 
1) Pick a representative selection of colonies (five-ten colonies) from the same plate 
and streak the mix onto a Whatman filter in a circular shape. Place the Whatman 
filter on a selective media agar plate and incubate for two days at 30 C 
2) Pre-soak unused Whatman filters in a petri dish containing 2.5-3 ml of z-buffer/x-
gal solution 
3) Transfer the colony bearing Whatman filter with forceps to pool of liquid nitrogen 
for 10 seconds 
4) Remove filter and let thaw. Repeat procedure if necessary 
5) Place filter, colony side up, on pre-soaked Whatman filter 
6) Incubate at 30 ºC until any blue colonies appear 
 
2.3.3.3 Immuno-dotblot assaying 
 
2.3.3.3.1 Generation of protein for immuno-dotblot assay 
Rat GABABR1aCCP1, (residues 17-98) -CCP2 (residues 96-159) and -CCP12 
(residues 17-159) were originally cloned by Dr Blein. The GABABR1aCCP12 
expressing P. pastoris KM71 strain was plated on minimal dextrose (MD) agar plates 
using sterile technique and grown for two days at 30 ºC. A single colony was used to 
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inoculate 10 ml of buffered minimal glycerol (BMG) medium. The starter culture was 
incubated at 30 ºC for two days with shaking at 250 rpm and then used to inoculate a 
further 1 litre of BMG medium which was divided equally into four 1-litre baffled 
conical flasks. The cultures were incubated for an additional two days at 30 ºC with 
shaking at 250 rpm (or until the OD600 nm reached approximately 14 units) in preparation 
for induction of GABABR1aCCP12 expression. The yeast cells were pelleted by 
centrifugation at 1800 g for five minutes at room temperature, the supernatant was 
discarded and the cell pellets were resuspended in 200 ml of buffered minimal methanol 
(BMM) medium. The cultures were then incubated at 25 ºC with shaking at 250 rpm to 
achieve induction of protein expression. The cells were pelleted by centrifugation and 
resuspended in fresh induction media daily, followed by continued incubation. The 
supernatant was filtered through a 0.2-µm syringe filter and stored at -20 ºC in the 
presence of 5 mM EDTA and 1 mM phenylmethanesulfonyl fluoride (PMSF) (final 
concentrations) while awaiting purification. The EDTA and the PMSF inhibit 
metalloproteases and serine proteases respectively. The P. Pastoris supernatants were 
filtered through a 0.2-µm filter and concentrated at 4 °C from 1 litre down to 20 ml 
using a N2-pressurized stirred cell (Millipore) containing a membrane with a molecular 
weight cut-off of various sizes depending on the protein. For CCP1-2 a 5000 Mw cut-off 
membrane was used, for CCP1 a 3000 Mw cut-off membrane and for CCP2 a 1000 Mw 
cut-off membrane was used for concentration of the supernatant. 
In preparation for purification the concentrated supernatants containing either 
CCP1 or CCP12 were buffer-exchanged into 12.5 mM sodium acetate (pH 5.3) while 
supernatant containing CCP2 was buffered in 50 mM sodium acetate (pH 4.6), using a 
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PD10 column (GE healthcare). A crude purification was carried out by cation-exchange 
chromatography using a MonoS column (Mono S HR 5/5, Amersham Biosciences, Little 
Chalfont, UK) operated at 1 ml/min on an AKTA FPLC system. A representative trace 
and corresponding SDS-PAGE gel of the initial purification step is shown in Figure 15. 
The protein was eluted with a 0–1 M NaCl gradient over 25 column volumes. The 











Figure 15 Initial purification of recombinantly expressed GABABR1aCCP12 by cation 
exchange chromatography 
Chromatogram to the left and SDS-PAGE to the right show separation of GABABR1aCCP12 
from host cell proteins when purified by MonoS cation-exchange chromatography. The A280 
absorbance trace, salt gradient and conductivity are shown in blue, pink and brown respectively. 
GABABR1aCCP12 with a molecular weight of 16.2 kDa is indicated by arrow. 
 
N-glycosylation sites present at Asn23 and Asn83 required deglycosylation with 
Endoglycosidase Hf (NEB, 6000 units/mg of recombinant protein) for 7 h at 37 °C for 
constructs CCP1 and CCP12. Traces of glycosylated material were removed by 
concanavalin A (conA)-sepharose chromatography (Amersham Biosciences). ConA 
binds molecules that contain α-D-mannose, and the cleaved protein was collected in 
flow-through mode. Endoglycosidase Hf was removed by cation-exchange 




chromatography using a MonoS column (a representative SDS-PAGE gel is shown in 










Figure 16 GABABR1aCCP12 final purification by MonoS cation exchange chromatography 
GABABR1aCCP12, sized 16.2kDa, was purified in three chromatography steps. Faint smaller 
molecular weight bands present in some preparations, as seen on this gel indicate small 
amounts of degradation products. The protein sample was run on 10-20% acrylamide Tris-HCl 
SDS-PAGE  under reducing conditions and stained with EZ Blue (Sigma). 
 
 
Yields of protein were in the order of 4-5 mg/l of growth medium. Protein 
concentrations were calculated from optical density measurements at 280 nm and a 
theoretical extinction coefficient based on the protein sequence (ProtParam Tool, 
available at www.expasy.org). The N-terminal sequence of each protein construct was 
confirmed by amino acid sequencing (Dr. A. Cronshaw, University of Edinburgh, UK). 


















Figure 17 SDS-PAGE showing the recombinantly expressed and purified GABABR1a 
modules CCP1, CCP2 and CCP12                                                                                                              
Samples were run on 10-20 % acrylamide Tris-glycine SDS-PAGE under reducing conditions 
and protein sizes are shown by the protein markers on the left side of the gels.  
 
2.3.3.3.2 Immunodetection of protein 
Western immunoblotting and co-immunoprecipitation techniques were not able 
to detect binding of laminin to GABABR1aCCP12. Indeed, no interaction could be 
detected in any method that involved running the protein on SDS-PAGE. A dot-
immunoblot was used as an alternative method for detection of these putative protein 
interactions.  
Dot-blot assays were carried out as follows: 
A sample containing 4 pmol of the potential partner protein (various sources of laminin, 
SDS-PAGE can be seen in Figure 30) were dotted on a nitrocellulose membrane and air-
dried for five minutes. Non-specific binding of antibodies was blocked by incubation of 
the membrane, in a 2% (w/v) solution of non-fat dried milk powder in tris-buffered 
saline (TBS), for one hour at ambient temperature. The membrane was then incubated in 
the presence of 2 µM GABABR1aCCP12 protein overnight. Following incubation, the 



















with antibodies. The membrane was incubated with a primary sheep antibody s908 
(raised against GABABR1aCCP1) diluted 1:100 in TBS-tween containing 2% (w/v) non-
fat dried milk powder at room temperature for two hours. The membrane was then 
washed three times for 10 minutes with TBS-tween containing 2% (w/v) non-fat dried 
milk powder, followed by incubation with a secondary monoclonal anti-sheep/goat 
antibody, A8062 (Sigma, Gillingham UK), for one hour at room temperature. The 
secondary antibody was diluted 1:25000 in TBS-tween with 2% (w/v) non-fat dried milk 
powder. The membrane was finally washed three times for ten minutes with TBS-tween. 
All incubations were carried out on a rocking platform. For detection of alkaline 
phosphatase, BCIP®/Nitro-blue tetrazolium chloride was employed and the alkaline 
phosphatase substrate kit (Sigma, UK) was used as a substrate for detection of alkaline 
phosphatase on immunoblots. The substrate tablet was dissolved in 10 ml of water and 







2.4.1 Establishment of the Y2H system for investigating of 
interactions mediated by the GABABR1aCCPs  
The C-terminal LG domains of laminin were selected as candidates for an 
interaction with the CCPs of GABABR1a as there is precedent for CCP module-LG 
domain interactions in the literature. A cartoon illustrating the composition of laminin 
can be seen in Figure 20. It was initially attempted to amplify the entire α5 chain from a 
human cDNA library. However, this fragment is very large (~400 kDa) and the attempt 
proved unsuccessful.  
In the present study, the cDNA encoding the gene for LAMA5 LG1-5 (residues 
2733-3695) was successfully amplified from a human cDNA library and inserted into 
the pCR®4Blunt-TOPO® cloning vector (Invitrogen, Paisley UK). The Nde1/Xho1 
restriction sites were incorporated by PCR and the DNA fragment was inserted into the 
Nde1/Xho1 sites of the cloning vector pGADT7 AD (Clontech) (Figure 18). Orientations 
and correct reading frames of all constructs were confirmed by restriction digests and 




















Figure 18 Y2H construct for LAMA5 LG1-5  
Double digest (restriction enzymes NdeI/XhoI) demonstrating that the construct containing the 
incorporated gene LAMA5 LG1-5 (2900 bp) was incorporated into the plasmid pGADT7. The full 
size of the construct (10840 bp) is demonstrated by its linearisation with restriction enzyme SalI.  
 
 
Furthermore, the cDNA encoding the gene for rat GABABR1aCCP1 (residues 17-98) 
was successfully amplified by PCR and inserted into the Nde1/Nco1 sites of the cloning 
vector pGBKT7 DNA-BD (Clontech). Additionally, cDNA encoding the genes of the C-
terminal tail of FTM2 (residues 1068-1184) and FTM3 (residues 377-493) were 
successfully inserted, separately, into the Nde1/Xho1 sites of the cloning vector 









Figure 19  Y2H constructs for CCP1, FTM2 and FTM3  
Double digests (restriction enzymes NdeI/XhoI and NdeI/NcoI respectively) demonstrating that 
constructs contained the incorporated genes. FTM2 and FTM3 (both 348 pb) were incorporated 
into the plasmid pGADT7. CCP1 (243 bp) was incorporated into the plasmid pGBKT7.  
2900 bp





















Figure 20 Cartoon illustrating the composition of laminin  
The protein consists of the three chains; α in green, β in red, and γ in blue. The α-chain contains 
five C-terminal LG domains, circled in red. Cartoon (Aumailley et al., 2005) 
 
2.4.1.1 Control experiments  
Prior to performing the Y2H assay, it was important to verify that the constructs 
were able to express protein. In order to establish this, in-vitro transcription-translation 
experiments were carried out to demonstrate protein expression. Yeast two-hybrid 
assays with single-construct transformations were employed to confirm that no construct 
gave a positive result when expressed alone. In vitro transcription-translation was used 
to ensure expression of protein by the genes encoding the GABABR1aCCPs, fibulin C-
terminal modules FTM2 and FTM3 and the LAMA5 LG1-5. [35S]-Cys-labeled protein 
fragments were prepared by in vitro transcription-translation of the plasmids used in the 
Y2H study employing the TNT® T7/SP6 coupled reticulocyte lysate system as described 
by the manufacturer (Promega). The in vitro transcription-translation assay was kindly 
performed by Dr Brian Collier, MRC Edinburgh. The reactions carried out using rabbit 
reticulocyte lysate demonstrated that the constructs were indeed able to produce the 
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desired proteins in vitro. As seen in the photographic film illustrating the transcription-
translation in Figure 21, the plasmid carrying the gene for GABABR1aCCP1 produced 
protein of the expected size (9.4 kDa), as did the plasmids for FTM2 (13.3 kDa) and 












Figure 21 Photographic film demonstrating the in vitro transcription-translation of 
constructs used in Y2H studies  
GABABR1aCCP1 (9.4 kDa), FTM2 (13.3 kDa) FTM3 (12.9 kDa) and LAMA LG1-5 (104 kDa) are 
successfully produced and of the correct size in vitro.  
 
 
Single-construct transformations were carried out for all constructs used in the 
present study as a negative control to confirm that no single protein gave a positive 
signal in the Y2H system. All constructs were individually transformed into S. 
cerevisiae and the recombinant organisms were tested for growth on media lacking 
specific nutritients and for enzymatic activity. No constructs were able to promote 
growth on media that lacked other nutrients than the specific one produced by that 
particular construct. Similarly, no construct alone promoted enzymatic activity when 






















shown to behave as desired and could subsequently be used in co-expression 










Figure 22 Single construct transformations  
All constructs were tested for suitability in the Y2H assay, to confirm that no construct alone 
could achieve enzymatic activity. All constructs tested negative by producing white/pink colonies. 
If a protein can produce enzymatic activity without an interacting partner, it would give a false-
positive result (blue colour). 
 
2.4.1.2 Co-expression of potentially interacting proteins 
The two plasmids pGBKT7 and pGADT7, containing bait and prey respectively, 
were co-transformed into the S. cerevisiae strain, AH109, employing a standard lithium 
acetate transformation protocol with some alterations (see below). Screening of 
transformants was carried out using nutritional markers by selecting for colony growth 
on low (-Leu/-Trp), medium (-Leu/-Trp/-His3) or high (-Leu/-Trp/-His3/-Ade2) 
stringency media plates. In accordance with standard procedures, low-stringency 
screening is used if the interaction is known to be weak or if the bait binds transiently 
with other proteins. In this case, a weak interaction and possibly multiple binding 







(-Leu/-Trp/-His3) stringency plates. Positive and negative controls were used in parallel 
with the test proteins, as summarised in Table 2. Positive clones were analysed for 
colony growth and β-galactosidase activity using an X-gal based colorimetric assay. 
In the current work colony growth and enzymatic activity as reflected in the 
development of a blue colour, were judged by eye. A test was considered to be weakly 
positives if it resulted in activation of just the LacZ reporter, while a strongly positive 
test is one where activation of both the LacZ and His3 reporter occurs. Thus potential 
interactions between pairs of proteins were categorized as follows. A ‘strong positive’ 
interaction was recorded if an intense blue/green colour developed, most or all of the 
colony area was colored in the average-intensity assay and rapid colony growth 
occurred. A‘weak positive’ interaction was characterized by the formation of colonies 
with a pale blue/green colour, only the outer edges of the colony area becoming colored 
in the average intensity assay and poor colony growth. A negative result i.e. ‘no 









Table 2 Controls for Yeast two-hybrid screening assays 
 
POSITIVE CONTROLS:  
 
pCL1     
Encodes the full-length Gal4 protein. 
 
pGBKT7-T + pGADT7-53 
SV40 large T-antigen and murine p53 protein are known to interact and therefore these 
colonies would be expected to be positive by Y2H. 
 
NEGATIVE CONTROLS:  
 
pGBKT7-T  
Encodes only a fusion of the SV40 large T-antigen and the Gal4 activating domain (i.e. no 
transactivating domain). 
 
pGBKT7-T + pGADT7-Lam  
SV40 large T-antigen and human lamin C are known not to interact with each other and 
therefore these colonies would be expected to be negative in the Y2H. 
 
Initially, transformation efficiencies were poor. A number of routes were 
subsequently explored with the aim of optimising the transformation protocol. For 
example, in an attempt to overcome the problem of a low number of transformants, the 
addition of DMSO prior to heat-shocking of the cells was excluded, which increased 
efficiency (since in this study, excluding this component from the transformation 
reaction generally increased the transformation efficiency by generating more colonies). 
Furthermore, the post-transformation incubation time was increased for some slow-
growing constructs and this was accompanied by close monitoring of enzymatic assay 
activity.  
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2.4.2 Validation of the interactions between GABABR1aCCP1 
and FTM2 and FTM3 
 
2.4.2.1 Colony-lift filter assay  
Co-transformations of the constructs for GABABR1aCCP1 and FTM2, as well as 
for the constructs for GABABR1aCCP1 and FTM3 were performed as described above. 
Positive clones were selected for on minimal media, transferred by lifting the colonies to 
nitrocellulose membranes and subjected to a colorimetric β-galactosidase assay. Each 
experiment was carried out in triplicate with consistent results. A strong positive 
interaction between GABABR1aCCP1 and FTM2 was observed, as can be seen in Figure 
23. On the other hand GABABR1aCCP1 and FTM3 show only a weakly positive result 

































Figure 23 Colony-lift filter assay  
The assay shows a strong positive result (blue colour) for the interaction between 
GABABR1aCCP1 and FTM2 (e and f) and a weakly positive result (blue colour) for the 
interaction between GABABR1aCCP1 and FTM3 (g). Arrows indicate positive clones. Positive 
controls (a and b) (blue), negative controls (c and d) (white).  
b)  POSITIVE CONTROL
pGBKT7-T + pGADT7-53
a)  POSITIVE CONTROL 
pCL1 
pGBKT7-TpGBKT7-T + pGADT7-Lam
d)  NEGATIVE CONTROLc)  NEGATIVE CONTROL
CCP1+FTM2 (low stringency )
c)  TEST





2.4.2.2 Average intensity assay 
In order to investigate the approximate strength of a putative interaction between 
these two proteins using the Y2H assay, a representative sample of the population 
consisting of ten colonies, was examined. To achieve this, the colonies were pooled and 
re-streaked on Whatman filter paper, and then analysed for growth and enzymatic 
activity. The intensity of enzymatic response was judged by eye and then classified 
(strong, weak or negative) according to the criteria listed above.  
The results from an average-intensity assay for the interaction of 
GABABR1aCCP1 with FTM2 and FTM3 are shown in Figure 24. The assay was 
repeated in triplicate and gave reproducible outcomes. These results confirm a strong 
positive result for the interaction between GABABR1aCCP1 and FTM2, and a weakly 
positive result for the GABABR1aCCP1 with FTM3 interaction. It may be concluded 
that GABABR1aCCP1 interacts more strongly with FTM2 than with FTM3, in the Y2H 
























Figure 24 Average-intensity assay for the putative interactions of GABABR1aCCP1 with 
FTM2 and FTM3  
Galactosidase assays were performed on a pool of ten colonies in each case. Low stringency 
assays: 1) Positive control T7+53 (blue) 2) Negative control T7+lamin (white/pink) 3) 
CCP+FTM2 gives a strong positive signal, 4) CCP+Fib3 gives a weakly positive signal. Medium-
stringency assay: 1) Positive control T7+p53 (blue), 2) CCP+Fib2 gives strong positive signal 
consistent with a physiologically meaningful interaction between these proteins, 3) CCP+Fib3 












Low stringency plate    ( -Leu/ -Trp)
1)  Positive control  T7+53 POSITIVE
2) Negative control T7+lam NEGATIVE
3) GABA B CCP1 +Fibulin2
4) GABA B CCP1+Fibulin3 TEST
Medium stringency plate   ( -Leu/ -Trp/-His)
1) Positive control T7 -t +53 POSITIVE
2) CCP1+Fib2 TEST
3) CCP1 +Fib 3 TEST
TEST
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2.4.3 Characterisation of the potential interaction between 
GABABR1aCCP1 and laminin α5 LG 1-5 
 
2.4.3.1 Colony lift assay 
Co-transformations of the constructs for GABABR1aCCP1 and LAMA5 LG1-5 
were performed as described earlier. Positive clones were selected for on minimal 
media, transferred by colony-lift to nitrocellulose membranes and subjected to β-
galactosidase assay. Each experiment was carried out in triplicate and delivered 
consistent results. 
A weakly positive result was obtained for the interaction between 
GABABR1aCCP1 and LAMA5 LG1-5 as shown in Figure 25. No colony growth was 
observed on medium- or high-stringency plates, (i.e. with three or four sources of 

































Figure 25 Colony-lift filter assay showing a weakly positive result for the potential 
interaction of GABABR1aCCP1 with LAMA5 LG1-5  
Positive controls (blue colour) are shown in a) and b) and negative controls (white/pink colour) 
are shown in c) and d) (as summarized inTable 2). e) shows a weakly positive outcome for the 
interaction between GABABR1aCCP1 and LAMA5 LG1-5 on low-stringency plates (blue colour). 
b)  POSITIVE CONTROLa)  POSITIVE CONTROL 
pGBKT7-T + pGABT7-Lam
pGBKT7-T + pGADT7-53pCL1 





2.4.3.2 Average-intensity assay 
The results from an average-intensity assay for the interaction between 
GABABR1aCCP1 and LAMA5 LG1-5 are shown in Figure 26. The assay was 
performed in triplicate with reproducible results. The weakly positive signal obtained is 














Figure 26 Average-intensity assay  
β-galactosidase assays were performed on a pool of ten colonies in each case. 1) Positive 
control- T7+p53 (blue), 2) Negative control- T7+lamin (white/pink) 3) GABABR1aCCP1 + 
LAMA5LG1-5 exhibits a weak or transient interaction as indicated by the weakly positive result  
(blue) of Y2H under low-stringency conditions. 
 
2.4.3.3 Immuno-dotblots 
Immuno-dotblots were used as a means of providing an alternative approach to 
the investigation of interactions between the CCP modules of GABABR1a and laminin. 
A nitrocellulose membrane was dotted with a variety of laminin-derived fragments and 
Low stringency plate    ( -Leu/ -Trp)
1)  Positive control  pGBKT7-T + pGADT7-53 POSITIVE
2) Negative control T7+lam NEGATIVE
3) GABAB CCP1 + LAMA5 LG1-5 TEST
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then incubated with recombinantly expressed GABABR1aCCP12 prior to washing (as 
described previously). The membrane was then probed with GABABR1aCCP1-specific 
antibody, followed by an alkaline phosphatase conjugated secondary antibody (as 
described in 0) which was detected with BCIP®/Nitro-blue tetrazolium chloride alkaline 
phosphatase substrate. The experiment was performed in triplicate and gave 
reproducible results.  
There is literature precedence for an interaction between CCPs of C4BP and LG 
modules of protein S (Fernandez and Griffin, 1994; Hardig and Dahlback, 1996; Hardig 
et al., 1993; Hillarp and Dahlback, 1990). In a collaborative experiment (J. White, 
personal communication) an interaction of GABABR1aCCP12 was detected with one or 
more components in a commercial preparation of laminin, using a pull-down assay. This 
source of laminin contains the chains α5, β1 or β2 and γ1. Hence, recombinantly 
expressed LAMA5 LG1-3 and LAMA5 LG4-5 (kindly provided by Dr. Sasaki, Max-
Planck Institute) were tested for interaction with GABABR1aCCPs. As illustrated by the 
immuno-dotblot in Figure 27, a positive signal was observed for LAMA5 LG4-5, while 
only a very weak interaction was inferred for LG1-3. However, laminin-1 (α1, β1, γ1) 
seemed to interact relatively strongly with the CCPs, which suggests the presence of 
















Figure 27 Immuno-dotblot demonstrating the interaction of GABABR1aCCP12 with several 
laminin preparations  
Nitrocellulose membrane was probed with alkaline phosphatase-conjugated GABABR1aCCP1 





2) Laminin from human placenta
3) Laminin- 1 4) LAMA5 LG1-3




2.5.1 The Y2H was established as a system to investigate 
protein-interaction partners of the GABABR1a CCP 
modules 
A striking feature of the GABAB receptor is the presence in the extracellular 
domain of the GABABR1a subunit of two CCP modules. These modules are of a type 
that, in other proteins, has been shown to engage in specific protein-protein interactions. 
The identification of physiologically relevant protein interaction partners for the CCP 
modules of GABABR1a could open up a new line of investigation since it might point to 
novel functions of the receptor. The proteins of the ECM are obvious candidates. The 
current work involved establishing whether previous, mainly unpublished, reports of 
interactions with laminin and fibulin could be confirmed and elaborated upon. 
The first task was to establish in the lab appropriate techniques for investigating 
protein-protein interactions. Initially, it was necessary to address the question: Is the 
yeast two-hybrid (Y2H) system a suitable method to use in the study of weak 
interactions such as are suspected to occur between the GABABR1aCCPs and fibulin, 
and GABABR1aCCPs and laminin? Although the Y2H is primarily used for high-
throughput screening of interacting proteins, there is literature precedent for its use in 
investigating known or suspected interaction between two proteins (Miernyk and 
Thelen, 2008; Mukherjee, 2001). The concern once the system has been established is to 
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analyse the data vigorously and judge whether the outcome is reliable. A major potential 
pitfall is the occurrence of false-positive results. To minimize the possibility of false-
positive readings in the present study, clones were re-tested, and only classified as true 
positives in cases where an interaction was observed in both colony-lift and average-
intensity assays. The YTH results were then cross-checked by performing an alternative, 
independent assay based on immuno-dotblot (Rual et al., 2005; Stelzl et al., 2005). 
Another drawback of Y2H is that the test proteins are generally overexpressed, thus 
artificially enhancing the concentration of the potential binding partners. To minimize 
this problem, the Y2H system employed in the current study uses low-copy number 
plasmids. With this approach there remains a risk of false-negatives due to low 
expression (Lalonde et al., 2008). 
Although the Y2H system has the benefit of being a eukaryotic, in vivo, method 
it could be argued that expression of mammalian proteins in non-native cells, i.e. yeast 
cells in this case, may not allow for correct protein folding and post-translational 
modification. Pertinent to the current study, the extracellular protein domains under 
investigation, expressed as fusion proteins with Gal4 domains may not appear as folded 
entities in the yeast nucleus (i.e. where they need to be if they are to contribute to 
transcription factors). In particular, proteins imported into the nucleus are unlikely to 
contain disulphide bonds (such as are present within CCP modules, for example) due to 
the reducing environment within both the cytoplasm and nucleoplasm. Nonetheless, 
there are several examples in the literature of the use of Y2H to detect protein 
interactions between extracellular proteins (Lee et al., 2005; Overall et al., 2002; Oxford 
et al., 2004). The nucleus may be regarded as a ‘less stressful’ environment compared to 
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the cell surface, and therefore it is possible that some protein domains will fold correctly 
despite the absence of stabilizing disulphide bridges, as has been further argued in the 
literature (Overall et al., 2002). In this respect it is interesting to note that CCP1 of 
GABABR1a is a natively unfolded domain that presumably folds upon binding to an 
interaction partner (Blein et al., 2004). 
 
2.5.2 Screening for GABABR1aCCP1 interaction with fibulin-2 
(FTM2) and potentially with fibulin-3 (FTM3) 
It was successfully demonstrated in the present study that the proposed 
interaction of GABABR1aCCP1 with the C-terminal fragment of fibulin-2, FTM2, is 
detectable using the Y2H. This result confirms and strengthens unpublished data 
collected by Dr Julia White (personal communication). An interaction of the 
GABABR1aCCP1 with the equivalent domain of fibulin-3, FTM3, could not be 
conclusively identified by Y2H in the current study. A GABABR1aCCP1/FTM2 
interaction was later confirmed by pull-down experiments (Blein et al., 2004).   
The possibility that both modules (i.e. CCP12) are required for the interaction with 
FTM3 was investigated using immuno-dotblots where the double module was used as an 
interacting partner (data not shown). Still no interaction could be detected for FTM3. 
The observation by Y2H that GABABR1aCCP binds to FTM2 over FTM3 is intriguing. 
The fibulin fragments used in the present study are the C-terminal fragments, and there 
is 20% sequence identity between them as shown in Figure 28, approximately 28% of 




Figure 28 Sequence alignment of C-terminal fragments of fibulin-2 and fibulin-3 used in 
the current Y2H study 
24 of 116 residues are identical ~ 20%. 33 of 116 residues are conserved substitutions ~ 28%  
 
 
2.5.3 The putative interaction between the CCP modules of GABABR1a 
and laminin has been further characterised 
It the current study, a weak or transient interaction of the GABABR1aCCP1 with 
the LAMA5 LGs was demonstrated by Y2H, although it is very close to the detection 
limit. Indeed less colony growth was observed (in colony-lift assays) for the 
GABABR1aCCP1:LAMA5 LG1-5 interaction compared to the weak or transient 
GABABR1aCCP1:FTM3 interaction described in the previous section.  By using the 
immuno-dotblot technique, a more definite result for interaction with laminin was 
obtained. It was also successfully demonstrated by immuno-dotblot that several 
commercially available sources of laminin interact with GABABR1aCCP12.  It was 
further determined by immunoblotting that α5 LG4-5 out of the five LG modules of the 
C-terminal fragment of LAMA5 is sufficient for this interaction. It was hypothesized 
that by testing laminin-1 (α1, β1, γ1), a negative result would help to rule out the β1 and 
γ1 chains as participating interaction partners. However, a positive result was obtained. 
Nonetheless, this potentially physiologically relevant interaction of a CCP module from 
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the GABAB receptor with LAMA5 LG1-5 adds a second example of CCP modules that 
interact with LG domains, discussed previously in the case of C4BP (Fernandez and 
Griffin, 1994; Hardig and Dahlback, 1996; Hardig et al., 1993; Hillarp and Dahlback, 
1990).  
In the immuno-dotblot assay, the recombinantly expressed GABABR1aCCP12 
double module, rather than the single CCP1 module, was used when screening for the 
laminin interaction. Although the first CCP module (CCP1) appears to be sufficient for 
interaction according to surface plasmon resonance (Chapter 3), the second CCP module 
(CCP2) may help to stabilize the interaction. The use of CCP12 in the immuno-dotblot, 
might explain why this assay gave a stronger positive result (compared to Y2H) for the 
interaction with the LAMA5 LGs. 
It therefore remains to be tested if CCP1 is sufficient for the interaction with 
laminin as tentatively inferred from Y2H. Alternative techniques for verifying protein-
protein interactions detected by Y2H include surface plasmon resonance-based methods 
and isothermal titration calorimetry (ITC) techniques. Detection of a transient or weak 
interactions may require special techniques such as chemical cross-linking (Miernyk and 
Thelen, 2008; Trakselis et al., 2005). Further work using surface plasmon resonance is 
described in Chapter 3.   
 In conclusion, this chapter has shown for the first time that laminin is an 
interacting partner for GABABR1aCCP1, and that the α5 LG domains appear to be 
involved in this interaction. Furthermore, the binding of the C-terminal fragment of 

























 The first aim was to establish in our laboratory surface plasmon resonance 
(SPR), performed on a Biacore instrument, as an independent biochemical technique by 
which to verify the interaction of the GABABR1aCCP modules with the extracellular 
proteins laminin-1 and laminin-10/11.  The second aim was to use SPR to assess the 
extent to which one or both of the CCP modules are required for these interactions. The 
third aim was to employ SPR to investigate which domains or fragments of laminin are 




There exists substantial literature precedent for direct participation of CCP 
modules in protein:protein interaction sites. These small disulfide-stabilised protein 
modules have a conserved three-dimensional structure that serves as a framework for the 
support of variable loops and turns endowing considerable potential diversity in 
molecular recognition capabilities. Typically, two or three contiguous CCP modules 
contribute to a specific protein-binding site. It is therefore noteworthy that it is the 
presence or absence of the tandem pair of N-terminal CCP modules in GABABR1 that 
distinguishes the two most abundant receptor isofoms. The possibility that these 
modules mediate interactions with other proteins is intriguing; such interactions might 
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introduce a previously unobserved pharmacological distinction between the receptor 
isoforms, or they might be important in establishing differences in spatial or temporal 
distributions of receptor sub-types. Identification and characterisation of the putative 
binding partners is therefore highly desirable. Results obtained from the Y2H study (see 
Chapter 2) encouraged further investigation of the involvement of the CCP modules in 
the proposed interaction with laminin.  
 
3.3 Materials and methods 
 
3.3.1 Surface Plasmon Resonance Theory 
 Surface plasmon resonance (SPR) is a phenomenon that occurs when plane-
polarised light strikes the interface between two media of different refractive indices. In 
the Biacore system the interface occurs between a glass sensor chip and aqueous buffer. 
The glass, which has a higher refractive index than the buffer, is coated with a gold film. 
Total internal reflection is a condition that pertains when a light beam hits this interface 
at a specific angle called the plasmon resonance angle, θSPR, and is reflected back into 
the medium from which it came. Under these circumstances the incoming light causes 
free electrons (plasmons) on the gold surface to resonate. 
 Binding of molecules to the matrix on the back of the gold surface (furthest away 
from the glass) causes a change in refractive index. This can be detected as a change in 
the plasmon resonance angle. There are various types of sensor chips. The most common 
one, the CM5 chip, has a carboxymethylated dextran matrix attached to the back of the 
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gold surface. One of the interacting proteins, called the ligand, is covalently attached to 
the matrix (e.g. by amine coupling) while the putative binding partner, called the 
analyte, is passed over the surface of the sensor chip at a set flow rate. A binding event 
results in a change in the refractive index, which is detected in a real-time sensogram. 
The sensogram shows binding as resonance units (RU) versus time, where the resonance 
units represent the change in θSPR. One resonance unit corresponds approximately to the 
binding of one picogram per mm2 of analyte. Surface plasmon resonance can be used to 




3.3.2.1 Buffers and reagents 
Table 3 List of buffers and reagents used during the current study  
 
Buffer* Reagent 
Sensor chip activation solution 1:1  N-hydroxysuccinimide (NHS) : N-ethyl-N-
(3-dimethyl-aminopropyl)carbodiimide (EDC) 
Coupling buffer 10 mM sodium acetate, pH 4.0/4.5/ 5.0/ 5.5 
Regeneration buffer 30 mM or 50 mM NaOH 
HBS-P+ running buffer 0.01 M HEPES, 0.15 M NaCl and 0.05% v/v 
Surfactant P20, pH 7.4 





3.3.2.2 Sensor chips 
Table 4 List of sensor chips used during the current study 
Sensor chip* Description 
Series S sensor chip CM5 (certified) carboxymethylated dextran 
Series S sensor chip SA (certified) carboxymethylated dextran pre-immobilized with 
streptavidin for immobilization of biotinylated 
interaction partners 
Series S sensor chip NTA (certified)  carboxymethylated dextran pre-immobilized with 
nitrilotriacetic acid (NTA*). His-tagged molecules are 
immobilized via Ni2+/NTA chelation 
*All sensor chips were supplied by Biacore. 
 
3.3.2.3 Proteins 
The protein laminin-1 was purchased from Sigma (product number: L2020, from 
basement membrane of Engelbreth-Holm-Swarm mouse sarcoma) while laminin-10/11 
was purchased from Chemicon (catalogue number AG56P, from human placenta). 
Recombinantly expressed laminin fragments α1 LG1-3, α1 LG4-5, α5 LG1-3 and α5 
LG4-5 were generously provided by Dr Takako Sasaki, Max-Planck Institute for 
Biochemistry. The analyte proteins GABABR1aCCP1, -CCP2 and -CCP12 were cloned, 
recombinantly expressed and purified as described in Chapter 2. The CCP module-
containing proteins were exchanged into sodium acetate buffer, freeze-dried and, prior to 
running SPR experiments, resuspended in HBS-P+ running buffer (see Table 3). Protein 
concentrations were determined by measuring absorbance (280 nm) on an Ependorf 
BioPhotometer. All proteins were analysed by 10-20% acrylamide tris-glycine SDS-




























Figure 29 10-20 % tris-glycine SDS-PAGE showing the protein used in the SPR study  
As previously shown in figure 17. Samples were run under reducing conditions and protein sizes 
are shown by the protein markers on the left side of the gels. The gel was run as described in 
the standard methods. GABABR1aCCP1, -CCP2 and -CCP12 are all of a high standard of purity 












Figure 30 SDS-PAGE showing laminin proteins used in the SPR study  
Left-hand side: (5% TBE gel) Full-length laminins. Lane 1) Laminin-1 (mouse sarcoma- 
L2020). The individual chains appear as the dominant 400-kDa and 200-kDa bands under 
reducing conditions, although several additional bands in the region of 35 to 130 kDa are also 
visible.  Lane 2) Laminin-10/11 (human placenta- AG56P); in this pepsinised preparation the  
dominant bands appear as approximately 130 kDa, 160 kDa and 200 kDa, although several  
smaller bands in the region of 60 kDa and 100 kDa are just visible. Right-hand side: (10-20 % 
tris-glycine gel) laminin fragments. Lane 1) α5 LG4-5. The dominant band is 40 kDa, but  
degraded protein or contaminants are visible by SDS-PAGE. Lane 2) Recombinant β1 VI/V. The 
dominant band is 60 kDa, but some minor contaminants are present. Lane 3) LN73. The 
dominant band is 75 kDa and this preparation appears fairly clean by SDS-PAGE. Lane 4) 
LN65. The dominant band is 25 kDa, however this band appears degraded and smeary by SDS-
PAGE. Lane 5) LN78. This fragment of 450 kDa consists of three chains that have been 
pepsinised and would be expected to run separately under reduced conditions. In fact, a range 












3.3.3.1 The Biacore T100 instrument 
 The SPR data was collected on a Biacore T100 system in the School of 
Biological Sciences at the King’s Buildings, University of Edinburgh. The T100 system 
features four detector flow-cells, which can be used in single, paired or serial runs. 
Running buffer or buffered sample solution is passed through the flow-cells 
continuously. In the following experiments, the flow-cells were used pair-wise and 
treated identically, except that the ligand was immobilised on only one flow-cell. Thus 




 Pre-concentration of ligands on the CM5 sensor surface was performed by means 
of electrostatic attraction. This procedure was performed to optimise conditions for the 
subsequent immobilisation. The ligand in coupling buffers of different pH values was 
passed over an inactivated sensor surface. Effective pre-concentration should take place 
at a pH that lies between the pKa of the dextran surface (pH 3.5) and the isoelectric point 
of the ligand (Figure 31). The pre-concentration of the ligand at various pH values is 
shown in a series of sensograms in Appendix B.I, a representative example is illustrated 









Figure 31 Illustration of pre-concentration of the ligand on the chip sensor surface by 
electrostatic attraction at a suitable pH. 
Pre-concentration should take place at a pH that lies between the pKa of the dextran surface (pH 
3.5) and the isoelectric point of the ligand. Under these conditions the overall charge of the 
protein will be positive and the charge of the dextran surface will be negative, creating an 
electrostatic interaction between the two. 
 
The example shown is for GABABR1aCCP12 passed over an untreated sensor surface at 













Figure 32 Sensogram of pre-concentration of GABABR1aCCP12  
The ligand was diluted in four differenly pH-ed buffers (see key), injected over the chip surface 
and analysed for electrostatic attraction to the chip surface. On this basis, pH 5.5 was selected 



























sTime (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5













3.3.3.3 Immobilisation of ligand 
The ligands in this study were immobilised on CM5 chips unless otherwise 
stated. Alternative sensor chips used in the current study were SA- and NTA chips. 
Ligands were covalently linked to the dextran matrix of the CM5 chip using amine 
coupling, which is the most common method. The amine-coupling chemistry is 
illustrated in Figure 33. Immobilisation was carried out by activating the sensor surface 
with a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and thereafter attaching the ligand via its amine 
groups at a flow rate of 5 µl/min. Any unbound active ester groups on the sensor surface 
were then deactivated using ethanolamine, pH 8.5. A reference surface was created by 









Figure 33 Amine-coupling chemistry on the surface of a CM5 chip  
The dextran matrix is represented by the long, patterned vertical line. The ligand attaches to the 






































 A representative sensogram recorded during immobilisation of a ligand is shown 
in Figure 34, which is for amine-coupling of laminin-1 to a CM5 chip. All sensograms 
recorded for ligand immobilisations can be found in Appendix B.II. A stock of the 
ligand at 20-30 µg/ml was made up in coupling buffer at pH values between 4.5 and 5.5 
(depending on pre-concentration data, Table 5) and passed over the activated surface of 
flow-cell 2. A reference surface was created on flow-cell 1, as described earlier. The 
optimal amount of ligand that should be immobilised on the sensor surface was 
determined by Equation 1, where Rmax was set to 100. The amount of laminin-1 
immobilised on the chip corresponded to 5070 response units (RU). 
 






ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 RU to     
minimise mass transfer 
 
Rmax was set to 100 RU 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
analyte (CCP1-2)  : 16 200 Da 
ligand (laminin-1)  : 800 000 Da     

























Laminin-1  30 µg/ml 5.0 4938 Ru 5070 Ru 800 000  
Laminin-
10/11  
40 µg/ml   4.0 455 Ru 390 Ru (pepsinised) 
CCP12  10 µg/ml  5.5 81 Ru 235 16 200  
CCP12 
(SA*) 
50 nM - 235 Ru 230 Ru 16 200 
α1 LG1-3 20 µg/ml 5.5 506 Ru 612 Ru 82 000 
α1 LG4-5 20 µg/ml 5.5 272 Ru 465 Ru 44 000 
α5 LG4-5 
(NTA*) 
200 nM - 493 Ru 429 Ru 40 000 













Figure 34 Immobilisation of the ligand laminin-1 on a CM5 sensor chip  
The dashed red line highlights the baseline before immobilisation, and the brace shows the 
increase in baseline after immobilisation. The amount of ligand immobilised produced a 
response of 5070 RU. 
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 Streptavidin coupling was performed by first conditioning both the SA sensor-
chip test surface and reference surface with three injections of 1 M NaCl in 50 mM 
NaOH followed by an injection of a 50 nM solution of biotinylated CCP12 on the test 
surface. When the desired immobilisation was reached, the remaining active groups 
were blocked by an injection of 1 mM biotin on both surfaces. 
 His-tag coupling was performed by conditioning both the NTA sensor-chip test 
surface and the reference surface with two injections of 50 mM NaOH, followed by an 
injection of 500 µM NiSO4 in HBS-P+ buffer over the test surface. Both surfaces were 
stripped with 350 mM EDTA in PBS-P+. Finally the test surface was primed with 500 
µM NiSO4 in HBS-P+ followed by injection of His-tag labelled protein to desired 
immobilisation level. 
 
3.3.3.4 Analyte binding 
All analyses were performed on a Biacore T100 at a flow-rate of 30 µl/min. Prior 
to injection of analyte, both flow-cell surfaces were equilibrated with HBS-P+ buffer. 
Individual analytes at various concentrations were injected over both the flow-cell that 
contained immobilised ligand, and over the reference flow-cell (containing no ligand), 
for 60 or 180 seconds and association data were collected.  The surfaces were then 
washed with HBS-P+ buffer for a further 300 seconds and dissociation data were 
collected. After each injection the chip surface was washed with regeneration buffer; 20 
mM NaOH was chosen as the regeneration buffer because 50 mM MgCl2, 1 M NaCl 















Figure 35  Regeneration scouting  
Various methods of regeneration were investigated in order to break up the interaction 
complexes under study, prior to a new injection of analyte. The sensogram shows a trace from 
the active surface (not reference-subtracted). MgCl2, glycine and NaCl all proved unsuccessful 
at regenerating the surface. Sodium hydroxide successfully regenerated the surface; 
unfortunately it could destroy the active protein surface over time so only a very low 
concentration of 20 mM was used.  
 
 
3.3.3.5 Data analysis 
 Data were analysed, and the association and dissociation constants (ka and kd), 
were calculated, using the Biacore T100 evaluation software version 1.1. In some cases 
the kinetic rates of binding and dissociation were too fast to fit accurately to sensogram 
curves, and therefore ka and kd could not be measured. Determination of the affinity 
constant (KD), which is calculated as the concentration of ligand required to occupy 50% 
of available binding sites, was also attempted; however this was not possible in cases 
























3.4.1 Determination of the interaction of GABABR1aCCP 
modules with laminin-1 and laminin-10/11 
 The results of the SPR experiments are shown in figures 36-41, where the 
laminin-10/11 interaction with the various GABABR1a modules are illustrated in figures 
36-38 and the laminin-1 interaction with the modules are illustrated in figures 39-41. 
The results show that the double module GABABR1aCCP12 binds to laminin-10/11 
immobilised on a CM5 chip (Figure 36). This interaction had previously been 
demonstrated in immuno-dotblot assays (as illustrated in 2.4.3.3). The sensograms show 
that the predominant mode of binding involves fast-on, fast-off kinetics consistent with a 
low (e.g. Kd = 10-4 – 10-3 M) affinity. Furthermore, as shown in Figure 39, 
GABABR1aCCP12 also binds to immobilised laminin-1.  In this case, there are at least 
two components to the sensorgrams; a fast-on, fast-off (low affinity) process is 
superimposed on a much slower association/dissociation (higher affinity). It proved 
unfeasible to extract any reliable affinity constants from this data, as the response does 
not reach equilibrium. Interestingly, the number of response units recorded for the 
interaction with laminin-1 is greater than obtained with laminin-10/11 despite the same 
level of each laminin having been coupled to the chip (100 RU) – this implies laminin-1 
has, overall, a higher affinity for GABABR1aCCP12 compared to lamininin-10/11. 
 The binding of single-module, GABABR1aCCP1, to the immobilised laminin-
10/11 (Figure 37), is dominated by a slow association rate (ka = 150 ms-1) and a complex 
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dissociation curve that has a very slow component. Due to strong binding of CCP1 to 
both laminin surfaces, the regeneration protocol is insufficient at successive higher 
concentrations of analyte, which explains the poor reproducibility obtained for the 
highest CCP1 concentrations in the binding level plot (Figure 42). Attempts to fit the 
sensorgrams to various models – 1:1 binding, bivalent analyte, two-state reaction – were 
unsuccessful and therefore it was not possible to extract a Kd value for this interaction. 
Nonetheless, the overall slow-on/slow-off behaviour is consistent with a high-affinity 
aspect to the binding. The sensorgrams for GABABR1aCCP1 binding to laminin-1 
(Figure 40) are particularly difficult to interpret and could be explained in several ways 
including the possibility of non-specific aggregation/precipitation at the chip surface – 
therefore these data were not considered further.   
In the case of GABABR1aCCP2, binding to both laminin-10/11 (Figure 38) and 
laminin-1 (Figure 41) produces very low responses, although there is some evidence of 
slow on and off-rates. Furthermore, the interaction appeared to have reached saturation 
prior to the end of the injection, which was not the case for the CCP1 module 
interaction. In summary, module CCP2 shows a much weaker binding compared to both 
the CCP1 module (for laminin-10/11) and the CCP12 double module. 
In general, the analyses of the interactions studied were reproducible, as 
indicated by the superimposable response curves of the duplicate injections; the 





























Figure 36  Sensogram illustrating the binding of the GABABR1aCCP12 to laminin-10/11  
The CCP12 module-pair was injected over the sensor surfaces at concentrations ranging from 
100 nM - 100 µM (see key, concentrations in nM). The inset shows the proteins tested for 
interaction in the experiment. Adjustment of sensogram consists of the reference readings 













































































Figure 37  Sensogram illustrating the binding of the GABABR1aCCP1 to laminin-10/11  
The CCP1 module was injected over the sensor surfaces at concentrations ranging from 100 nM 














































































Figure 38  Sensogram illustrating the binding of GABABR1aCCP2 to laminin-10/11 
The CCP2 module was injected over the sensor surfaces at concentrations ranging from 100 nM 

















































































Figure 39 Sensogram illustrating the binding of GABABR1aCCP12 to laminin-1  
The CCP12 module-pair was injected over the sensor surfaces at concentrations ranging from 

















































































Figure 40 Sensogram illustrating the binding of GABABR1aCCP1 to laminin-1  
The CCP1 module was injected over the sensor surfaces at concentrations ranging from 100 nM 















































































Figure 41 Sensogram illustrating the binding of GABABR1aCCP2 to laminin-1  
The CCP2 module was injected over the sensor surfaces at concentrations ranging from 100 nM 



































































Figure 42 Binding level plots providing an overview of the binding levels of the 
GABABR1aCCP modules to laminin-10/11 and laminin-1 respectively  
Plot A represents binding to immobilised laminin-10/11. Plot B represents binding to immobilised 
laminin-1. Each green point represents a binding response, injected ligands (in increasing 
concentrations) are labelled below the plots. Due to the difficulties in regenerating the chip 
surface after CCP1 injections, the last data points exhibited poorer reproducibility i.e. duplicate 




 To further verify the binding, GABABR1aCCP12 was immobilised on a CM5 
chip in order for the interaction to be studied in reverse, i.e. using laminin as the analyte. 
However, this proved unsuccessful initially, as the amine-coupled CCP modules 
appeared not to bind laminin-1 or laminin-10/11 (data not shown). An alternative 
immobilisation strategy for immobilisation was therefore used, whereby 
GABABR1aCCP12 that had been labelled with biotin (previously, by Dr Stan Blein) was 
coupled to a streptavidin-coated (SA) sensor-chip surface. In this new format, 
GABABR1aCCP12 was successfully shown to bind to laminin-1 (Figure 43); a weak but 
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strategy for immobilising GABABR1aCCP12 was adopted for further studies involving 









Figure 43    Laminin-1 binds to immobilised GABABR1aCCP12  
The biotinylated CCP12 was immobilised on an SA-sensor chip surface. A sensogram resulting 
from injection of 1 µM laminin-1 demonstrates binding to GABABR1a-CCP12. The reference 


















Figure 44   Laminin-10/11 binds very weakly to immobilised GABABR1aCCP12  
Biotinylated CCP1-2 was immobilised on an SA sensor chip. The sensogram illustrates an 
injection of 0.5 µM laminin-10/11 and shows that the protein is binding weakly but detectably to 
GABABR1a-CCP12 immobilised in this orientation. The reference reading has been subtracted 






































3.4.2 Screening of laminin fragments as interaction partners for 
GABAB receptor modules CCP12  
 A range of laminin fragments was employed to map the potential protein 
interaction domains within laminin. These had been recombinantly expressed, or 
obtained by digestion of full-length laminin, and subsequently purified by Dr Takako 
Sasaki. 
 
Table 6 Fragments of laminin screened for interaction with GABABR1aCCP12. The fragments 
are shown in Figure 45. 
 
Fragment MW (kDa) 
LN 86 (fullength laminin-1) 800 
L2020 (laminin-1) [Sigma] 800 
LN 78 (E1X-Nd) 450 
LN 65 (E10) 25 
LN65a (P1X) 350 
LN73 (E4) 75 
Recombinant α1 VI/V 60 
Recombinant α1 VIb/IIIa 150 
Recombinant β1 VI/V 60 
Reconbinant γ1 VI/V 60 
Recombinant α1 LG1-3 82 
Recombinant α1 LG4-5 44 
Recombinant α5 LG1-3 57 






















Figure 45 Overview of laminin fragments used in screen, as described in Table 6                 
The laminin fagments were either recombinantly expressed or digested from intact laminin and 
purified (provided by Sasaki). The chains are coloured as previously described in Figure 10. 
 
Sensograms for the different laminin fragment binding (or otherwise) to CCP12 are 
shown in Figure 46.
A      B
LN86 (Laminin-1)  1 µM     
          
Figure 46 Sensograms showing the range of laminin fragments described in Table 6 
injected over immobilised GABABR1a-CCP12 
The reference readings have been subtracted from the data. Inserted image illustrate the laminin 
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Figure 46 continued.  
Spikes seen at the beginning/end of injections are due to running- and sample buffers not being 
perfectly matched. The reference readings have been subtracted from the data. The responses 
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Figure 46 continued. Sensograms showing the range of laminin fragments described in 
Table 6  injected over immobilised GABABR1a-CCP12 
The reference readings have been subtracted from the data. The responses can also be found 






























































































































































K      L 






















































M       N 
 a5 LG4-5      3 µM       





















































Figure 46 continued. 
Spikes seen at the beginning/end of injections are due to running- and sample buffers not being 
perfectly matched. The α1 LG4-5 fragment gives a negative response, indicating that the 
fragment binds non-specifically and more to the reference surface. The reference readings have 




























































































 The sensograms obtained from SPR experiments in which these fragments were 
injected over biotin-immobilsed GABABR1aCCP12 are shown in Figure 46. 
Interestingly, the shapes of the sensograms for the interaction between α1 LG1-3 and 
GABABR1aCCP12 are similar to those of the difficult-to-interpret sensograms obtained 
for the laminin-1/ GABABR1aCCP1 interaction; this might suggest similar events - 
aggregation or precipitation, for example - occurring in both cases. The interaction 
between α5 LG4-5 and GABABR1aCCP12, on the other hand, is the most convincing, 
and appears to be of higher affinity compared to the other fragments screened. This 
result is in agreement with the immuno-dotblots (Section 2.4.3.3). The α1 LG4-5 
fragment gives a negative response, which is most likely caused by nonspecific binding 
to the reference surface. The LG4-5 of the α1- and α5 chains are 25% identical (and 











Figure 47 Sequence alignment of laminin α1 lG4-5 and α5 lG4-5 
 CLUSTAL 2.0.10 multiple sequence alignment 
 
 
Lama1_LG4-5      KKLSVELSIRTFASSGLIYYMAHQN--QADYAVLQLHGGRLHFMFDLGKGRTKVSHPALL 58 
Lama5_LG4-5      NWPSLSMHVLPRSSRGLLLFTARLRPGSPSLALFLSNGHFVAQMEGLG-TRLRAQSRQRS 59 
                 :  *:.: : . :* **: : *: .  ... *::  :*  :  * .**  * :..      
 
Lama1_LG4-5      SDGKWHTVKTDYVKRKGFITVDGR---ESPMVTVVGDGTMLDVEGLFYLGGLPSQYQARK 115 
Lama5_LG4-5      RPGRWHKVSVRWEKNRILLVTDGARAWSQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSK 119 
                   *:**.*.. : *.: ::..**    ..       :*:       :::****:. :: * 
 
Lama1_LG4-5      IGNITHSIPACIGDVTVNSKQLDKDSPVSAFTVNRCYAVAQEGTYFDGSGYAALVKEGYK 175 
Lama5_LG4-5      LP-VTVGFSGCVKRLRLHGRPLGAPTRMAGVTP-CILGPLEAGLFFPGSGGVITLDLPGA 177 
                 :  :* .:..*:  : ::.: *.  : ::..*     .  : * :* *** .  :.     
 
Lama1_LG4-5      VQSDVNITLEFRTSSQNGVLLGISTAKVD-AIGLELVDGKVLFHVNNGAGRITAAYEPKT 234 
Lama5_LG4-5      TLPDVGLELEVRPLAVTGLIFHLGQARTPPYLQLQVTEKQVLLRADDGAGEFSTSVT--R 235 
                 . .**.: **.*. : .*::: :. *:.   : *::.: :**::.::***.::::      
 
Lama1_LG4-5      ATVLCDGKWHTLQANKSKHRITLIVDGNAVGAESPHTQSTSVDTNNPIYVGGYPAGVKQK 294 
Lama5_LG4-5      PSVLCDGQWHRLAVMKSGNVLRLEVDAQSNHTVGP-LLAAAAGAPAPLYLGGLPEPMAVQ 294 
                 .:*****:** * . ** : : * **.::  : .*   :::..:  *:*:** *  :  : 
 
Lama1_LG4-5      CLRSQTSFRGCLRKLALIKS 314 
Lama5_LG4-5      PWP--PAYCGCMRRLAVNRS 312 
                      .:: **:*:**: :* 
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In order to compare the responses for each fragment used in this interaction 
study, the response was reported as ‘RUs per kilodalton’ (kDa) (Table 7). This was 
necessary as the response signal measured depends on the molecular weight of the 
analyte - i.e. a large analyte gives a larger RU value than a small analyte for the same 
number of molecules bound to the sensor surface. 
 
Table 7 Responses, normalised for molecular weight, obtained on the Biacore T100 when 
various laminin fragments were injected over GABABR1aCCP12 immobilised on a CM5-sensor 
chip.  
 
Fragment CCP12  response 
(RU) for 3 µM 
ligand, unless 
otherwise stated 
Analyte MW(kDa) Normalised 
response 
(RU/kDa) 
LN 86 (laminin-1) 5 (1 µM) 800 0.0063  (0.19*) 
LN 78 (EX1Nd) 13.6 450 0.030 
LN 65 (E10)  3.2 25 0.13 
LN65a (P1X) 2.2 350 0.006 
LN73 (E4) 2.2  (2 µM) 75 0.029 (0.044*) 
Recombinant α1 VI/V 2.6 60 0.043 
Recombinant α1 VIb/IIIa 0.2 150 0.0013 
Recombinant β1 VI/V 0.2 60 0.0033 
Reconbinant γ1 VI/V 0.4 60 0.0067 
Reconbinant α1 LG1-3 24.7 82 0.20 
Reconbinant α1 LG4-5 -5.9 44  - 
Reconbinant α5 LG1-3  0.1 57 0.0018 
Reconbinant α5 LG4-5 41.9 39.5 1.1 
L2020 (laminin-1) 85.0 (1 µM) 800 0.11 (0.31*) 
* If further normalised to a 3 M analyte concentration, and based on an assumption that this 













Figure 48 Bar graphs illustrating a comparison of the responses for each laminin 
fragment 
The two bar graphs show the two alternative analyte normalisations discussed in Table 7. The 
fragments α5 LG4-5, α1 LG1-3, LN 65 (E10) and full length laminin-1 (L2020) (figure 46, panel 
M, panel J, pandel D and panel N respectively) appear to bind the best to GABABR1aCCP12. 
However, from inspection of the sensograms inFigure 46, the interaction of α1 LG1-3 is 
questionable and might be an artefact of precipitation. 
  
 Since laminin-1 and laminin-10/11 had been shown to interact with 
GABABR1aCCP12, both in immuno-dotblot assays (see Section 2.4.3.3) and by SPR it 
was decided to investigate these interactions in more detail. The recombinantly 
expressed α1 LG1-3 and α1 LG4-5 (i.e. fragments from the α-chain of laminin-1) and α5 
LG4-5 (i.e. a fragment of laminin-10/11) were immobilised (by amine-coupling) on a 
CM5 chip surface. The active surfaces were used to test for binding of some or all of 
GABABR1aCCP12, -CCP1 and -CCP2. No detectable binding could be demonstrated 
(data not shown). In an alternative strategy, a hexa-His-tagged version of α5 LG4-5 
(provided by Dr Takako Sasaki) was immobilised on a NTA sensor chip; injection of 
GABABR1aCCP12 over this sensor chip yielded sensorgrams (Figure 49) that are 
similar, overall, to the results obtained when the double CCP module contruct was 
flowed over immobilised full-length laminin (Figure 39). Evidence for binding to α5 



































































































































LG4-5 immobilised on the NTA-chip was also obtained for both GABABR1aCCP1 
(Figure 50) and GABABR1aCCP2 (Figure 51), however, as with full-length laminin-1, 

















Figure 49 Sensogram illustrating the binding of GABABR1aCCP12 to α5 LG4-5  
The CCP12 double module was injected over the NTA sensor chip surfaces at concentrations 
ranging from 100 nM - 100 µM (see key, concentrations in nM).  Adjustment of sensogram was 









































































Figure 50 Sensogram illustrating the binding of GABABR1aCCP1 to α5 LG4-5  
The CCP1 single module was injected over the NTA sensor chip surfaces at concentrations 

















































































































Figure 51 Sensogram illustrating the binding of GABABR1aCCP2 to α5 LG4-5  
The CCP2 single module was injected over the NTA sensor chip surfaces at concentrations 





















































































As was mentioned previously, there is a substantial precedent for the 
involvement of CCP modules at sites of interaction between two proteins. Most 
examples in the literature are drawn from the mammalian complement system 
(Kirkitadze and Barlow, 2001). The β-strand rich three-dimensional structures of CCP 
modules feature loops and turns of diverse length and sequence that are conducive to 
specific molecular recognition processes. Furthermore, the cooperation of tandem CCP 
modules, connected by a short linker of non-conserved residues, in formation of a 
common binding site adds a further dimension of potential diversity. Frequently, the 
CCP modules concerned lie at the N-terminal end of the protein; for example, N-
terminal CCP modules of factor H, C4b-binding protein alpha-chain, membrane cofactor 
protein, and complement receptor types 1 and 2, all participate in protein-protein 
interactions. In the case of the GABAB receptor it is the presence of the pair of an N-
terminal pair of CCP modules in GABABR1a that distinguished it from GABABR1b, 
these being the two most abundant receptor subtypes (Hawrot et al., 1998).   
 As was described in the Introduction, the N-terminal CCP module of the GABAB 
receptor module-pair has properties characteristic of a natively unstructured domain 
(despite the presence of two intact disulphides) (Blein et al., 2004) – such domains may 
adopt a more compactly folded form upon binding to a partner in interactions that are 
often “low-affinity but high-specificity” in nature, and are typical of multivalent cell-cell 
or cell-extracellular matrix contacts (Dyson and Wright, 2005; Blein et al., 2004) 
Indeed, the previous chapter presented evidence - based on yeast-two-hybrid (Y2H) 
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studies (reinforced by immuno-dotblots) – suggesting the extracellular matrix proteins 
laminin and fibulin serve as protein binding partners for the GABABR1a N-terminal 
region. The second of the GABABR1a CCP modules is compactly folded and has the 
appearance of a typical CCP-module structure – in theory it could serve as a mere 
spacer, or it could provide the initial binding contacts with a partner protein in an 
interaction that involves subsequent folding of the N-terminal module.  
Thus – based on the literature, biochemical intuition and the results of the 
previous chapter - various theories presented themselves in respect of the functional role 
of the GABABR1a CCP module pair. Our first hypothesis was that there is a directly 
detectable interaction (corresponding to the one that can only be inferred from the Y2H 
results) between one, or both, of the GABABR1a CCP modules and one or more 
domains of the abundant extracellular matrix protein laminin (or fibulin).  This notion 
progressed to a model for binding in which the two modules act in a synergistic manner 
when it comes to recognition of ECM proteins with the N-terminal module providing 
most of the specificity and a slow off-rate for the complex, while the second module 
contributes binding energy to the initial encounter. In turn, the formation of a specific 
complex with laminin (for example) could modulate pharmacological activity, or 
localise receptors to specific regions of the cell surface, or have developmental 
consequences – for example in modulation of synapse formation or neurite outgrowth. 
This is studied further in chapter 4. 
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3.5.1 Surface plasmon  resonance (SPR) verified interaction of 
GABABR1a CCP modules with laminin-1 and laminin-10/11 
Some of these ideas were tested by the work described in this chapter (and some 
will be tested in the work of the next chapter). In particular, the interaction with laminin 
warranted further investigation due to the predominance of this protein as a major 
constituent of basal lamina. Biochemical support (in addition to the previously reported 
immuno-dotblots) and quantification were required to back up the Y2H study and hence 
to add credibility to a claim for this putative protein-protein interaction being 
physiologically relevant. This was particularly important for the current study since the 
physiological interactions under investigation are extracellular in nature while Y2H is a 
technique that detects interactions as they occur between two proteins on the regulatory 
region of a gene within the nucleus.  Having established the existence of a biochemically 
detectable interaction (discussed below), it was desirable to identify which domains or 
modules of the respective proteins are involved. With respect to the two 
GABABR1aCCP modules it was hoped to establish their relative contributions and 
whether they cooperate in binding. On the laminin side, it was important to discover 
which domains are involved in the interaction since this might shed light on which 
members of the laminin family (see Introduction) are likely to be involved; moreover 
knowledge of whereabouts on the large laminin molecule the CCP module(s) dock could 
have implications for the functional consequences of the interaction.  
The method of choice in this study was surface plasmon resonance on the basis 
that it uses relatively small amounts of material and can detect and quantify weak 
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interactions. From the GABAB receptor side, constructs containing one or both of the 
two CCP modules were convenient to work with although they do not provide any 
insight on the potential role of the remainder of the large extracellular domain(s) in the 
interaction. The commercially available laminin-1 is a preparation from mouse 
Engelbreth-Holm-Swarm tumors, which produces large amounts of basement 
membrane. The main components of the basement membrane of mouse sarcoma are 
laminin and type-IV collagen. Traces of collagen are removed by subsequent high-salt 
(1.7 M NaCl) extractions, followed by DEAE-cellulose separation; nonetheless a small 
amount of contamination by this protein may be present as evident by several further 
bands in the range 35–130 kDa that are apparent on SDS-PAGE below the predominant 
laminin bands of 440 kDa and 220 kDa (Figure 30). The laminin-1 preparation thus 
contains naturally synthesised protein that is likely to be correctly folded and processed. 
The commercially available laminin-10/11 preparation (mainly laminin-10) was 
prepared from human placenta, by high-salt extraction and mild pepsin digest followed 
by affinity purification using a monoclonal anti-laminin antibody. Small protein 
contaminants were present in addition to the expected pepsinised 130 and 160 kDa 
components, according to analysis by SDS-PAGE. Furthermore, the mild pepsin 
treatment may have damaged binding sites present on the protein, which may explain 
why this preparation appears less potent than laminin-1 at binding GABABR1aCCP12. 
Overall, the laminin-1 preparation appeared to be cleaner and less heterogeneous than 
the laminin-10/11 preparation.  
The SPR results presented in this chapter confirm that a direct interaction occurs 
between laminin-1 and the double module GABABR1aCCP12. The sensorgrams 
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obtained (Figure 39) show clearly that the interaction is dominated by a “slow-on; slow-
off process”.  Such an observation normally reflects high-affinity binding (i.e. in the 
sub-µM range). While it did not prove possible in the current work to extract an accurate 
Kd from the experimental data, this inference of tight binding supports the physiological 
relevance of the originally Y2H-based finding. Although an interaction does not need to 
be tight in order to be important (for example it may be part of a multi-valent cell-cell 
interaction), a higher-affinity interaction is less likely to be non-specific.  The difficulty 
in fitting the SPR data to any of the standard models for intermolecular interactions 
arises from what appears to be a convolution of a tight and a weak interaction; and this 
has a number of possible explanations.  It might be that only a portion of the laminin-1 
preparation is fully active; according to such a theory, this fully functional population of 
molecules is responsible for the high-affinity component of the sensorgram, while 
superimposed on this could be weaker binding (to for example clipped or unfolded 
laminin-1 molecules). Another theory is that the procedure of amine-coupling used for 
immobilisation of laminin-1 on the carboxymethylated dextran matrix of the sensor chip 
would have generated a heterogeneous mixture of orientations of the bound molecule 
and therefore the complete or partial occlusion of a range of potentially important 
binding surfaces.  There is also the potential for two physiological binding sites – with 
very different affinities - for CCP modules on the same laminin-1 protein molecule.  
Finally, from the perspective of the GABAB receptor, it is feasible that the natively 
unfolded state of CCP1 could result in a more complex mode of binding than that 
represented in any of the models utilised by the fitting software.  For example, the 
requirement for folding on the surface of laminin might not affect the measured on-rate 
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(dominated by the initial encounter) but could disfavour dissociation (as monitored by 
the off-rate). Such a complex curve will not fit a standard 1:1 fit, while using a complex 
model or exponentials will not necessarily give a more meaningful model (Rich and 
Myszka, 2008). 
It was subsequently shown that, in respect of binding to full-length laminin-1, neither of 
the single CCP modules yielded SPR data (Figure 40 and Figure 41) that was as 
convincing as the equivalent data obtained with the double module (Figure 39). In the 
case of the N-terminal module, CCP1, it was not possible to detect much dissociation of 
module from the laminin-bearing chip surface.  This could reflect either a very slow off-
rate due to formation of a tight complex; but it could also reflect irreversible 
precipitation of the unfolded module on the matrix (albeit in a laminin-dependent 
manner, since data from the control flow-cell has been subtracted from the curves 
shown). The CCP1-laminin-10/11 interaction (Figure 37) furthermore appears to be 
partially limited to mass transport at higher concentrations of analyte, increasing the risk 
of re-binding of analyte before it can diffuse away. On the other hand, CCP2 produced 
only a very small number of response units in the SPR experiments with laminin-1.  
Overall these data (for CCP1, CCP2 and CCP12 binding) are consistent with the idea 
that CCP1 is the dominant interaction site and binding involves a kinetically complex 
reaction in which CCP1 adopts a more compact fold upon binding to its target. They are 
also not inconsistent with the idea that the two modules participate cooperatively in the 
binding process - CCP2 provides an initial weak docking surface, while CCP1 provides 
the specificity.  
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The results in this chapter also confirm that the GABABR1aCCP modules bind 
lamininin-10/11 although this is a “fast-on: fast- off process” (Figure 36).   This is at 
first sight a curious result given the slow-on: slow-off binding observed with laminin-1.  
It is important to recall (see above) that the laminin-10/11 preparation contains 
pepsinized molecules (while laminin-1 does not) – and that overall the laminin-10/11 
preparation has more degradation problems than the laminin-1. Given this inferior 
quality it is somewhat surprising that CCP1 alone appears to binds laminin-10/11 with 
slow off- and on-rates– it is worth scrutinising the data and observing that this latter 
interaction gives rise to a higher number of response units compared to CCP12. It might 
be that what is being observed here is binding to a subpopulation of the molecules on the 
chip that are functionally intact.  
 
3.5.2 Screening of laminin fragments for binding to 
GABABR1aCCP12 
In a subsequent more detailed study of the interaction between laminin and 
GABABR1a, a range of truncated proteins covering large parts of the vast laminin 
molecule (although excluding the coiled-coil region) were investigated as potential 
binding partners. A goal here was to explore which of the laminin domains contributes 
most prominently to the interaction. The truncated products screened in this study 
included both pepsinised native laminin fragments and recombinantly expressed regions 
of laminin. Some of the preparations appeared to contain contaminations and/or 
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degradation as judged from SDS-PAGE (Figure 30), however it was not attempted to 
purify these fragments further due to very limited amount of available material. 
Protein:protein interactions involving laminins are generally complex in nature 
as a consequence of their very large size and the presence of numerous domains and 
multiple chains. While laminin was reported to interact with its 67-KDa receptor via an 
EGF-like domain on its short beta arm (Panayotou et al., 1989), most cellular receptors 
of laminins (including integrins, dystroglycan and syndecan) interact with the globular 
(LG) domains or the VI domain of the long alpha-chain (Suzuki, Yokoyama, Nomizu, 
2005). In the light of these results, it is intriguing (Figure 51) that a His-tagged laminin 
LG4-5 construct, immobilized on the SPR sensor chip, exhibited “slow-on, slow-off” 
binding kinetics with GABABR1aCCP2 (and a response of over 400 RU). This 
interaction between CCP modules and LG4-5 was also detected by SPR performed in 
the inverse sense (Figure 46, panel 15) with the GABABR1a CCP12 immobilized on the 
chip and LG4-5 as analyte, although the response is smaller (41.9 RU for a 39.5-kDa 
fragment) and the on- and off-rates are somewhat higher. It is difficult to ensure that 
immobilization of the CCP12 modules mimics their orientation in vivo, allowing full 
access to binding sites. Biotinylated protein was shown to be more active than protein 
immobilised with standard amine-coupling. However, the CCP12 modules appear to be 
more active as an analyte. Indeed all of the studies performed with immobilized 
GABABR1aCCP12 produced small responses that require cautious interpretation. 
For example, it appears that fragment LN78 (Figure 46, panel B) bound 
significantly more strongly to immobilised CCP12 than did LN65a (13.6 RU compared 
to 2.2 RU - these fragments are similar in molecular weight, i.e. 450 and 350 kDa, 
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respectively). This is interesting as the very weakly (or non-) binding LN65a fragment is 
identical to LN78 with the exception of the N-terminal V/VI domains of all three chains 
(see Figure 52). The LN73 and LN65 fragments, which correspond to the N-terminal 
two domains of the β1 chain present in laminin-1 and laminin-10/11, respectively, 
showed only weak binding (giving rise to 2.2 RU and 3.2 RU for these small fragments 
of 75 and 25 kDa, respectively). The recombinantly expressed fragment β1 V1/V also 
bound weakly (3.6 RU for a 60-kDa fragment) to CCP12. The recombinantly expressed 
α1 LG1-3 fragment gave a significant response of 24.7 RU (82-kDa fragment). 
However, the sensogram looks similar to that obtained for CCP1:laminin-1 (Figure 40), 
with little or no dissociation, which may suggest precipitation on the sensor chip surface. 
Overall, according to this survey of fragments (summarized in Figure 52), the LG 
domain region appears to dominate the interaction with CCPs, while other regions may 










Figure 52 Cartoon illustrating an overview of the binding laminin fragments in the current 
study 
Laminin fragments LN78, LN73, LN65 and β1 V1/V contribute to binding of GABABR1a CCPs, 
while the recombinant α5 LG4-5 fragment appears to dominate the interaction. The response 
seen for the recombinant α1 LG1-3 fragment may be caused by precipitation on the sensor chip 
surface.  
 
A similar situation may prevail for the interaction with acetylcholinesterase; it was 
recently reported that acetylcholinesterase also interacts with these LG domains, 
specifically with the alpha chain LG4 domain (Johnson et al., 2008), while a previous 
report (Paraoanu and Layer, 2004) had implicated the beta chain IV domain of laminin 
in acetylcholinesterase binding. This suggests the intriguing possibility of GABABR1a/2 
competing for the same binding sites on laminin as acetylcholinesterase. Finally it is 
worth reiterating that CCP modules of C4BP bind LG domains of Protein S (Hardig and 
Dahlback, 1996; Hardig et al., 1993; Hillarp and Dahlback, 1990; Fernandez and Griffin, 
1994) and therefore a CCP-LG interaction is not unprecedented.  
 
 




















The first aim of the work described in this chapter was to establish, in our 
laboratory, Xenopus laevis oocytes as a model system with which to characterize some 
functional aspects of the GABAB receptor. The second aim was to use a two-electrode 
voltage clamp technique to investigate pharmacological differences between the oocyte-
expressed isoforms GABABR1a and GABABR1b. The third aim was to use this 
technique to investigate pharmacological responses to the agonist, baclofen, of the 





The function and pharmacology of the GABAB receptor have previously been 
studied extensively in Xenopus oocytes and membrane preparations (Billinton et al., 
1999; Pfaff et al., 1999; White et al., 1998) Nonetheless, the functional role of the two 
N-terminal CCP modules of GABABR1a remained unclear. In the previous two chapters, 
it was established that these CCP modules are able to mediate interactions between the 
receptor and the extacellular matrix.  Not only were such interactions detected in a Y2H 
approach, they could also be measured in an in vitro setting using surface plasmon 
resonance.  For example in the case with laminin-1, the interaction displays slow-
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on/slow-off characteristics that are consistent with specificity and high-affinity (as 
opposed to a random non-specific interaction). This interaction was dominated by 
contacts between the CCPs and laminin α5 LG domains 4 and 5. Such an observation 
immediately raises the question: what is the functional role of this interaction?  One 
possibility is that laminin modulates the response of the receptor to GABA. In this 
respect it is worth noting that GABA, as well as being the dominant inhibitory 
neurotramitter in adult CNS, contributes to many developmental processes (Bolteus, 
2006). Acting through both the ionotropic and metabotropic GABA receptors, GABA 
can influence cell proliferation and neuronal migration (Manent and  Represa 2007). 
These cellular processes are intimately associated with the extracellular matrix that 
provides both physical support for cells and the medium through which they move and 
communicate. Thus some complex interplay between GABA, the GABAB receptor and 
the extracellular matrix could exist, with the CCP modules playing a central role. If 
laminin binding modulates the affinity of the receptor for GABA, this should be 
detectable using standard pharmacological approaches. In the current study the 
pharmacology of the two isoforms and the potential functional impact of the presence of 









4.3 Materials and Methods 
 
 
4.3.1 Xenopus laevis oocyte expression system  
The oocyte from the South African clawed toad, Xenopus laevis, is a well-
characterised and extensively used model system within the field of molecular 
pharmacology. Notably the surface of the oocyte bears few endogenous ion channels and 
receptors, which makes it a suitable model for studying expression and function of 
recombinantly expressed ion channels and receptor proteins in vivo. Ovaries in adult 
female frogs mainly contain stage V and VI oocytes, which are fully grown (~1.2 mm in 
diameter) and best suited for experimental studies.  The cells have a characteristic 
division into two halves: the pale white-yellow vegetal pole, and the dark-brown animal 










Figure 53 Xenopus laevis toad and oocyte  
To the left: an image of a South African clawed toad, Xenopus laevis. To the right: an image of 
oocytes undergoing micro-injection. The animal and vegetal poles are clearly visible in dark 









4.3.2.1 TEVC reagents 
 
Table 8 Buffers and reagents used during all two-electrode voltage clamp (TEVC) experiments 
for characterisation of the GABABR1a and GABABR1b isoforms 
 
Buffers Reagent 
Barth’s solution, pH 7.35 88 mM NaCl 
1 mM KCl 
2.4 mM NaHCO3 
0.82 mM MgCl2 
0.77 mM CaCl2 
15 mM Tris-Hcl 
50 IU/ml penicillin 
50 µg/ml streptomycin 
 
TEVC external buffer “low [K]” 
adjusted to pH 7.35 with 1 M NaOH 
115 mM NaCl 
2.5 mM KCl 
1.8 mM CaCl2 
10 mM Hepes 
10 µM EDTA 
 
TEVC external buffer “medium [K]” 
adjusted to pH 7.35 with 1 M NaOH 
90 mM NaCl 
25 mM KCl 
1.8 mM CaCl2 
10 mM Hepes 
10 µM EDTA 
 
TEVC external buffer “high [K]” 
adjusted to pH 7.35 with 1 M NaOH 
75 mM NaCl 
40 mM KCl 
1.8 mM CaCl2 
10 mM Hepes 
10 µM EDTA 
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Table 9 Drugs and concentrations used for TEVC experiments.  
All drugs were diluted to the desired concentration in ‘TEVC external buffer med [K+]’ (Table 8). 
All reagents were supplied by Tocris (Bristol UK) 
 
Drugs Concentrations 
Baclofen (GABAB receptor agonist)  1 µM, 3 µM, 10 µM, 100 µM 




4.3.2.2 Primer design  
The sequences of the genes under investigation were confirmed using 
www.ensemble.org. Primers were designed using Sigma-Genosys software, synthesized 
commercially by Sigma-Genosys and re-suspended in ultra-pure water for use at a 
concentration of 10 µM. (For the sequences of primers used in this study, see Appendix 
C.I). 
 
4.3.2.3 Constructs encoding GABAB receptor subunits and GIRK 
subunits 
Constructs encoding the genes for human GABABR1a, GABABR1b, GABABR2 
and rat inward-rectifying potassium (KIR) channel subunits GIRK3.1 and GIRK3.4 
were obtained from Dr Julia White (GlaxoSmithKline, Stevenage UK) (GABABR1a) 
and Dr Randy Hall (Emory University, Atlanta, USA) (all others). GABABR1a had been 
cloned into the expression vector pcDNA3.1 (Invitrogen) and RNA transcription in vitro 
is driven by the T7 promoter. GABABR1b, GABABR2 and KIR channel subunits 
GIRK3.1 and GIRK3.4 had been cloned into the expression vector pSGEM (as 
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illustrated in Figure 54), which is a modified version of pGEMHE, optimised for 
Xenopus oocyte expression since it contains 3’ and 5’-untranslated regions (UTR) from 
Xenopus -Globin and a polyA tail (Villmann et al., 1997). These help stabilise the RNA 
transcript and aid translation in the oocyte.  RNA transcription in vitro is driven by the 










Figure 54 Plasmid maps  
Left hand side: Plasmid diagram of pSGEM, a plasmid derived from pGEMHE (Liman et al., 
1992). Right hand side: Gene-Plasmid maps illustrating the additional MCS in the plasmid 






4.3.3.1 Generation of a new GABABR1a construct 
The GABABR1a construct in vector pCDNA3.1, as supplied at the outset of this 
work, failed to transcribe cRNA in vitro. Restriction-enzyme digestion and automated 
sequencing of the construct revealed an additional multiple-cloning site in the plasmid 












resulted in a separation of the T7 promoter from the gene encoding GABABR1a 
following the digestion step used to linearise the plasmid. Several alternative strategies 
were therefore explored in an attempt to overcome this problem and achieve higher 
expression levels of the GABABR1a isoform. A direct cloning approach to moving the 
GABABR1a cDNA from the pcDNA3.1 vector to the alternative, Xenopus-optimised, 
pSGEM vector was hindered because there were no mutually compatible restriction sites 
shared between the multiple cloning sites of the respective vectors. A subsequent 
attempt at introducing appropriate restriction sites by PCR amplification of the entire 
R1a gene proved difficult.  
 
4.3.3.1.1 Incorporation of restriction sites utilising an oligo nucleotide adapter 
An adaptor was designed to incorporate new restriction sites into the pSGEM 
vector (Villmann et al., 1997). The adaptor consisting of two oligonucleotide sequences 
that were designed so that when allowed to anneal, external overhangs would result in 
matching restriction sites for NotI and XhoI; an internal restriction site for XbaI was also 
included within the sequences (Figure 55). Subsequently, the vector pSGEM was 
digested with the restriction enzymes Not1 and Xho1, and an attempt was made to 
incorporate the adaptor into the pSGEM vector.  The final steps would have entailed 
digestion of pSGEM and pcDNA3.1 with Xba1/Xho1, and then incorporation of the 
digested GABABR1a insert into pSGEM. Due to difficulties encountered in annealing 
the two short oligoneucleotide sequences to each other, under a range of annealing 
conditions, no product could be detected. Note that due to the small size of the adaptor - 
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approximately 20 base pairs - it was difficult to follow the attempted creation of the 











Figure 55 Illustration of adaptor designed to incorporate desired restriction sites into the 
pSGEM vector.  
 
 
4.3.3.1.2 Cloning the gene for GABABR1a into pRSSP  
In response to these difficulties, a new construct for GABABR1a expression was 
generated in the pRSSP vector (derived from the pSP64T vector) (Veyhl et al., 2006), 
which contains many of the elements present in the pSGEM vector used for the other 
constructs, and is particularly well-suited for facilitated expression in Xenopus oocytes 
(Kuner and Schoepfer, 1996). The pRSSP construct was generated using a multistep 
cloning approach (Figure 65).  
 
pSGEM digested 










GABAB R1a in pRSSP
Gene insert
T7 promoter





Digest of  2nd ½ R1a
 
Figure 56 Two-step cloning approach 
 A two-step cloning approach was used to insert the GABABR1a gene into the pRSSP plasmid, 
in which part of the GABABR1a gene was amplified by PCR and inserted into pRSSP followed 
by insertion of the remaining part of gene by restriction digests. 
 
 
To minimise the risk of mismatched base pairs when amplifying such a relatively large 
gene, a fragment was generated by PCR-amplifying only the first part of the GABABR1a 
gene (Figure 58) from the previously prepared pcDNA3.1D/V5-His-TOPO construct, 
incorporating new AflIII and BglII sites. The pRSSP vector was digested with restriction 
enzymes NcoI and BglII (Figure 58), and the PCR-generated fragment of the 
GABABR1a gene was incorporated into pRSSP (the AlfIII and NcoI recognition sites are 





Recognition Site AlfIII: 
 
Recognition Site NcoI: 
 
 
Figure 57 The restriction enzymes AlfIII and NcoI have compatable recognition sites 
AlfIII has a degenerate site, which means that the enzyme will recognise both A and G in the ‘R’ 














Figure 58 Agarose gel for first cloning step  
Left-hand side: digest of pRRSP vector with restriction enzymes NcoI and BglII to separate 
vector from previously (unrelated) incorporated gene. The upper band of 2955 bp was gel 
purified. Right-hand side: PCR amplification of the first half of the GABABR1a gene to 
incorporate new AflIII and BglII sites. 
 
 
In step 2 of the procedure, the second half of the GABABR1a gene was digested from 
pcDNA3.1D/V5-His-TOPO using BglII/XhoI and the resulting fragment was inserted 
into the BglII/XhoI sites of the pRSSP vector (Figure 59), which already contained the 





























Figure 59 Agarose gel for second cloning step  
Left-hand side: Restriction digest of pcDNA3.1 construct with BglII and XhoI to isolate the 
second half of the GABABR1a gene. The gene fragment of 1600 bp was gel purified. The 
pRRSP contruct containing the first half of GABABR1a was digested with BglII and XhoI, 
removing 16 bp and the remaining plasmid of 4200 bp was gel purified.  Right-hand side: The 
final construct was digested with BglII and XhoI separately to verify the incorporation of the 
whole GABABR1a gene, giving a fragment of 5800 bp.  
 
 
4.3.3.1.3 Polymerase chain reaction (PCR)  
Conditions for the PCR were optimized by varying annealing temperatures from 
50 °C to 68 °C. The following conditions, resulting in a single strong band of the correct 
size, were chosen for amplification of the genes. 
 
An aliquot of 1 µl 10 mM dNTP (containing the four deoxyribonucleotides: dATP, 
dCTP, dGTP and dTTP) was mixed with 1 µl of 1:100-diluted plasmid DNA 
(approximately 200 ng), 1 µl forward-primer (10 µM), 1 µl reverse-primer (10 µM), 0.5 
µl (2.5 U) Herculase hot-start polymerase, 5 µl Herculase 10x reaction buffer 





























The PCRs were carried out according to the following scheme: 
95 ºC 2 minutes 
95 ºC 30 seconds 
65 ºC* 30 seconds      30 cycles 
72 ºC 1 minute 
72 ºC 10 minutes 
4 ºC hold 
*or varied according to optimization  
 
4.3.3.1.4 General restriction digest procedure 
In the restriction enzyme digestion procedure, 2 µg DNA (plasmid DNA or PCR 
product) was added to microcentrifuge (Eppendorf) tubes containing restriction enzyme 
digest mix, which was made up of 1 µl (10 U) of each restriction enzyme, 2 µl NEBuffer 
(compatible with the restriction enzymes used), 2 µl 10x BSA (for some digests only) 
and 11 µl ddH2O (all from New England Biolabs).  The DNA digest mixtures were 
incubated at 37 °C for one hour. The digested DNA products were analysed by agarose 
gel and purified using a gel-purification kit from Qiagen. 
 
4.3.3.2 Ligation and transformation procedures for all constructs  
A 2-µl aliquot of the PCR-generated  DNA for GABABR1a was added to a 
ligation reaction mixture including Quick T4 DNA ligase, Quick ligation reaction buffer 
2x (New England Biolabs), 0.5 µl (50 ng) of restriction-digested and gel-purified vector. 
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The reaction was incubated, at room temperature, for ten minutes and performed in 
parallel with a negative control reaction (containing water instead of the DNA insert). 
 
4.3.3.3 Transformation 
E. coli “One Shot Top10” competent cells (Invitrogen, UK) were subjected to 
transformation by heat shock, as follows. An aliquot of 50 µl of Top10 cells was 
removed from a -80 °C freezer and thawed on ice before 2 µl of the ligated product (see 
above) was added and gently agitated. The mixture was left on ice for 30 minutes before 
the heat-shock step. The cell-ligation mixture was then incubated in a water bath at 42 
°C for 45 seconds and then placed on ice for two minutes. The mixture was then re-
suspended in 1.0 ml of SOC medium (Invitrogen) and incubated at 37 °C, with shaking 
at 200 rpm for 60 minutes. Aliquots of 50-200 µl of the mixture were plated on LB agar 
plates containing 50 µg/ml ampicillin and incubated at 37 °C overnight.  
 
4.3.3.4 Preparation of plasmid DNA 
Colonies were picked from the selective plates and inoculated into 5.0 ml of LB 
medium containing 50 µg/ml ampicillin, then incubated at 37 °C, with shaking, 
overnight. Cells were then pelleted by centrifugation at 13000 rpm for 60 seconds. 
Recombinant plasmids were purified from cell pellets by alkaline lysis using the Qiaprep 
miniprep kit (Qiagen). Following re-suspension of the cell pellet in buffer P1, cells were 
lysed by addition of buffer P2 for up to five minutes and then neutralized by addition of 
buffer N3 and gentle mixing. The suspension was centrifuged in a table-top centrifuge 
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(Eppendorf) for ten minutes to accumulate the precipitate, and then the supernatant was 
transferred to a Qiaprep silica-gel membrane column. The column was spun at 13000 
rpm for 60 seconds in an Eppendorf bench-top centrifuge and the flow-through was 
(ultimately) discarded.  The membrane-bound DNA was washed with buffer PE, the 
flow-through discarded and the centrifugation step repeated. Finally, the membrane 
column was transferred to a fresh (and carefully cleaned) Eppendorf microcentrifuge 
tube, and the purified plasmid DNA was eluted with 50 µl ddH2O by centrifugation at 
13000 rpm for 60 seconds. The plasmid DNA was analysed by analytical restriction 
enzyme digest and PCR in order to confirm the correct insertion of the gene, followed 
by DNA sequencing to confirm a correct reading frame. 
 
4.3.3.5 In vitro cRNA synthesis from GABABR1a/R1b/R2 and GIRK 
cDNA constructs 
  RNA was synthesised from mini-prep/midi-prep-derived DNA using a modified 
protocol for the RiboMaxTM (Promega, Madison) large-scale RNA production system 
with T7 polymerase (for GABABR1a in pcDNA3.1), or SP6 RNA polymerase (for 
GABABR1a in pRSSP, GABABR1b/-R2 and GIRK3.1/-3.4, all in pSGEM). All 
solutions and materials were handled with gloves to avoid RNase contamination. 
Solutions were made up from diethylpyrocarbonate (DEPC)-treated water. DEPC-
treated water was made by adding one gram of DEPC to one litre of double-distilled 
water (ddH2O) and incubated overnight at room temperature, followed by autoclaving to 
inactivate the DEPC. 
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4.3.3.6 Template linearization 
DNA constructs were linearised using the unique restriction sites displayed in 
Table 10 prior to RNA synthesis. 
 
Table 10 Restriction enzymes for linearising DNA constructs prior to RNA synthesis 
DNA construct Restriction site used 
R1a in pcDNA3.1  BspHI 
R1b in pSGEM NheI 
R2 in pSGEM NheI 
GIRK 3.1 in pSGEM MluI 
GIRK 3.4 in pSGEM MluI 
R1a in pRSSP MluI 
 
Approximately 10 µg of plasmid DNA was added to 40 µl of digestion mixture that 
contained 4 µl restriction enzyme buffer (New England Biolabs), 30 U of restriction 
enzyme, (and for NheI digestions, 4 µl of BSA) and the remaining volume was made up 
to 100 µl with DEPC-treated ddH2O. The DNA mixture was incubated at 37 ºC for one 
hour and then analysed by loading 1 µl onto a 1% (w/v) agarose gel made up with Tris-
acetate-EDTA (TAE) -buffer that was also used as running buffer. The gel was run at 10 
V/cm. The digested DNA was subsequently cleaned by phenol/chloroform extraction 
followed by chloroform extraction. Finally, the DNA was precipitated with 3 M NaAc 
(pH 5.2) and 100% ethanol. 
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4.3.3.7   cRNA synthesis and purification 
On the assumption that 50% (5 µg) of the digested DNA had been recovered 
following linearization and purification, the RNA synthesis reaction mixture was made 
up as follows: 8.5 µl of digested DNA template re-suspended in DEPC-treated ddH2O, 4 
µl of mixture containing 25 mM each of ATP, UTP and CTP and 8 mM GTP , 1.5 µl of 
10 mM m7G(5’)ppp(5’)G sodium capping, 4 µl of SP6 or T7 polymerase buffer and 2 µl 
SP6 or T7 polymerase. The reaction mixture was incubated at 37 ºC for one hour and 
then analysed by loading 1 µl onto a 1 % agarose gel made up with TAE-buffer that was 
also used as running buffer. The gel was run at 10 V/cm. 
 For purification, the RNA reaction mixture was made up to 100 µl with DEPC-
treated ddH2O. Contaminating DNA was removed by addition of 20 µl 2 M NaAc, pH 4, 
followed by 50 µl water-saturated phenol and 10 µl chloroform. The mixture was 
vortexed, centrifuged and the aqueous phase transferred to a clean Eppendorf 
microcentrifuge tube. An equal volume of isopropanol was added and the resulting 
mixture was incubated at –20 °C overnight. The mixture was then centrifuged at 13000 
rpm for 30 minutes at 4 °C in an Eppendorf bench-top centrifuge and the supernatant 
discarded. The pellet was washed in 70% ethanol and re-suspended in 20 µl nuclease-
free water. The RNA products were analysed by loading 1 µl on a 0.8% agarose gel 
containing formaldehyde in 5x MOPS buffer. A sample buffer mixture containing 1.5 µl 
of 5 x MOPS buffer, 2.6 µl formaldehyde and 7.5 µl formamide, and a loading buffer 
mixture containing 2 µl loading buffer and 0.5 µl (1 mg/ml) ethidium bromide, were 
incubated at 65 °C for three minutes. An aliquot of 11 µl of the sample buffer mixture 
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and 2.5 µl of the loading buffer mixture were then added to each one-µl RNA sample, 
and sample mixtures were incubated at 65 °C for a further three minutes. Then 1x 
MOPS buffer was used as running buffer, and the gel was run at 10 V/cm. RNA 
concentrations were determined from optical density measurements at 260 nm. 
 
4.3.3.8 RNA sample preparation for oocyte micro-injection 
The cRNAs for GABABR1a or GABABR1b, GABABR2, GIRK 3.1 and GIRK 
3.4 were mixed in a nominal ratio (by weight) of 8:8:1:1. The ratio was determined 
based on baclofen-evoked currents being large enough to be able to detect whithout the 
oocyte being compromised by the holding potential becoming too large, and avoiding 
excessively high expression levels of injected protein. Mixtures were diluted ten-fold 
with nuclease-free water in order to yield appropriate expression levels, resulting in 
measurable baclofen-evoked currents (approximately 0.3 µA for R1a and 3 µA for R1b). 
The optimal amount of cRNA injected per oocyte is displayed in Table 11. 
 
Table 11 Optimised ratios of cRNA mixtures used to micro-inject oocytes.  
 R1  R2 GIRK 3.1 GIRK 3.4 
R1a mix 15 ng 15 ng 1.8 ng 1.8 ng 
R1b mix 15 ng 15 ng 1.8 ng 1.8 ng 
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4.3.3.9     Preparation of stage V-VI oocytes 
Xenopus laevis were anesthetised and the ovarian lobes were removed surgically 
(surgery performed by members of Dr Niki Gray’s group, human genetics unit, MRC 
Edinburgh). Oocytes were separated manually into bundles of 10-20 oocytes and treated 
with collagenase type-1A (50 U/ml) for 30 minutes at room temperature with shaking.  
Following collagenase treatment the oocytes were washed three times with Barth’s 
solution and then left to recover at 19 °C overnight. The following day the oocytes were 
defolliculated manually and RNA was injected using a Nanoject injector (Drummond 
Scientific, USA). Each oocyte was injected with 46 nl RNA (33.6 ng total amount RNA) 
and placed in an individual well of a 24-well plate containing 1.8 ml of Barth’s solution. 
The oocytes were incubated at 19 C for 2-5 days to allow expression of receptors and 
ion channels to occur, prior to use for TEVC recordings.  
 
4.3.3.10   Two-electrode voltage clamp (TEVC) recordings 
The TEVC recordings were made with a Geneclamp 500 amplifier (Axon 
Instruments, UK) and responses to 10 µM baclofen were measured at a holding potential 
of –100 mV.  Voltage and current electrodes for recordings were made of thin-walled 
borosilicate glass (GC150TF-7.5, Harvard Apparatus, Kent) pulled using a PP-830 
electrode puller (Narashige Instruments, Japan) and filled with 3 M KCl. The electrode 
resistances ranged between 0.2 and 0.5 M.  Oocyte were placed in a recording 
chamber containing TEVC external buffer “low [K]” (i.e. 2.5 mM potassium, Table 8) 
and impaled with the voltage and current electrodes. At this stage the oocyte was 
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continuously perfused with buffer. The resting potential of each oocyte was noted and it 
was thereafter voltage-clamped at -100 mV. The holding current for each oocyte was 
noted whereupon the perfusion buffer was changed to TEVC external buffer “medium 
[K]” (i.e. 25 mM potassium cloride). Experiments were carried out that involved 
recording the responses of a GABABR1a/R2 or GABABR1b/R2-expressing oocyte to the 
agonist baclofen and the antagonist CGP55845. All drugs were made up in TEVC 
external buffer “medium [K]” and perfused at a rate of ~8 ml/min.  
 
4.3.3.11   Current-Voltage response curves 
The current-voltage (I-V) relationship of GIRK3.1/3.4-activated currents 
expressed in oocytes was also studied using TEVC. The I-V relationship was determined 
from the response of oocytes co-expressing GABABR1a/GABABR2 and GIRK3.1/3.4, 
or oocytes co-expressing GABABR1b/GABABR2 and GIRK3.1/3.4, in the presence of 
10 µM baclofen by step depolarisations from -100 to -20 mV in 20 mV increments. Data 
from four or five oocytes for each isoform are averaged. The theoretical membrane 
equilibrium is -31 mV, according to the Nernst equation, when external potassium 













Where EK is the electric potential across the membrane due to the potassium 
concentration gradient, R is the universal gas constant (8.3 J K-1), T is the absolute 
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temperature in Kelvin, [K+]out and [K+]in are the potassium concentrations outside and 
inside membrane, zF is the number of electric charges carried by a mole of K+ ; z is the 
valency of ion species (1 for K+) and F is the Faraday constant 9.65×10 4 C mol-1. 
 
4.3.3.12   Protein expression  
Due to lack of suitable antibodies for western blotting, protein expression levels 
proved difficult to test experimentally. Instead in vitro transcription-translation was 
explored. [35S]-Cys-labeled protein fragments were prepared by in vitro transcription-
translation of the plasmids used in the TEVC study using the TNT® T7/SP6-coupled 
reticulocyte lysate system as described by the manufacturer (Promega). The in vitro 
transcription-translation assay was kindly performed by Dr B. Collier, human genetics 
unit, MRC Edinburgh. The reactions carried out using rabbit reticulocyte lysate 
demonstrated that the constructs were able to produce the desired proteins in vitro. As 
seen in the autoradiograph (Figure 60) of the in vitro transcription-translation, the 
plasmids carrying the genes for GABABR1b (94 kDa), GABABR2 (105 kDa), 
GABABR1a (108 kDa), GIRK 3.1 (56 kDa) and GIRK 3.4 (47 kDa) all produced protein 

































Figure 60 Autoradiograph demonstrating the in vitro transcription-translation of all 
constructs used in the TEVC studies  
The GABABR1a, GABABR1b, GABABR2 GIRK3.1 and 3.4 constructs used in the present study 























































4.4.1 Characterization of the GABAB receptor using Xenopus 
laevis oocytes as a model system 
 
4.4.1.1 Successful generation of RNA encoding for GABAB receptors 
and potassium channels 
  The pharmacology of GABAB receptors were studied by expressing the receptor 
subtypes GABABR1a or R1b together with GABABR2 and the potassium channels 
GIRK3.1 and GIRK3.4 in Xenopus oocytes. Responses of oocyte-expressed GABAB 
receptor isoforms R1a/R2 and R1b/R2 evoked by agonist baclofen and antagonist 
CGP55845 were recorded by two-electrode voltage clamp (TEVC).   
The RNA sequences corresponding to the GABAB receptor subunits GABABR1b 
and GABABR2, and the ion channels, GIRK3.1 and GIRK3.4, were generated 
successfully by synthesising cRNA from the plasmids which incorporated the genes. 
The initial GABABR1a construct failed to transcribe cRNA in vitro (as discussed in 
4.3.3.1).  New GABABR1a constructs was therefore generated in the pcDNA3.1D/V5-
His-TOPO vector as well as in the pRSSP vector; both constructs were tested and the 
latter construct was used for further studies as the vector pRSSP possessed similar 
advantages, with respect to optimisation for expression in Xenopus oocytes, as did 
pSGEM. It was subsequently confirmed, using a transcription-translation approach, that 
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the new GABABR1a construct used in this study was able to express protein of the 
expected size in vitro (Figure 60). 
 
4.4.1.2 Co-expression of both GABAB receptor subunits is required 
for function 
It was confirmed in the current study that none of the individual GABAB receptor 
subunits GABABR1a, GABABR1b or GABABR2, were able to activate potassium 
inwardly rectifying currents when expressed alone in oocytes together with GIRKs. On 
the other hand, when expressed together, GABABR1a/GABABR2 or 
GABABR1b/GABABR2, are able to activate GIRK currents in response to the 
application of 10 µM baclofen. The results of this study are thus consistent with the fact 
that GABAB receptors expressed in oocytes can recruit endogenous G-proteins and 
thereby activate inwardly rectifying potassium channels.  The results also confirmed that 
co-expression of both GABAB subunits (together with GIRK subunits) is required for 
activity.  
 
4.4.1.3 Optimisation of GABABR1a expression and recording 
conditions 
A major aim of this work was to compare pharmacological responses of 
GABABR1a/R2 versus GABABR1b/R2 as a step towards establishing biological roles 
for the two CCP modules that are unique to the GABABR1a subunit. The results of this 
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study indicated that oocytes expressing GABABR1a/GABABR2 evoked a consistently 
smaller and less stable baclofen-mediated response compared to the response obtained 
with GABABR1b/GABABR2 under the same conditions.  
To enhance the baclofen-evoked response of GABABR1a/GABABR2 several 
steps were taken. Firstly, [K+] in the TEVC external buffer was increased from its 
physiological value (2.5 mM) to 25 mM. Initially 40 mM potassium was tried, however 
this created a very high holding potential, resulting in short lifespans for the oocytes. 
This intermediate (25 mM) concentration of external potassium resulted in holding 
currents in the range of ~ -3-4 µA. Secondly, the amounts of injected cRNAs encoding 
the various proteins were optimised. It was suspected that excessive amounts of any 
particular cRNA would overload the translation machinery of the cell, leading to poor 
expression and rapid deterioration of the oocyte. By injecting less of GIRK cRNA, fewer 
potassium channels were expressed, this meant that a lower holding current needed to 
clamp the oocyte at -100 mV and resulted in a longer recording-life of the oocyte. 
Thirdly, it was found that in the case of GABABR1b/GABABR2, on average two days of 
incubation of oocytes, post-injection, was required to attain a useful level of protein 
expression. Prior to this time, no baclofen-evoked currents could be observed. Longer 
incubation resulted in very high recording currents (possibly due to high expression of 
receptors) followed by deterioration of oocytes. The GABABR1a/GABABR2 constructs, 
on the other hand, required longer incubation, post-injection - typically three to five days 
- in order to observe detectable baclofen-evoked responses. Thus incubation times were 
extended for the GABABR1a/GABABR2 constructs. 
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These measures improved baclofen-evoked response observed for 
GABABR1a/R2-expressing oocytes and enhanced oocyte lifespan while recording. 
However, the overall response of the oocytes expressing the GABABR1a isoform 



























Figure 61 A representative trace of baclofen-evoked GABABR1a/R2 currents              
It was demonstrated that 10 µM baclofen evokes a smaller response compared to that obtained 
with the R1b/R2 isoform.  The R1a/R2 response is blocked by 5 µM of the GABAB receptor 
antagonist CGP55845. The drug was washed off with medium-potassium buffer and the current 































































































Figure 62 A representative trace of baclofen-evoked GABABR1b/R2 currents        
It was demonstrated that 10 µM baclofen evokes a large response, which can be blocked by 5 
µM of the GABAB receptor antagonist CGP55845. The drug was washed off with medium-





4.4.1.4 Current-voltage curves (IV) 
Current-voltage (IV) curves demonstrate the characteristic behaviour of the 
potassium channels used in the system. It was successfully confirmed from the current-
voltage curves (Figure 63 and Figure 64) that both GABABR1a/R2 and GABABR1b/R2, 
when co-expressed with GIRK3.1/3.4, demonstrate inward rectification which is an 
expected behaviour from potassium channels. The theoretical equilibrium potential for 
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K+ ions is -31 mV according to the Nernst equation, when [K+]ext = 40 mM. Pleasingly, 
this theoretical value is very similar to the experimental values seen in Figure 63 and 
Figure 64. 
 



















Figure 63 GABABR1a/R2 current-voltage relationship  
Current-voltage plot demonstrating the inward current behaviour of potassium channels coupled 
to the GABABR1a/R2 receptor and expressed in oocytes (n=4, error bars illustrate standard error 













Figure 64 GABABR1b/R2 current-voltage relationship 
Current-voltage plot demonstrating the inward current behaviour of potassium channels coupled 
to the GABABR1b/R2 receptor and expressed in oocytes  (n=5, error bars illustrate SEM values). 
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4.4.2 Pharmacological differences between the oocyte-
expressed isoforms GABABR1a and GABABR1b 
 
4.4.2.1 Exploration of differences in potency of baclofen at the two 
GABAB receptors isoforms 
Throughout this study baclofen-evoked currents and CGP55845-mediated block 
of these currents were investigated at the holding potential of -100 mV. Figure 61 and 
Figure 62 show typical TEVC traces recorded from oocytes expressing GABABR1b/R2 
and GABABR1a/R2 receptors where baclofen-evoked inward currents are detected that 
are blocked by CGP55845. No apparent pharmacological differences have previously 
been proven for the two isoforms GABABR1a and R1b, although some that were 
originally suggested (Leaney and Tinker, 2000; Ng et al., 2001; Parker et al., 2004) 
proved to be controversial (Jensen et al., 2002; Lanneau et al., 2001; Shimizu et al., 
2004; Sills et al., 2005). Their affinities for baclofen were originally reported to be very 
similar (Malitschek et al., 1998), however an investigation of the receptor behaviour 
over a range of high and low concentrations of agonist was needed to test wether they 
display identical pharmacological behaviour in our system.  
 
4.4.2.1.1 Saturating concentrations of baclofen 
In order to determine a concentration of baclofen that is sufficient to saturate the 
receptor, baclofen-evoked responses were measured at concentrations of 10 µM and 100 
µM, both of which have previously been reported to be suitable (Nehring et al., 2000; 
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Uezono et al., 2006). The experiments were initiated with the lower concentration of 
baclofen, and then the oocytes were perfused with TEVC external buffer for four 
minutes to wash off the agonist, followed by application of the higher concentration of 
baclofen. Very little difference in response was obtained, for either of the two GABAB 
receptor isoforms, when the concentration of baclofen was increased from 10 to 100 µM 
[for GABABR1a-expressing oocytes: 274 nA (10 µM baclofen) versus 283 nA (100 µM 
baclofen); for GABABR1b-expressing oocytes: 3360 nA (10 µM baclofen) versus 3270 
nA (100 µM baclofen)] (Figure 65). The experiment was also carried out in the reverse 
order, i.e. with 100 µM baclofen applied first followed by 10 µM - this reversal 
produced identical results. A value of 10 µM baclofen was therefore regarded as near-
saturating and was chosen for future experiments on this basis. It is worth noting for all 
experiments in the present study that a delay in response was observed in oocytes 
expressing GABABR1a/R2 receptors, while GABABR1b/R2 receptors responded almost 
instantly to drug application. This could be related to differences in receptor activation 































Figure 65 Saturation is achieved at 10 µM baclofen  
Currents were measured for the GABABR1a/R2 and GABABR1b/R2 receptors when perfused 
with 10 µM and 100 µM baclofen (n=3, error bars illustrate SEM values). Very little difference in 
response for the same isoform was observed between the two concentrations studied. 
 
 
4.4.2.1.2 Lower concentrations of baclofen 
The GIRK currents obtained for the two isoforms GABABR1a/GABABR2 and 
GABABR1b/GABABR2 in response to 1, 3 and 10 µM baclofen were measured, as 
shown in Figure 66 (Raw data in Appendix C.III). A representative TEVC trace for each 





























Figure 66 Differences in responses to low concentrations of baclofen  
Currents were measured for the GABAB R1a/R2 and GABAB R1b/R2 receptor when perfused 
with 1 µM, 3 µM and 10 µM baclofen (R1a/R2, n= 5;  R2/R1b, n= 3; error bars illustrate the SEM 
values).  Note that the responses for GABABR1b/R2 are 10 fold larger than for GABABR1a/R2 
 
 
In the case of GABABR1a/R2, the GIRK currents measured in response to 1 µM and 3 
µM baclofen are ~30% and 65%, respectively, of the response for 10 µM baclofen (n=5). 
For GABABR1b/R2, the values were 75% (1 µM) and 95% (3 µM) of the 10 µM 
response (n=3) as seen in Figure 67.  One explanation is that baclofen saturates at lower 



















































































Figure 67 Illustration of relative responses to variation of baclofen concentrations  
The response value recorded at 10 µM for each construct is labelled ‘100%’ and the responses 
at 3 µM and 1 µM is determined as relative percentage in relation to the 10 µM value. The 
standard error of mean (SEM) is indicated as error bars.    
 
 
4.4.2.1.3 Step-wise application of baclofen 
The difference in response to various baclofen concentrations was further 
demonstrated by recording TEVC traces (Figure 68 and Figure 69). While IV plots 
demonstrate the characteristic behaviour of an inwardly rectifying ion channel, TEVC 
traces show drug-evoked responses of the receptor in ‘real-time’. Figure 68 illustrates 
how, in the case of oocytes expressing GABABR1a/R2 receptors, incremental additions 
of baclofen (from 1 µM to 3 µM to 10 µM) produce an approximately steady 
enhancement of the response for each stepwise increment in baclofen concentration.  
This implies the binding site for baclofen is not fully saturated at 10 µM. Figure 69, on 
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the other hand, illustrates how similar incremental increases of baclofen - from 1 µM to 
3 µM to 10 µM - to GABABR1b/R2, result in a different pattern. There is a relatively 
large initial response to 1 µM baclofen, followed by smaller increases, as baclofen is 
incremented, indicating that baclofen has nearly saturated its binding site on the receptor 
at a concerntation of 10 µM. Thus these data also indicate a higher potency of baclofen 
for GABABR1b/R2 compared to GABABR1a/R2. However, the affinity for baclofen has 



















Figure 68 Baclofen-evoked response of an oocyte expressing GABABR1a/R2 receptors. 
Stepwise increases of baclofen concentration from 1 µM to 10 µM evoke a steadily increasing 
response. TEVC external ‘low K+ buffer' was switched to 25 mM K+ solution. 1 µM, 3 µM and 10 
µM baclofen were applied in a stepwise manner followed by 10 µM baclofen + 1 µM CGP55845. 
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Figure 69 Baclofen-evoked response of an oocyte expressing GABABR1b/R2 receptors. 
Stepwise increase of baclofen from 1 µM to 10 µM produce only small differences in response 




4.4.2.2 Assessing differences in response between the two isoforms 
of the GABAB receptor elicited by the antagonist CGP55845 
 
4.4.2.2.1 Lower concentrations of CGP55845 
The GABAB receptor selective antagonist CGP55845 was used throughout this 
study to investigate the inhibition of baclofen-evoked currents on GABABR1a and 
GABABR1b when expressed together with GABABR2 in Xenopus oocytes. The 
inhibition of GIRK currents obtained for GABABR1a/R2 and GABABR1b/R2, in 
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measured. The results appear to demonstrate that the potency of the antagonist 
CGP55845 is lower for GABABR1a/R2 than for GABABR1b/R2 (Figure 72). In the case 
of GABABR1a/R2, CGP55845 reduced by some 60% the GIRK currents measured in 
response to 10 µM baclofen. In the case of GABABR1b/R2, the GIRK currents measured 
in response to 10 µM baclofen were about 90% inhibited by the GABAB receptor 
antagonist CGP55845. This was explored as described further in the next section.  
 
4.4.2.2.2 Step-wise application of CGP5584  
Differences in response to stepwise application of CGP55845 were observed 
between the two isoforms as seen in Figure 70 and Figure 71. CGP55845 appears to 
block a 10 µM baclofen-evoked GIRK current in oocytes expressing GABABR1b/R2 in 
a more pronounced way, and at lower concentrations, compared to its effect on 
GABABR1a/R2. This indicates the antagonist is more potent at (i.e. less drug is needed 
to produce a given effect on) GABABR1b/R2. A solution of 0.3 µM CGP55845 blocked 
the measured current by about 50 % in the case of GABABR1a/R2 compared to 90% for 
GABABR1b/R2. Higher concentrations of antagonist, up to 10 µM, result in only a very 
slight further reduction in the case of GABABR1b/R2, indicating the lower concentration 
of antagonist used is able to compete effectively with the near-saturating concentration 
of baclofen used in this experiment (Figure 71). In the case of GABABR1a/R2 on the 
other hand, incremental additions of CGP55845 above the starting concentration of 0.3 
µM further reduced the baclofen-evoked response up to a maximum of 64% (10 µM 
CGP55845) as illustrated in Figure 70. This suggests that CGP55845 has a stronger 
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potency for GABABR1b/R2. Thus the antagonist CGP55845 appears to be less potent at 
blocking baclofen-evoked responses in GABABR1a/R2, despite the fact that baclofen is 
also less potent at this receptor isoform. These results imply that this antagonist 
struggles to compete with baclofen in the case of GABABR1a/R2 but competes 
effectively in the case of GABABR1b/R2. Potency depends on both affinity and efficacy 
of the drug. However, the system used in this study is not suitable to measure affinity of 


















Figure 70 Effects of stepwise application of CGP55845 on currents recorded from an 
oocyte expressing GABAB R1a/R2 receptors 
A dose of 10 µM of antagonist CGP55845 blocks the baclofen-evoked response by an average 
of about 65%. External K+ buffer was switched to 25 mM K+ solution. 10 µM baclofen was 
applied followed by a stepwise application of 10 µM baclofen plus 0.1 µM, 0.3 µM , 1 µM, 3 µM 






























































































Figure 71 Effects of stepwise application of CGP55845 on currents recorded from an 
oocyte expressing GABABR1b/R2 receptors 
A dose of 10 µM of antagonist CGP55845 blocks the baclofen evoked response by an average 




To summarise, although no differences in affinity for baclofen or CGP55845 
have previously been reported for the individual isoforms GABABR1a/R2 and 
GABABR1b/R2, differences in potency of CGP55845 were revealed in the current study, 
which may be linked to differences in affinity. CGP55845 shows a less efficient block of 
baclofen-evoked responses, at the investigated concentrations, in oocytes expressing 
GABABR1a/R2 receptors, compared to GABABR1b/R2, indicating a higher 
concentration of the antagonist is required for the same level of blocking of responses 




























































































Figure 72  Percentage blocking of a baclofen-evoked response in GABABR1a/R2- (blue) or 
GABABR1b/R2- (purple) expressing oocytes.  
Blocking was measured at different concentrations of CGP55845 as seen in the figure. The 
difference in antagonist potency between isoforms is significant for the two concentrations of 3 
µM (p=1.48*10-05) and 5 µM (p=2.03*10-06). The standard error of mean (SEM) is indicated as 
error bars (n= 20-30 for 3 µM and 5 µM, and n= 5-10 for the remaining concentrations. 
 
 
4.4.3  Pharmacological responses to baclofen of GABABR1a and 
GABABR1b in the presence of laminin 
It was determined previously in the current study (Chapter 2 and Chapter 3) that 
the CCP modules of the GABAB receptor and the extracellular protein laminin can 
interact with one another. It is not known, however, whether this interaction occurs in 
vivo, nor is it known if the interaction has any effect on the function of the receptor. To 

































oocytes expressing GABABR1a/R2 or GABABR1b/R2 receptors were perfused with 
baclofen, and the response recorded to obtain a baseline. The individual oocytes were 
thereafter incubated with laminin or buffer (as a negative control) for two hours; this 
incubation period was followed by an identical perfusion of baclofen, and the response 
was recorded.  
Surprisingly, in the cases of both laminin-incubated and buffer-incubated 
GABABR1b/R2-expressing oocytes, the detected responses appear to be consistently 
larger after the incubation compared to before the incubation (Table 12). The increase in 
response to baclofen for GABABR1b/R2-expressing oocytes incubated in the presence 
of laminin is greater than that for control oocytes incubated in buffer. On the other hand, 
and in contrast, GABABR1a/R2-expressing oocytes incubated in the presence of laminin 
showed a complete loss of response to baclofen post-incubation (Figure 73). A smaller 
decrease in response to baclofen was observed in the case of GABABR1a/R2-expressing 
oocytes that had been incubated in buffer without laminin.  
 
Table 12. Results show precentage difference in baclofen-evoked response after incubation with 
laminin or buffer respectively. 
R1a Oocyte 1 Oocyte 2  Average 
Laminin incubation -100% -100% - -100% 
Buffer incubation - 33%    - 53% - - 43% 
R1b Oocyte 1 Oocyte 2 Oocyte 3 Average 
Laminin incubation +96% +84% +120%  +100% 





























Figure 73 Effect of laminin on baclofen-evoked responses in GABAB receptors.  
Oocytes expressing GABABR1a/R2 or GABABR1b/R2 were incubated with laminin or buffer 
(negative control) and the difference in response to baclofen before and after incubation was 
determined. Laminin completely inhibited the response to baclofen in GABABR1a/R2 expressing 
oocytes (n=2) while the response was enlarged in oocytes expressing GABABR1a/R2 post 

























4.5.1 Xenopus laevis oocytes as a model system for 
characterizing the GABAB receptor 
For the purposes of the present study it was essential to establish a means of 
measuring the functional activity of GABABR2/R1a and GABABR2/R1. In this respect, 
the Xenopus oocyte system adopted in the current work has many advantages including 
the following: the oocyte is well characterized and widely used and accepted as a model 
system; the oocyte contains histones, RNA polymerases, tRNA, ribosomes etc., which 
enables the study of transcription and translation of injected cDNA or cRNA (Colman et 
al., 1984); the translation of exogenous RNA occurs in a normal living cell, and is 
therefore devoid of the artifacts that might be associated with a cell-free (in vitro) 
system; foreign proteins expressed in oocytes are correctly post-translationally modified 
and proteins containing multiple subunits are correctly oriented (Baker et al., 2007)  
A potential disadvantage is that the Xenopus oocyte system necessitates the study 
of mammalian GABAB receptors expressed in a non-native cell, but this is not regarded 
as a major limitation given our aim of comparing the characteristics of different isoforms 
of the same functional receptor.  The use of oocytes has, however, some more serious 
experimental limitations. Oocytes can be very sensitive to seasonal variations, which 
affect the level of protein expression as well as the survival time of the cell (Witchel et 
al., 2002). Indeed, oocytes sometimes deteriorate within a few days of removal from the 
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ovary, which complicates experiments where long incubation times (more than three 
days) are essential for protein expression. Moreover, expression levels can vary between 
individual oocytes and batches of oocytes because expression is transient. These issues 
can rapidly increase the number of experiments (and thereby the time) needed to achieve 
consistent and statistically significant results.  A further consideration is that the 
physiological functions of oocyte proteins and mammalian proteins are optimal at 
different temperatures due to body temperature differences (16-20 ºC versus 37 ºC) – 
this could potentially affect the biochemical properties of the mammalian proteins under 
study (Witchel et al., 2002).  
The present study was conducted to extend knowledge of the GABAB receptor, 
and in particular of the isoforms, GABABR1a and GABABR1b. In the current work, the 
GABAB receptor was successfully expressed in Xenopus oocytes together with inwardly 
rectifying potassium channels. It was subsequently demonstrated that the expression of 
both subunits R1 and R2 of the receptor is required for activity. This observation is 
consistent with previous work (Bettler et al., 2004; Marshall et al., 1999; Mohler and 
Fritschy, 1999). Furthermore, the GABAB receptor was shown in this work (and in 
previous studies) to be coupled to inwardly rectifying potassium channels. The typical 
behaviour of an inwardly rectifying ion channel was demonstrated in the form of a 
current-voltage (I-V) plot. The responses obtained for GABABR1a/R2 recorded in this 
study were in good agreement with the responses for both GABABR1a/R2 and for 
GABABR1b/R2 previously reported (White et al., 1998). Unexpectedly, however, 
GABABR1b/R2 consistently evoked much larger responses to baclofen when expressed 
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in oocytes, compared to GABABR1a/R2 in the present study and compared to both 
isoforms as previously reported (White et al., 1998).  
It seems unlikely that this difference between the baclofen-induced responses 
elicited by the two isoforms has a genuine pharmacological explanation, as no such 
differences have been reported previously for this well-studied receptor. Instead, the 
discrepancy could be due to variations in expression levels between the two isoforms. In 
this respect it is worth noting that the GABABR1a and GABABR1b trasncripts used here 
originated from different vectors. On the other hand, these vectors are highly similar in 
that they both contain 3’- and 5’-untranslated regions from a Xenopus β-globin gene. 
Nonetheless it remains a possibility that different expression levels prevail, despite 
injection of the same amounts of RNA, due to variation in cRNA stability between 
constructs; this could result in degradation of RNA in the cytoplasm (Tokmakov et al., 
2006). Alternatively, it could be that the GABABR1a/R2 isoform is in fact being 
expressed well but is retained within the oocyte due to trafficking problems related to 
the presence of the two CCP modules at its N-terminus (not present in GABABR1b). 
Given that protein trafficking is a temperature-sensitive process, it may be altered in the 
case of GABABR1a due to the fact that oocytes are maintained at lower temperatures 
(Wagner et al., 2000). A further possibility is that reduced signalling in the case of 
GABABR1a may be due to differences in G-protein coupling between the two receptor 
isoforms, whereas R1a has been reported to signal preferentially through Goα, R1b 
signals equally through Goα and Giα (Leaney and Tinker, 2000). A final possibility is that 
Xenopus endogenous proteins interact selectively with the R1a isoform, and thereby 
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interfere with the interaction of R1a and R2, as has been reported for IKs channels 
(Wagner et al., 2000). 
The two receptor isoforms, GABABR1a/R2 and GABABR1b/R2, appeared to 
exhibit differences in response to baclofen at lower concentrations (3 and 5 µM). The 
expression levels of the two receptors may vary between the two isoforms, as discussed 
above, which would explain a difference in the absolute response to baclofen. However, 
this does not explain the differences in potency of baclofen towards the two isoforms, 
i.e. the observation that less agonist is required to saturate the response in 
GABABR1b/R2 than in GABABR1a/R2. In a similar vein, CGP55845 is less potent at 
GABABR1a/R2 compared to GABABR1b/R2.  
Differences in sensitivity between GABAB receptor isoforms towards other drugs 
– such as saclophen and CGP35348 - have been reported (Deisz et al., 1997). It was 
originally reported that gabapentin is an agonist for the GABABR2/R1a but not for 
GABABR2/R1b (Ng et al., 2001). It was claimed that this isoform-selective agonist was 
the first proof of pharmacologically distinct isoforms. This remains a controversial 
finding. Several research groups have been unable to confirm any agonistic (or 
antagonistic) properties for gabapentin at the GABAB receptor, let alone an isoform-
specific agoinst (Jensen et al., 2002; Lanneau et al., 2001). In the present study, a further 
unexpected observation was that a delay in response was noted in oocytes expressing 
GABABR1a/R2 receptors upon application of drugs. For GABABR1b/R2 receptors, on 
the other hand, the response was immediate.  
A particularly puzzling aspect of putatively isoform-specific agonists and 
antagonists is the fact that the ligand-binding site has been reported to be located well 
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away from the N-terminal domains that distinguish the two isoforms (Deriu et al., 2005). 
On the other hand, in the absence of structural data it is impossible to know this for sure. 
Moreover in the current work it was the downstream effects of ligand engagement (as 
opposed to direct measurements of affinity) that were observed - it is possible that the 
CCPs have a subtle, indirect, effect on the response of the receptor to occupation of the 
ligand-binding site. There might be differences, for example, in the conformational 
changes that are proposed to occur in the ectodomain upon binding of agonist/antagonist 
(Billinton et al., 2001; Bridges and Lindsley, 2008). 
According to the Venus fly-trap model, the two major subdomains within the 
ectodomain of GABABR1 are conformationally mobile and can hinge towards one 
another; this closed conformation is stabilised by ligand. Closure of the “fly-trap” causes 
changes in the conformation of the transmembrane helical domain that are transmitted to 
the inside of the cell. The presence of the CCP modules could destabilise the active 
(closed) conformation such that higher occupancy of the ligand-binding site is required 
for a comparable amount of transduction to occur although the actual affinity for ligand 
is not altered (Bridges and Lindsley, 2008).  It is also possible that different G-proteins 
are involved in coupling the receptor isoforms to the ion channels (Leaney and Tinker, 
2000), explaining the delayed responses observed for GABABR1a/R2, but this has not 
been fully assessed in this study and further work is needed to investigate such a 
possibility.  
It is tempting to speculate on possible a functional role for the isoform specificity 
observed in the current study. Of note is that the isoforms have distinct different 
expression patterns, both in regional and developmental distributions. GABABR1a is 
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evenly distributed across the brain while GABABR1b is predominantly expressed in 
cerebral cortex, thalamus and cerebellum (Fritschy et al., 1999). Moreover, GABABR1a 
is the predominant isoform during development, while GABABR1b becomes the main 
isoform in adult brain (Fritschy et al., 1999; Mohler et al., 2001).  This is discussed 
further in Chapter 5.  
The levels of expression of mRNA for the receptor subunits R1 and R2 are 
differentially regulated. This is unexpected given that the receptor requires a 
functionally obligate heterodimer. One possible explanation is that dimerisation of 
GABAB R1 and R2 represents just one out of several functions of these two proteins. 
Additional functions could include dimerisation with an as-yet unidentified receptor 
subunit (Billinton et al., 2001; Clark et al., 2000), or with another GPCR; indeed, such 
an interaction was reported for the GABAAγ2S and GABAB1 receptor subunits 
(Balasubramanian et al., 2004), allowing the GABABR1 subunit to be trafficked to the 
cell surface in the absence of the R2 subunit. Furthermore, functional crosstalk between 
the two receptor types A and B has been reported (Balasubramanian et al., 2004), 
increasing internalisation of the GABAB receptor when bound to the GABAA subunit, 
and thereby opening up the possibility of multiple receptor combinations and 
pharmacological diversity.  
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4.5.2 Pharmacological responses to baclofen on GABAB 
receptor isoforms R1a and R1b in the presence of Laminin 
The pharmacological diversity of the metabotropic GABAB receptor observed in 
vivo remains (Bettler et al., 2004; Marshall et al., 1999) a matter of contention in vitro, 
notwithstanding the results described in the previous sections. The in vitro diversity may 
require auxillary proteins, possibly interacting with the CCP modules of GABABR1a. As 
outlines in the introduction, laminin and fibulin could act in this way. 
The preliminary results of the present study indicated an inhibition of the 
response to baclofen of GABABR1a/R2 following incubation with laminin (compared to 
the smaller effect in the control that was incubated with buffer). No such inhibition was 
seen for GABABR1b/R2. Instead, a slightly increased response to baclofen was seen for 
oocytes expressing GABABR1b/R2 after incubation with both laminin and buffer.  
It should be noted that it proved difficult to maintain healthy GABABR1a/R2-
expressing oocytes able to sustain the multiple recordings required for this experiment. 
Surprisingly these oocytes deteriorated more rapidly than oocytes expressing 
GABABR1b/R2 or non-injected oocytes. This led to a very small sample size being used 
for these experiments. The loss of responsiveness in the buffer control for 
GABABR1a/R2 underlines the difficulty of maintaining stable GABABR1a/R2-
expressing oocytes throughout the experiments. Nonetheless, it is intriguing that the 
GABABR1a/R2-expressing control (buffer-incubated) oocytes responded to baclofen, 
whereas the laminin-treated GABABR1a/R2-expressing oocytes did not. It would be of 
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interest to investigate whether a smaller interacting fragment of laminin, like α5LG4-5, 



















Overall conclusions and future work 
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5 Chapter 5 Overall conclusions and future work 
A central question in metabotropic GABA receptor biology is: how can the wide 
functional diversity observed in vivo be reconciled with the very limited or unknown 
pharmacological variations that have been detected in vitro? The current work set out to 
investigate the functional consequences of the presence of two CCP modules within the 
extodomain of the R1a subunit of the GABABR1a/R2 dimer. 
The results of the current study on laminin and fibulin, based primarily on yeast-
two-hybrid assay and surface plasmon resonance, strongly suggest that these modules, 
which are of a type found in dozens of mammalian extracellular proteins, recognise and 
bind directly to two proteins of the ECM, laminin and fibulin. Moreover, the results have 
helped to pin down the domains involved – namely the C-terminal LG domain of the 
laminin alpha5 chain, and the C-terminal fragment of fibulin-2. In the case of laminin, 
the involvement of LG domains is in agreement with observations of interactions 
involving these types of domains in other proteins (Fernandez and Griffin, 1994; Hardig 
and Dahlback, 1996; Hardig et al., 1993; Hillarp and Dahlback, 1990). In addition, 
laminin-1 was identified as an interacting partner, suggesting multiple laminins acting as 
binding parners to the GABAB receptor. In a follow-up study (discussed further below), 
our collaborators in the Bettler group (University of Basel) have gone on to show that a 
splice variant (GABABR1j), consisting solely of the two CCP modules, binds to specific 
sites on neurones with low-nM affinity, although they were unable to identify the 
targeted protein.  
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The physiological purpose of the interaction between the GABAB receptor R1a 
and the ECM is intriguing, especially in the light of literature that was published during 
the course of the present study (further details below). In the current work, this issue was 
addressed by expression of functional GABABR1a/R2 and GABABR1b/R2 receptors in 
the Xenopus laevis model system. This approach yielded surprising results in that 
GABABR1b/R2 receptors exhibited a larger response to baclofen than had previously 
been reported; on the other hand, baclofen-evoked responses were consistently more 
difficult to measure for GABABR1a/R2. In the current study, the agonist baclofen as 
well as the antagonist CGP55845 was also more potent at GABABR1b/R2 compared to 
GABABR1a/R2. Thus the current study has contributed to the controversy over 
differential responsiveness of isoforms to small-molecule ligands. Moreover the small-
ligand results are hard to explain from a structural perspective although it is worth 
remembering that no experimentally derived structure yet exists for the GABAB 
receptor. As was discussed in Chapter 4, the intriguing differences in spatial and 
temporal distribution of the two isoforms are not irreconcilable with putative differences 
in ligand affinities. But further work is needed to clarify these issues. 
In the light of these unexpected trace data, the results obtained in the presence of 
laminin have to be regarded with caution. Nonetheless, and despite the limited number 
of observations, the apparent abolition of the baclofen-evoked response in 
GABABR1a/R2–expressing oocytes following incubation with laminin is noteworthy. 
By contrast the response to baclofen in the GABABR1b/R2-expressing oocytes remained 
unperturbed, or was increased, by treatment of the oocytes with laminin. While these 
experiments need to be repeated a sufficient number of times to establish statistically 
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rigorous data, such differences between R1a and R1b in the effects of laminin could 
have major implications for the field. 
Thanks to numerous recent reports, it is becoming ever more widely accepted 
that several neurotransmitter receptors have extracellular binding partners, and these 
interactions are suspected to modulate both synaptic localisation and signaling of the 
receptors. For example, both agrin and laminin have been linked to the clustering of 
acetylcholine receptors at neuromuscular junctions (Sugiyama et al., 1997; Weston et al., 
2007). Neural agrin was named after its function in aggregating acetylcholine receptors 
in development of neuromuscular junctions.  The C-terminal laminin-LG domain of 
agrin is involved in clustering of the receptor (Ferns et al., 1993; Ngo et al., 2007), by 
signaling through muscle specific kinase (MuSK) and thereby activating the proteins 
‘downstream-of-tyrosine-kinase-7’ (Dok-7), casein kinase 2 (CK-2) and rapsyn (Ngo et 
al., 2007). Laminin-1 (α1β1γ1) was identified as being involved in the clustering of 
acetylcholine receptor (Sugiyama et al., 1997). The α1-chain is most likely the 
interacting chain (as laminin-2 (α2β1γ1) and laminin-11 (α5β2γ1) were reported not 
involved), by signalling through a different pathway than agrin. Laminin-clustering has 
been shown not to require MuSk but to require Rac, Rho and rapsyn (Weston et al., 
2007). In another example, the N-terminal 92 residues of the extracellular domain of the 
ionotropic AMPA receptor subunit GluR2 was shown to make a specific and direct 
interaction with the ectodomain of N-cadherin, a single-pass transmembrane protein that 
plays a key role in synaptogenesis, neurite outgrowth, axon guidance and dendrite 
arborisation (Saglietti et al., 2007). Moreover, candidates for clustering of the AMPA 
receptor are the neuronal pentraxins. Pentraxins are thought to be involved in neuronal 
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uptake and clearing proteins away during synaptic remodeling (Kirkpatrick et al., 2000). 
The AMPA subunit GluR4 binds neuronal pentraxin 1 (NP1) and neuronal pentraxin 
receptor (NPR) via its N-terminal extracellular domain; this interaction was reported to 
be involved in recruitment of the subunit to synapses (Sia et al., 2007). Furthermore, 
naturally occurring secreted isoforms of other receptors comprising CCP modules have 
been found to have a physiological effect on receptor function. The CCP domain-
containing soluble receptor IL-15 receptor α for example, can inhibit IL-15 activity 
while a truncated soluble form of the same receptor increases IL-15 activity (Bulanova 
et al., 2007). 
Recently our collaborators performed studies of the truncated isoform 
GABABR1j, which consists solely of the two CCP modules. These provide further 
context for interpretation of the laminin/fibulin interactions. This small two-CCP module 
protein was found to inhibit the effect of pre-synaptic GABAB heteroreceptors on 
glutamate release.  Such an observation is striking since the affected heteroreceptors 
contain the R1a subunit (Vigot et al., 2006), not the R1b subunit. Indeed, no such effect 
was measurable on autoreceptors or post-synaptic heteroreceptors that contain the R1b 
subunit.  These important results suggest that R1j is competing selectively with the CCP 
portion of R1a, presumably for an extracellular binding partner protein. An appropriate 
interaction partner presumably lies on, or in the vicinity of, the pre-synaptic release 
machinery, although the physiological role of this putative interaction remains a matter 
of speculation. To test the hypothesis that the binding partner is, in fact, fibulin-2 we 
supplied samples of recombinant fibulin-2 to the Bettler group (Tiao et al., 2008). These 
co-workers showed that incubation of hippocampal slices with recombinant fibulin-2 (40 
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nM) did not perturb baclofen-mediated antagonism of evoked glutamate release. Nor did 
40-nM fibulin-2 neutralize the inhibitory action of 40-nM recombinant R1j at 
heteroreceptors. Thus we concluded that the impairment of heteroreceptors by the R1j 
protein does not involve scavenging of fibulin-2. On the other hand, we did not test any 
laminin fragments in these studies and laminin remains a potential partner.  In order to 
complete the characterization of the interaction with laminin in vivo, a study involving 
hippocampal slices expressing GABABR1a/R2 heteroreceptors could be studied with an 
addition of laminin, similarly to the study by Tiao (2008), to investigate if the laminin 
interaction is involved in the localisation of the R1a subunit to glutamatergic release 
sites.  
In addition to a strengthening precedent amongst neuroreceptors for ectodomain-
mediated functionally critical protein:protein interactions, there is growing evidence for 
distinct differences in regional and developmental expression patterns of GABABR1a 
versus R1b. Thus GABABR1a expression appears to be evenly distributed throughout 
the brain, while GABABR1b is predominantly expressed in cerebral cortex, thalamus 
and cerebellum. Moreover, GABABR1a is the predominant isoform during development, 
while GABABR1b becomes the main isoform after postnatal-week three (Fritschy et al., 
1999; Mohler et al., 2001). Recently, differences in the subcellular localisation of the 
two receptor isoforms was reported which supports the possibility of distinct functions 
in vivo (Vigot et al., 2006). GABABR1a was reported to be primarily expressed at 
glutamatergic terminals, while GABABR1b was found opposite glutamate release sites, 
supporting distinct pre- and postsynaptic functions. Distinct physiological roles have 
been suggested, where R1a plays a role in synaptic plasticity but R1b does not (Vigot et 
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al., 2006). while R1b is responsible for the long lasting inhibition of dentric Ca2+ spikes 
(Perez-Garci et al., 2006). Together, these observations suggest distinct additional roles 
of GABABR1a over GABABR1b that are likely attributable to its CCP modules. Thus, 
precedent and differential expression both support a hypothesis that the interaction of 
GABABR1a with laminin, demonstrated in the current study, may play a role in 
development of neural pathways or synaptic connections.  
To investigate further the role of the CCP modules, it would be of interest to 
study the receptor isoforms in vivo, where the presence of auxilary proteins may modify 
pharmacology of the receptor through interaction with the R1a CCPs. An in vivo system 
consisting of brain slices from homozygous mice lacking the R1a or R1b isoform 
respectively (R1a-/- and R1b-/-), as described by Vigot et al 2006, would aid the study of 
such an effect. Furthermore one could use brain preparations from different stages of 
development, or supplement with specific laminin modules of interest, to exhaust the 
possibility of pharmacological differences between the GABAB receptor isoforms. 
In conclusion, this thesis has emphasised the complexity of the different isoforms 
of the GABAB receptor, highlighting the involvement of CCP modules binding to the 
extracellular partners laminin and fibulin.  Interactions involving the CCP modules 
might introduce as of yet unobserved pharmacological distinctions between the receptor 
isoforms, or they might be important in establishing differences in spatial or temporal 
distributions of the receptor sub-types. The biological significance of the interaction 
remains to be investigated further.        
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APPENDICES 
Appendix A.  
I. Primers for YTH construct: 
 
Laminin alpha5 chain LG domains 1-5 (residues 2733-3695) was amplified from a human 
cDNA library using the following primers 
Forward: 5’ GTC AAG GTG CCC ATG AAG TT 3’ 
Reverse: 5’ C TGT GTC CTA GGC GGC TG 3’ 
 
Laminin alpha5 for cloning into pGADT7 
Forward (Nde1 site): 5’ GG GAA TTC CAT ATG CCC ATG AAG TTC AAC 3’ 
Reverse (Xho1 site): 5’ CC TGT CTC GAG CTA GGC GGC TGG 3’ 
 
No primers were used for the other constructs used in this study, as they could be transferred 
























Laminin 1 (CM5): 
Laminin-1 (L2020) was diluted in four different pH buffers, injected over the chip surface and 




























sTim e (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5







Laminin-10/11 (AG56P) was diluted in four different pH buffers, injected over the chip surface 




























sTime (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5













Laminin alpha1 LG1-3 (CM5): 
 
Due to insufficient amount of protein available, Laminin alpha1 LG1-3 was diluted in only two 
different pH buffers (pH5 and pH5.5), injected over the chip surface and analysed for 







































Laminin alpha1 LG4-5 (CM5): 
Laminin alpha1 LG4-5 was diluted in four different pH buffers, injected over the chip surface 
and analysed for electrostatic attraction to the chip surface. The ligand appears to be highly 























sTime (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5











GABAB CCP1-2 (CM5): 
GABABR1a CCP1-2 was diluted in four different pH buffers, injected over the chip surface and 
analysed for electrostatic attraction to the chip surface. The reaction appears to be very fast. pH 



























sTime (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5









II. Immobilisation of ligands 
 
Laminin-1 (CM5): 
The theoretical amount of Laminin L2020 immobilised on the chip (RL) was calculated to be 







R max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 100 Ru 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (CCP1-2)  : 16 200 Da 
ligand (laminin-1)  : 800 000 Da     
RL was calculated to be : 4938 Ru 
 
 
Immobilisation of the ligand, laminin-1 on a CM5 sensor chip. The actual amount of ligand 
immobilised produced a response of 5070 Ru.  
     Response Response  
 Flow cell Procedure Method Ligand Bound (RU) Final (RU) Target Reached 
 1 Blank Amine   165.5 N/A 






























The theoretical amount of laminin 10/11 immobilised on the chip (RL) was calculated to be                       






ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 100 Ru 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (CCP1-2)  : 16 200 Da 
ligand (laminin10/11:)  : 75 000 Da  (estimation of smaller fragment,  as protein is 
pepsinised) 
RL was calculated to be    455Ru 
 
Immobilisation of laminin-10/11 on a CM5 sensor chip. The amount of ligand actually 
immobilised produced a response of 390 Ru,  
     Response Response  
 Flow cell Procedure Method Ligand Bound (RU) Final (RU) Target Reached 
 1 Blank Amine   167,5 N/A 





































The theoretical amount of CCP1-2 immobilised on the chip (RL) was calculated to be                       






ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 300 Ru 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (laminin fragments:) 60 000 Da (estimated average fragment size) 
ligand (CCP1-2)  : 16 200 Da   
RL was calculated to be    81Ru 
 
 
Immobilisation of CCP1-2 on a CM5 sensor chip. The amount of ligand actually 
immobilised produced a response of 235 Ru,  
 
Flow cell Procedure Method Ligand Bound (RU) Final (RU) Target Reached 
 1 Blank Amine   167.8 N/A 




























Immobilisation of biotinylated CCP1-2 (SA chip):  
Conditioning of SA chip surface with three injections of 1M NaCl + 50 mM NaOH 
















Immobilisation of CCP1-2 on a SA sensor chip. The amount of ligand immobilised produced 
a response of 225 Ru, which was adjusted to 230 Ru after blocking of unreacted groups with 




















































Laminin 1 LG1-3 (CM5): 
The theoretical amount of Laminin 1 LG1-3 immobilised on the chip (RL) was calculated to 






ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 100 Ru 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (CCP1-2)  : 16 200 Da 
ligand (1 LG1-3:)  : 82000 Da     
RL was calculated to be : 506 Ru 
 
 
Immobilisation of Laminin α1 lg1-3 on a CM5 sensor chip. The amount of ligand actually 
immobilised produced a response of 455 Ru, due to insufficient amount of protein available.  
 
     Response Response  
 Flow cell Procedure Method Ligand Bound (RU) Final (RU) Target Reached 


































Laminin 1 LG 4-5 (CM5): 
The theoretical amount of Laminin 1 LG4-5 immobilised on the chip chip (RL) was 







ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 100 Ru 
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (CCP1-2)  : 16 200 Da 
ligand (1 LG 4-5)  : 44 000 Da     
RL was calculated to be : 272 Ru 
 
 
Immobilisation of Laminin α1 LG4-5 on a CM5 sensor chip. The amount of ligand actually 
immobilised produced a response of 295 Ru, after reference cell adjustment 465 Ru. 
     Response Response  
 Flow cell Procedure Method Ligand Bound (RU) Final (RU) Target Reached 
 3 Blank Amine   189.2 N/A 

































His-tagged 5 LG 4-5 (NTA chip):  
The theoretical amount of Laminin 5 LG4-5 immobilised on the chip chip (RL) was 







ManalyteR max    
              
Rmax describes the binding capacity of the sensor surface and is normally set to 100-300 Ru. 
 
Rmax was set to 200 Ru  
RL : immobilisation level   
Sm : stocichiometric ratio  (=1) 
 
analyte (CCP1-2)  : 16 200 Da 
ligand (1 LG 4-5)  : 40 000 Da     
RL was calculated to be : 493Ru 
 
 
Immobilisation of Laminin α1 LG4-5 on a CM5 sensor chip. The amount of ligand actually 
immobilised produced a response of 429 Ru. The chip surface was regenerated, the surface 













































Appendix C.  
I. Primers for constructs used in electrophysiology study: 
 
Primers used: for cloning of full length GABABR1a in pcDNA3.1/V5-His TOPO 
Forward: 5’ C ACC ATG TTG CTG CTG CTG 
Reverse: 3’TCA CTT ATA AAG CA    
 
Primers used: for two-step cloning approach of R1a in pRSSP 
Forward: 5’ CTT CTA CAT GTT GCT GCT G    
The forward primer was designed to incorporate the restriction digest site for AflIII 
Reverse: 3’ ATC CAC TGT GCA GTT GAT AG    
The reverse primer was design to amplify the gene up to just past a naturally occurring 





































































































































(Veyhl et al., 2006) 
The vector contains an SP6 promoter for in vitro RNA transcription, 3’ and 5’ UTR from 











































pSGEM  (derrived from the pGEMHE vector)  
(Villmann et al., 1997) 
The vector contains 3’ and 5’ UTR from Xenopus β-globin gene, flanking a 











































III. Data related to low concentrations of baclofen 
 
GABAB receptor responses at 1, 3 and 10 µM baclofen, including standard error of mean 
(SEM) for each concentration. 
 R1a   R1b   












nAmpere 60 139 203 6510 8090 8430 
 375 810 1250 4650 5910 6310 
 110 205 302 4960 6230 6510 
 142 324 467 - - - 
 248 517 776 - - - 
mean 187 399 600 5373 6743 7083 
SD 126 271 424 997 1177 1171 
SEM 56 121 189 575 680 676 
 
GABAB receptor relative percentage responses at 1, 3 and 10 µM baclofen.  




1 µM 31. % 75.9 % 
3 µM 66.5 % 95.9 % 
























IV. Data related to antagonist blocking 
 
i. Percentage of baclofen-evoked response blocked by 
antagonist CGP55845 in oocytes expressing 
GABABR1a/GABABR2.  
 
The percentage block is measured at the following concentrations of CGP55845; 10µM, 
5µM, 3µM, 1µM, 0.3µM 
 
R1a 10µM R1a 5µM R1a 3µM R1a 1µM R1a 0.3µM 
76 47 51 95 93 
79 47 100 72 60 
75 28 60 2 87 
80 100 28 75 2 
85 45 59 - 0 
36 45 88 - - 
51 53 93 - - 
33 100 81 - - 
- 89 35 - - 
- 50 67 - - 
- 34 76 - - 
- 73 79 - - 
- 100 82 - - 
- 75 59 - - 
- 71 62 - - 
- 90 70 - - 
- 65 50 - - 
- 86 100 - - 
- 75 84 - - 
- 75 65 - - 
- 60 42 - - 
- 100 0 - - 
- 79 0 - - 
- 100 0 - - 
- 61 85 - - 
- 15 - - - 
- 76 - - - 
- 85 - - - 
- 64 - - - 
- 53 - - - 
- 100 - - - 
- 35 - - - 
- 0 - - - 
- 0 - - - 
- 0 - - - 
- 0 - - - 
- 100 - - - 
- 70 - - - 
- 0 - - - 
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ii. Percentage of baclofen-evoked response blocked by 
the antagonist CGP55845 in oocytes expressing 
GABABR1b/ GABABR2.  
 
The percentage block is measured at the following concentrations of CGP55845; 10µM, 
5µM, 3µM, 1µM, 0.3µM 
 
R1b 10µM R1b 5µM R1b 3µM R1b 1µM R1b 0.3µM 
82 100 100 88 89 
100 100 93 90 86 
91 96 70 89 - 
92 91 93 100 - 
60 100 100 - - 
100 100 86 - - 
- 100 92 - - 
- 90 94 - - 
- 99 95 - - 
- 98 89 - - 
- 75 96 - - 
- 99 100 - - 
- 78 81 - - 
- 96 70 - - 
- 83 100 - - 
- 83 100 - - 
- 96 91 - - 
- 96 100 - - 
- 96 96 - - 
- 10 91 - - 
- 98 97 - - 
- 98 100 - - 
- 82 - - - 
- 100 - - - 













The GIRK currents obtained for the two isoforms GABABR1a/GABABR2 and 
GABABR1b/GABABR2 in response to 1, 3 and 10 µM baclofen as illustrated in Figure 66 
 R1a   R1b   
 1 µM bac 3 µM bac 10 µM bac 1 µM bac 3 µM bac 10 µM bac 
 60 139 203 6510 8090 8430 
 375 810 1250 4650 5910 6310 
 110 205 302 4960 6230 6510 
 142 324 467    
 248 517 776    
mean 187 399 599.6 5373.333 6743.333 7083.333 
SD 125.6463 270.9732 423.5496 996.5106 1177.172 1170.527 
SEM 56.19075 121.1829 189.4172 575.3357 679.6404 675.804 
 
 
Values in relative percent, where the value for 10 µM baclofen is set to 100% as illustrated in 
Figure 67. 
 
 R1a   R1b   
 1 µM bac 3 µM bac 10 µM bac 1 µM bac 3 µM bac 10 µM bac 
 29.5 68.5 100 77.22 95.96 100 
 30 64.8 100 73.69 93.66 100 
 36.4 67.9 100 76.19 95.69 100 
 30.4 69.4 100    
 31.95 66.6 100    
mean 31.66 67.4 100 75.7 95.10333 100 
SD 2.799 1.776 0 1.815 1.257 0 





















A statistical overview of the blocking properties by the antagonist CGP55845 of the baclofen 
induced responses displayed in the table below, indicating the standard deviation (SD) and 
the Standard Error of Mean (SEM) 
 
 R1a     
 10µM 5µM 3µM 1µM 0.3µM 
mean 64.4 58.7 60.6 61 48.4 
Median 75.5 64.5 65 73.5 60 
SD 21 33 29.5 40.6 45 
SEM 7.4 5.2 5.9 20.3 20 
95% conf 17.6 10.6 12 64.6 55.9 
99% conf 26 14 16.5 118.5 92.7 
size 9 41 26 5 6 
min 33 0 0 2 0 
max 85 100 100 95 93 
 
 
 R1b     
 10µM 5µM 3µM 1µM 0.3µM 
mean 87.5 94 92.5 91.8 87.5 
median 91.5 96 94.5 89.5 87.5 
SD 15 7.6 8.9 5.6 2 
SEM 6 1.5 1.9 2.8 1.5 
95% conf 15.8 3 3.9 8.8 18 
99% conf 24.8 4.3 5.4 16.2 73.5 
size 7 26 23 5 3 
min 60 75 70 88 86 




Airenne, T., H. Haakana, K. Sainio, T. Kallunki, P. Kallunki, H. Sariola, and K. 
Tryggvason. 1996. Structure of the human laminin gamma 2 chain gene 
(LAMC2): alternative splicing with different tissue distribution of two 
transcripts. Genomics. 32:54-64. 
Argraves, W.S., L.M. Greene, M.A. Cooley, and W.M. Gallagher. 2003. Fibulins: 
physiological and disease perspectives. EMBO Rep. 4:1127-31. 
Aumailley, M., L. Bruckner-Tuderman, W.G. Carter, R. Deutzmann, D. Edgar, P. 
Ekblom, J. Engel, E. Engvall, E. Hohenester, J.C. Jones, H.K. Kleinman, 
M.P. Marinkovich, G.R. Martin, U. Mayer, G. Meneguzzi, J.H. Miner, K. 
Miyazaki, M. Patarroyo, M. Paulsson, V. Quaranta, J.R. Sanes, T. Sasaki, K. 
Sekiguchi, L.M. Sorokin, J.F. Talts, K. Tryggvason, J. Uitto, I. Virtanen, K. 
von der Mark, U.M. Wewer, Y. Yamada, and P.D. Yurchenco. 2005. A 
simplified laminin nomenclature. Matrix Biol. 24:326-32. 
Baker, G., S. Dunn, and A. Holt. 2007. Expression and study of ligand-gated ion 
channels in Xenopus laevis Oocytes. In Handbook of neurochemistry and 
molecular neurobiology. Springer US. 
Balasubramanian, S., J.A. Teissere, D.V. Raju, and R.A. Hall. 2004. Hetero-
oligomerization between GABAA and GABAB receptors regulates GABAB 
receptor trafficking. J Biol Chem. 279:18840-50. 
Barlow, P.N., M. Baron, D.G. Norman, A.J. Day, A.C. Willis, R.B. Sim, and I.D. 
Campbell. 1991. Secondary structure of a complement control protein module 
by two-dimensional 1H NMR. Biochemistry. 30:997-1004. 
Beck, K., I. Hunter, and J. Engel. 1990. Structure and function of laminin: anatomy 
of a multidomain glycoprotein. FASEB J. 4:148-60. 
Bettler, B., K. Kaupmann, and N. Bowery. 1998. GABAB receptors: drugs meet 
clones. Curr Opin Neurobiol. 8:345-50. 
Bettler, B., K. Kaupmann, J. Mosbacher, and M. Gassmann. 2004. Molecular 
structure and physiological functions of GABA(B) receptors. Physiol Rev. 
84:835-67. 
Bettler, B., and J.Y. Tiao. 2006. Molecular diversity, trafficking and subcellular 
localization of GABAB receptors. Pharmacol Ther. 110:533-43. 
Billinton, A., A.O. Ige, J.P. Bolam, J.H. White, F.H. Marshall, and P.C. Emson. 
2001. Advances in the molecular understanding of GABA(B) receptors. 
Trends Neurosci. 24:277-82. 
Billinton, A., N. Upton, and N.G. Bowery. 1999. GABA(B) receptor isoforms 
GBR1a and GBR1b, appear to be associated with pre- and post-synaptic 
elements respectively in rat and human cerebellum. Br J Pharmacol. 
126:1387-92. 
Blein, S., R. Ginham, D. Uhrin, B.O. Smith, D.C. Soares, S. Veltel, R.A. 
McIlhinney, J.H. White, and P.N. Barlow. 2004. Structural analysis of the 
complement control protein (CCP) modules of GABA(B) receptor 1a: only 
one of the two CCP modules is compactly folded. J Biol Chem. 279:48292-
306. 
Bockaert, J., L. Fagni, A. Dumuis, and P. Marin. 2004. GPCR interacting proteins 
(GIP). Pharmacol Ther. 103:203-21. 
 223 
Bockaert, J., and J.P. Pin. 1999. Molecular tinkering of G protein-coupled receptors: 
an evolutionary success. EMBO J. 18:1723-9. 
Bolteus, A.B., A. 2006. Non synaptic GABAeric communication and postnatal 
neurogenesis. In the cell cycle in the central nervous system. D. Janigro, 
editor. Human Press Incorporated. 95-104. 
Bourne, H.R. 1997. How receptors talk to trimeric G proteins. Curr Opin Cell Biol. 
9:134-42. 
Bourne, H.R., D.A. Sanders, and F. McCormick. 1991. The GTPase superfamily: 
conserved structure and molecular mechanism. Nature. 349:117-27. 
Bouvier, M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat 
Rev Neurosci. 2:274-86. 
Bowery, N.G. 1993. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol. 
33:109-47. 
Bowery, N.G. 2006. GABAB receptor: a site of therapeutic benefit. Curr Opin 
Pharmacol. 6:37-43. 
Bowery, N.G., A. Doble, D.R. Hill, A.L. Hudson, J.S. Shaw, and M.J. Turnbull. 
1979. Baclofen: a selective agonist for a novel type of GABA 
receptor]proceedings]. Br J Pharmacol. 67:444P-445P. 
Bowery, N.G., D.R. Hill, A.L. Hudson, A. Doble, D.N. Middlemiss, J. Shaw, and M. 
Turnbull. 1980. (-)Baclofen decreases neurotransmitter release in the 
mammalian CNS by an action at a novel GABA receptor. Nature. 283:92-4. 
Bowery, N.G., and A.L. Hudson. 1979. gamma-Aminobutyric acid reduces the 
evoked release of [3H]-noradrenaline from sympathetic nerve terminals 
[proceedings]. Br J Pharmacol. 66:108P. 
Bridges, T.M., and C.W. Lindsley. 2008. G-protein-coupled receptors: from classical 
modes of modulation to allosteric mechanisms. ACS Chem Biol. 3:530-41. 
Bulanova, E., V. Budagian, E. Duitman, Z. Orinska, H. Krause, R. Ruckert, N. 
Reiling, and S. Bulfone-Paus. 2007. Soluble Interleukin IL-15Ralpha is 
generated by alternative splicing or proteolytic cleavage and forms functional 
complexes with IL-15. J Biol Chem. 282:13167-79. 
Calver, A.R., A.D. Medhurst, M.J. Robbins, K.J. Charles, M.L. Evans, D.C. 
Harrison, M. Stammers, S.A. Hughes, G. Hervieu, A. Couve, S.J. Moss, D.N. 
Middlemiss, and M.N. Pangalos. 2000. The expression of GABA(B1) and 
GABA(B2) receptor subunits in the cNS differs from that in peripheral 
tissues. Neuroscience. 100:155-70. 
Campbell, I.D., and A.K. Downing. 1998. NMR of modular proteins. Nat Struct Biol. 
5 Suppl:496-9. 
Carafoli, F., N.J. Clout, and E. Hohenester. 2009. Crystal Structure of the LG1-3 
Region of the Laminin {alpha}2 Chain. J Biol Chem. 284:22786-92. 
Carman, C.V., and J.L. Benovic. 1998. G-protein-coupled receptors: turn-ons and 
turn-offs. Curr Opin Neurobiol. 8:335-44. 
Chebib, M., and G.A. Johnston. 1999. The 'ABC' of GABA receptors: a brief review. 
Clin Exp Pharmacol Physiol. 26:937-40. 
Ciruela, F., M.M. Soloviev, W.Y. Chan, and R.A. McIlhinney. 2000. Homer-
1c/Vesl-1L modulates the cell surface targeting of metabotropic glutamate 
receptor type 1alpha: evidence for an anchoring function. Mol Cell Neurosci. 
15:36-50. 
 224 
Clark, J.A., E. Mezey, A.S. Lam, and T.I. Bonner. 2000. Distribution of the 
GABA(B) receptor subunit gb2 in rat CNS. Brain Res. 860:41-52. 
Coates, P.J., and P.A. Hall. 2003. The yeast two-hybrid system for identifying 
protein-protein interactions. J Pathol. 199:4-7. 
Colman, A., S. Bhamra, and G. Valle. 1984. Post-translational modification of 
exogenous proteins in Xenopus laevis oocytes. Biochem Soc Trans. 12:932-7. 
Colognato, H., C. ffrench-Constant, and M.L. Feltri. 2005. Human diseases reveal 
novel roles for neural laminins. Trends Neurosci. 28:480-6. 
Colognato, H., and P.D. Yurchenco. 2000. Form and function: the laminin family of 
heterotrimers. Dev Dyn. 218:213-34. 
Couve, A., A.K. Filippov, C.N. Connolly, B. Bettler, D.A. Brown, and S.J. Moss. 
1998. Intracellular retention of recombinant GABAB receptors. J Biol Chem. 
273:26361-7. 
Cryan, J.F., P.H. Kelly, F. Chaperon, C. Gentsch, C. Mombereau, K. Lingenhoehl, 
W. Froestl, B. Bettler, K. Kaupmann, and W.P. Spooren. 2004. Behavioral 
characterization of the novel GABAB receptor-positive modulator GS39783 
(N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): 
anxiolytic-like activity without side effects associated with baclofen or 
benzodiazepines. J Pharmacol Exp Ther. 310:952-63. 
Davies, C.H., M.F. Pozza, and G.L. Collingridge. 1993. CGP 55845A: a potent 
antagonist of GABAB receptors in the CA1 region of rat hippocampus. 
Neuropharmacology. 32:1071-3. 
de Vega, S., T. Iwamoto, T. Nakamura, K. Hozumi, D.A. McKnight, L.W. Fisher, S. 
Fukumoto, and Y. Yamada. 2007. TM14 is a new member of the fibulin 
family (fibulin-7) that interacts with extracellular matrix molecules and is 
active for cell binding. J Biol Chem. 282:30878-88. 
de Vega, S., T. Iwamoto, and Y. Yamada. 2009. Fibulins: multiple roles in matrix 
structures and tissue functions. Cell Mol Life Sci. 66:1890-902. 
Deisz, R.A., J.M. Billard, and W. Zieglgansberger. 1997. Presynaptic and 
postsynaptic GABAB receptors of neocortical neurons of the rat in vitro: 
differences in pharmacology and ionic mechanisms. Synapse. 25:62-72. 
Deriu, D., M. Gassmann, S. Firbank, D. Ristig, C. Lampert, J. Mosbacher, W. 
Froestl, K. Kaupmann, B. Bettler, and M.G. Grutter. 2005. Determination of 
the minimal functional ligand-binding domain of the GABAB1b receptor. 
Biochem J. 386:423-31. 
DiScipio, R.G. 1992. Ultrastructures and interactions of complement factors H and I. 
J Immunol. 149:2592-9. 
Durfee, T., K. Becherer, P.L. Chen, S.H. Yeh, Y. Yang, A.E. Kilburn, W.H. Lee, and 
S.J. Elledge. 1993. The retinoblastoma protein associates with the protein 
phosphatase type 1 catalytic subunit. Genes Dev. 7:555-69. 
Durkin, M.E., M. Gautam, F. Loechel, J.R. Sanes, J.P. Merlie, R. Albrechtsen, and 
U.M. Wewer. 1996. Structural organization of the human and mouse laminin 
beta2 chain genes, and alternative splicing at the 5' end of the human 
transcript. J Biol Chem. 271:13407-16. 
Dyson, H.J., and P.E. Wright. 2005. Intrinsically unstructured proteins and their 
functions. Nat Rev Mol Cell Biol. 6:197-208. 
Ekblom, P. 1995. Extracellular matrix in animal development. Role of extracellular 
matrix in animal development--an introduction. Experientia. 51:851-2. 
 225 
Engel, J. 1992. Laminins and other strange proteins. Biochemistry. 31:10643-51. 
Engvall, E. 1995. Structure and function of basement membranes. Int J Dev Biol. 
39:781-7. 
Engvall, E., D. Earwicker, T. Haaparanta, E. Ruoslahti, and J.R. Sanes. 1990. 
Distribution and isolation of four laminin variants; tissue restricted 
distribution of heterotrimers assembled from five different subunits. Cell 
Regul. 1:731-40. 
Erickson, A.C., and J.R. Couchman. 2000. Still more complexity in mammalian 
basement membranes. J Histochem Cytochem. 48:1291-306. 
Ferguson, S.S., J. Zhang, L.S. Barak, and M.G. Caron. 1998. Molecular mechanisms 
of G protein-coupled receptor desensitization and resensitization. Life Sci. 
62:1561-5. 
Fernandez, J.A., and J.H. Griffin. 1994. A protein S binding site on C4b-binding 
protein involves beta chain residues 31-45. J Biol Chem. 269:2535-40. 
Ferns, M.J., J.T. Campanelli, W. Hoch, R.H. Scheller, and Z. Hall. 1993. The ability 
of agrin to cluster AChRs depends on alternative splicing and on cell surface 
proteoglycans. Neuron. 11:491-502. 
Fields, S., and O. Song. 1989. A novel genetic system to detect protein-protein 
interactions. Nature. 340:245-6. 
Fisher, S.A., A. Rivera, L.G. Fritsche, C.N. Keilhauer, P. Lichtner, T. Meitinger, G. 
Rudolph, and B.H. Weber. 2007. Case-control genetic association study of 
fibulin-6 (FBLN6 or HMCN1) variants in age-related macular degeneration 
(AMD). Hum Mutat. 28:406-13. 
Franco, R., V. Casado, A. Cortes, C. Ferrada, J. Mallol, A. Woods, C. Lluis, E.I. 
Canela, and S. Ferre. 2007. Basic concepts in G-protein-coupled receptor 
homo- and heterodimerization. ScientificWorldJournal. 7:48-57. 
Fritschy, J.M., V. Meskenaite, O. Weinmann, M. Honer, D. Benke, and H. Mohler. 
1999. GABAB-receptor splice variants GB1a and GB1b in rat brain: 
developmental regulation, cellular distribution and extrasynaptic localization. 
Eur J Neurosci. 11:761-8. 
Fritschy, J.M., C. Sidler, F. Parpan, M. Gassmann, K. Kaupmann, B. Bettler, and D. 
Benke. 2004. Independent maturation of the GABA(B) receptor subunits 
GABA(B1) and GABA(B2) during postnatal development in rodent brain. J 
Comp Neurol. 477:235-52. 
Gallagher, W.M., C.A. Currid, and L.C. Whelan. 2005. Fibulins and cancer: friend or 
foe? Trends Mol Med. 11:336-40. 
Gallagher, W.M., L.M. Greene, M.P. Ryan, V. Sierra, A. Berger, P. Laurent-Puig, 
and E. Conseiller. 2001. Human fibulin-4: analysis of its biosynthetic 
processing and mRNA expression in normal and tumour tissues. FEBS Lett. 
489:59-66. 
Galliano, M.F., D. Aberdam, A. Aguzzi, J.P. Ortonne, and G. Meneguzzi. 1995. 
Cloning and complete primary structure of the mouse laminin alpha 3 chain. 
Distinct expression pattern of the laminin alpha 3A and alpha 3B chain 
isoforms. J Biol Chem. 270:21820-6. 
Galvez, T., B. Duthey, J. Kniazeff, J. Blahos, G. Rovelli, B. Bettler, L. Prezeau, and 
J.P. Pin. 2001. Allosteric interactions between GB1 and GB2 subunits are 
required for optimal GABA(B) receptor function. EMBO J. 20:2152-9. 
 226 
Galvez, T., M.L. Parmentier, C. Joly, B. Malitschek, K. Kaupmann, R. Kuhn, H. 
Bittiger, W. Froestl, B. Bettler, and J.P. Pin. 1999. Mutagenesis and modeling 
of the GABAB receptor extracellular domain support a venus flytrap 
mechanism for ligand binding. J Biol Chem. 274:13362-9. 
Gesty-Palmer, D., M. Chen, E. Reiter, S. Ahn, C.D. Nelson, S. Wang, A.E. Eckhardt, 
C.L. Cowan, R.F. Spurney, L.M. Luttrell, and R.J. Lefkowitz. 2006. Distinct 
beta-arrestin- and G protein-dependent pathways for parathyroid hormone 
receptor-stimulated ERK1/2 activation. J Biol Chem. 281:10856-64. 
Gether, U. 2000. Uncovering molecular mechanisms involved in activation of G 
protein-coupled receptors. Endocr Rev. 21:90-113. 
Ginham, R.L., S. Blein, P. Barlow, J.H. White, and R.A.J. McIlhinney. 2002. 
Interaction of 'Sushi' domain of GABAbR1a subunit with the extracellular 
matrix protein, fibulin. FENS Abstr 1:6. 
Grace, C.R., M.H. Perrin, M.R. DiGruccio, C.L. Miller, J.E. Rivier, W.W. Vale, and 
R. Riek. 2004. NMR structure and peptide hormone binding site of the first 
extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad 
Sci U S A. 101:12836-41. 
Greene, L.M., W.O. Twal, M.J. Duffy, E.W. McDermott, A.D. Hill, N.J. O'Higgins, 
A.H. McCann, P.A. Dervan, W.S. Argraves, and W.M. Gallagher. 2003. 
Elevated expression and altered processing of fibulin-1 protein in human 
breast cancer. Br J Cancer. 88:871-8. 
Hagg, T., C. Portera-Cailliau, M. Jucker, and E. Engvall. 1997. Laminins of the adult 
mammalian CNS; laminin-alpha2 (merosin M-) chain immunoreactivity is 
associated with neuronal processes. Brain Res. 764:17-27. 
Hall, R.A., L.S. Ostedgaard, R.T. Premont, J.T. Blitzer, N. Rahman, M.J. Welsh, and 
R.J. Lefkowitz. 1998. A C-terminal motif found in the beta2-adrenergic 
receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance 
regulator determines binding to the Na+/H+ exchanger regulatory factor 
family of PDZ proteins. Proc Natl Acad Sci U S A. 95:8496-501. 
Hamm, H.E. 1998. The many faces of G protein signaling. J Biol Chem. 273:669-72. 
Hardig, Y., and B. Dahlback. 1996. The amino-terminal module of the C4b-binding 
protein beta-chain contains the protein S-binding site. J Biol Chem. 
271:20861-7. 
Hardig, Y., A. Rezaie, and B. Dahlback. 1993. High affinity binding of human 
vitamin K-dependent protein S to a truncated recombinant beta-chain of C4b-
binding protein expressed in Escherichia coli. J Biol Chem. 268:3033-6. 
Harrison, D., S.A. Hussain, A.C. Combs, J.M. Ervasti, P.D. Yurchenco, and E. 
Hohenester. 2007. Crystal structure and cell surface anchorage sites of 
laminin alpha1LG4-5. J Biol Chem. 282:11573-81. 
Hawrot, E., Y. Xiao, Q.L. Shi, D. Norman, M. Kirkitadze, and P.N. Barlow. 1998. 
Demonstration of a tandem pair of complement protein modules in GABA(B) 
receptor 1a. FEBS Lett. 432:103-8. 
Hebert, T.E., S. Moffett, J.P. Morello, T.P. Loisel, D.G. Bichet, C. Barret, and M. 
Bouvier. 1996. A peptide derived from a beta2-adrenergic receptor 
transmembrane domain inhibits both receptor dimerization and activation. J 
Biol Chem. 271:16384-92. 
Heuss, C., and U. Gerber. 2000. G-protein-independent signaling by G-protein-
coupled receptors. Trends Neurosci. 23:469-75. 
 227 
Hill, D.R., and N.G. Bowery. 1981. 3H-baclofen and 3H-GABA bind to bicuculline-
insensitive GABA B sites in rat brain. Nature. 290:149-52. 
Hillarp, A., and B. Dahlback. 1990. Cloning of cDNA coding for the beta chain of 
human complement component C4b-binding protein: sequence homology 
with the alpha chain. Proc Natl Acad Sci U S A. 87:1183-7. 
Hohenester, E., D. Tisi, J.F. Talts, and R. Timpl. 1999. The crystal structure of a 
laminin G-like module reveals the molecular basis of alpha-dystroglycan 
binding to laminins, perlecan, and agrin. Mol Cell. 4:783-92. 
Holter, J., J. Davies, N. Leresche, V. Crunelli, and D.A. Carter. 2005. Identification 
of two further splice variants of GABABR1 characterizes the conserved 
micro-exon 4 as a hot spot for regulated splicing in the rat brain. J Mol 
Neurosci. 26:99-108. 
Hoshino, M., F. Matsuzaki, Y. Nabeshima, and C. Hama. 1993. hikaru genki, a CNS-
specific gene identified by abnormal locomotion in Drosophila, encodes a 
novel type of protein. Neuron. 10:395-407. 
Ige, O.M., and B.O. Onadeko. 2001. An open study to evaluate the safety and 
efficacy of zafirlukast ("Accolate") in patients with mild to moderate asthma 
in Ibadan, Nigeria. West Afr J Med. 20:220-6. 
Indyk, J.A., Z.L. Chen, S.E. Tsirka, and S. Strickland. 2003. Laminin chain 
expression suggests that laminin-10 is a major isoform in the mouse 
hippocampus and is degraded by the tissue plasminogen activator/plasmin 
protease cascade during excitotoxic injury. Neuroscience. 116:359-71. 
Janatova, J., K.B. Reid, and A.C. Willis. 1989. Disulfide bonds are localized within 
the short consensus repeat units of complement regulatory proteins: C4b-
binding protein. Biochemistry. 28:4754-61. 
Jensen, A.A., J. Mosbacher, S. Elg, K. Lingenhoehl, T. Lohmann, T.N. Johansen, B. 
Abrahamsen, J.P. Mattsson, A. Lehmann, B. Bettler, and H. Brauner-
Osborne. 2002. The anticonvulsant gabapentin (neurontin) does not act 
through gamma-aminobutyric acid-B receptors. Mol Pharmacol. 61:1377-84. 
Johnson, G., C. Swart, and S.W. Moore. 2008. Interaction of acetylcholinesterase 
with the G4 domain of the laminin alpha1-chain. Biochem J. 411:507-14. 
Jones, K.A., B. Borowsky, J.A. Tamm, D.A. Craig, M.M. Durkin, M. Dai, W.J. Yao, 
M. Johnson, C. Gunwaldsen, L.Y. Huang, C. Tang, Q. Shen, J.A. Salon, K. 
Morse, T. Laz, K.E. Smith, D. Nagarathnam, S.A. Noble, T.A. Branchek, and 
C. Gerald. 1998. GABA(B) receptors function as a heteromeric assembly of 
the subunits GABA(B)R1 and GABA(B)R2. Nature. 396:674-9. 
Kallunki, P., K. Sainio, R. Eddy, M. Byers, T. Kallunki, H. Sariola, K. Beck, H. 
Hirvonen, T.B. Shows, and K. Tryggvason. 1992. A truncated laminin chain 
homologous to the B2 chain: structure, spatial expression, and chromosomal 
assignment. J Cell Biol. 119:679-93. 
Kato-Takagaki, K., N. Suzuki, F. Yokoyama, S. Takaki, K. Umezawa, J. Higo, M. 
Mochizuki, Y. Kikkawa, S. Oishi, A. Utani, and M. Nomizu. 2007. Cyclic 
peptide analysis of the biologically active loop region in the laminin alpha3 
chain LG4 module demonstrates the importance of peptide conformation on 
biological activity. Biochemistry. 46:1952-60. 
Kaupmann, K., K. Huggel, J. Heid, P.J. Flor, S. Bischoff, S.J. Mickel, G. McMaster, 
C. Angst, H. Bittiger, W. Froestl, and B. Bettler. 1997. Expression cloning of 
 228 
GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. 
Nature. 386:239-46. 
Kaupmann, K., B. Malitschek, V. Schuler, J. Heid, W. Froestl, P. Beck, J. 
Mosbacher, S. Bischoff, A. Kulik, R. Shigemoto, A. Karschin, and B. Bettler. 
1998. GABA(B)-receptor subtypes assemble into functional heteromeric 
complexes. Nature. 396:683-7. 
Kerr, D.I., J. Ong, G.A. Johnston, J. Abbenante, and R.H. Prager. 1988. 2-Hydroxy-
saclofen: an improved antagonist at central and peripheral GABAB receptors. 
Neurosci Lett. 92:92-6. 
Kerr, D.I., J. Ong, R.H. Prager, B.D. Gynther, and D.R. Curtis. 1987. Phaclofen: a 
peripheral and central baclofen antagonist. Brain Res. 405:150-4. 
Kimura, N., T. Toyoshima, T. Kojima, and M. Shimane. 1998. Entactin-2: a new 
member of basement membrane protein with high homology to 
entactin/nidogen. Exp Cell Res. 241:36-45. 
Kirkitadze, M.D., and P.N. Barlow. 2001. Structure and flexibility of the multiple 
domain proteins that regulate complement activation. Immunol Rev. 180:146-
61. 
Kirkpatrick, L.L., M.M. Matzuk, D.C. Dodds, and M.S. Perin. 2000. Biochemical 
interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor 
binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 
and NP2. J Biol Chem. 275:17786-92. 
Kniazeff, J., T. Galvez, G. Labesse, and J.P. Pin. 2002. No ligand binding in the GB2 
subunit of the GABA(B) receptor is required for activation and allosteric 
interaction between the subunits. J Neurosci. 22:7352-61. 
Kobayashi, N., G. Kostka, J.H. Garbe, D.R. Keene, H.P. Bachinger, F.G. Hanisch, D. 
Markova, T. Tsuda, R. Timpl, M.L. Chu, and T. Sasaki. 2007. A comparative 
analysis of the fibulin protein family. Biochemical characterization, binding 
interactions, and tissue localization. J Biol Chem. 282:11805-16. 
Kohfeldt, E., T. Sasaki, W. Gohring, and R. Timpl. 1998. Nidogen-2: a new 
basement membrane protein with diverse binding properties. J Mol Biol. 
282:99-109. 
Kristensen, T., and B.F. Tack. 1986. Murine protein H is comprised of 20 repeating 
units, 61 amino acids in length. Proc Natl Acad Sci U S A. 83:3963-7. 
Kristiansen, K. 2004. Molecular mechanisms of ligand binding, signaling, and 
regulation within the superfamily of G-protein-coupled receptors: molecular 
modeling and mutagenesis approaches to receptor structure and function. 
Pharmacol Ther. 103:21-80. 
Kuner, R., G. Kohr, S. Grunewald, G. Eisenhardt, A. Bach, and H.C. Kornau. 1999. 
Role of heteromer formation in GABAB receptor function. Science. 283:74-
7. 
Kuner, T., and R. Schoepfer. 1996. Multiple structural elements determine subunit 
specificity of Mg2+ block in NMDA receptor channels. J Neurosci. 16:3549-
58. 
Labasque, M., E. Reiter, C. Becamel, J. Bockaert, and P. Marin. 2008. Physical 
interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-
terminus is essential for G protein-independent, arrestin-dependent receptor 
signaling. Mol Biol Cell. 19:4640-50. 
 229 
Lalonde, S., D.W. Ehrhardt, D. Loque, J. Chen, S.Y. Rhee, and W.B. Frommer. 
2008. Molecular and cellular approaches for the detection of protein-protein 
interactions: latest techniques and current limitations. Plant J. 53:610-35. 
Lanneau, C., A. Green, W.D. Hirst, A. Wise, J.T. Brown, E. Donnier, K.J. Charles, 
M. Wood, C.H. Davies, and M.N. Pangalos. 2001. Gabapentin is not a 
GABAB receptor agonist. Neuropharmacology. 41:965-75. 
Leaney, J.L., and A. Tinker. 2000. The role of members of the pertussis toxin-
sensitive family of G proteins in coupling receptors to the activation of the G 
protein-gated inwardly rectifying potassium channel. Proc Natl Acad Sci U S 
A. 97:5651-6. 
Lee, N.V., J.C. Rodriguez-Manzaneque, S.N. Thai, W.O. Twal, A. Luque, K.M. 
Lyons, W.S. Argraves, and M.L. Iruela-Arispe. 2005. Fibulin-1 acts as a 
cofactor for the matrix metalloprotease ADAMTS-1. J Biol Chem. 
280:34796-804. 
Lefkowitz, R.J. 1998. G protein-coupled receptors. III. New roles for receptor 
kinases and beta-arrestins in receptor signaling and desensitization. J Biol 
Chem. 273:18677-80. 
Legrain, P., and L. Selig. 2000. Genome-wide protein interaction maps using two-
hybrid systems. FEBS Lett. 480:32-6. 
Lehtinen, M.J., S. Meri, and T.S. Jokiranta. 2004. Interdomain contact regions and 
angles between adjacent short consensus repeat domains. J Mol Biol. 
344:1385-96. 
Liman, E.R., J. Tytgat, and P. Hess. 1992. Subunit stoichiometry of a mammalian K+ 
channel determined by construction of multimeric cDNAs. Neuron. 9:861-71. 
Liu, F., Q. Wan, Z.B. Pristupa, X.M. Yu, Y.T. Wang, and H.B. Niznik. 2000. Direct 
protein-protein coupling enables cross-talk between dopamine D5 and 
gamma-aminobutyric acid A receptors. Nature. 403:274-80. 
Lodish, H., Baltimore, D., Berk, A. 1995. Molecular cell biology. Scientific 
American Books, New York, NY. 
Loridon-Rosa, B., P. Vielh, H. Matsuura, H. Clausen, C. Cuadrado, and P. Burtin. 
1990. Distribution of oncofetal fibronectin in human mammary tumors: 
immunofluorescence study on histological sections. Cancer Res. 50:1608-12. 
Luttrell, L.M., S.S. Ferguson, Y. Daaka, W.E. Miller, S. Maudsley, G.J. Della Rocca, 
F. Lin, H. Kawakatsu, K. Owada, D.K. Luttrell, M.G. Caron, and R.J. 
Lefkowitz. 1999. Beta-arrestin-dependent formation of beta2 adrenergic 
receptor-Src protein kinase complexes. Science. 283:655-61. 
Luttrell, L.M., B.E. Hawes, T. van Biesen, D.K. Luttrell, T.J. Lansing, and R.J. 
Lefkowitz. 1996. Role of c-Src tyrosine kinase in G protein-coupled receptor- 
and Gbetagamma subunit-mediated activation of mitogen-activated protein 
kinases. J Biol Chem. 271:19443-50. 
Luttrell, L.M., and R.J. Lefkowitz. 2002. The role of beta-arrestins in the termination 
and transduction of G-protein-coupled receptor signals. J Cell Sci. 115:455-
65. 
Maatta, M., I. Virtanen, R. Burgeson, and H. Autio-Harmainen. 2001. Comparative 
analysis of the distribution of laminin chains in the basement membranes in 
some malignant epithelial tumors: the alpha1 chain of laminin shows a 
selected expression pattern in human carcinomas. J Histochem Cytochem. 
49:711-26. 
 230 
Mackie, E.J., R. Chiquet-Ehrismann, C.A. Pearson, Y. Inaguma, K. Taya, Y. 
Kawarada, and T. Sakakura. 1987. Tenascin is a stromal marker for epithelial 
malignancy in the mammary gland. Proc Natl Acad Sci U S A. 84:4621-5. 
Malitschek, B., D. Ruegg, J. Heid, K. Kaupmann, H. Bittiger, W. Frostl, B. Bettler, 
and R. Kuhn. 1998. Developmental changes of agonist affinity at GABABR1 
receptor variants in rat brain. Mol Cell Neurosci. 12:56-64. 
Margeta-Mitrovic, M., Y.N. Jan, and L.Y. Jan. 2000. A trafficking checkpoint 
controls GABA(B) receptor heterodimerization. Neuron. 27:97-106. 
Marshall, F.H. 2001. Heterodimerization of G-protein-coupled receptors in the CNS. 
Curr Opin Pharmacol. 1:40-4. 
Marshall, F.H., K.A. Jones, K. Kaupmann, and B. Bettler. 1999. GABAB receptors - 
the first 7TM heterodimers. Trends Pharmacol Sci. 20:396-9. 
Martin, S.C., S.J. Russek, and D.H. Farb. 1999. Molecular identification of the 
human GABABR2: cell surface expression and coupling to adenylyl cyclase 
in the absence of GABABR1. Mol Cell Neurosci. 13:180-91. 
Martin, S.C., S.J. Russek, and D.H. Farb. 2001. Human GABA(B)R genomic 
structure: evidence for splice variants in GABA(B)R1 but not GABA(B)R2. 
Gene. 278:63-79. 
Maurer, K.C., J.H. Urbanus, and R.J. Planta. 1995. Sequence analysis of a 30 kb 
DNA segment from yeast chromosome XIV carrying a ribosomal protein 
gene cluster, the genes encoding a plasma membrane protein and a subunit of 
replication factor C, and a novel putative serine/threonine protein kinase 
gene. Yeast. 11:1303-10. 
Mercuri, N.B., A. Bonci, A. Siniscalchi, A. Stefani, P. Calabresi, and G. Bernardi. 
1996. Electrophysiological effects of monoamine oxidase inhibition on rat 
midbrain dopaminergic neurones: an in vitro study. Br J Pharmacol. 
117:528-532. 
Miernyk, J.A., and J.J. Thelen. 2008. Biochemical approaches for discovering 
protein-protein interactions. Plant J. 53:597-609. 
Milligan, G., and J.H. White. 2001. Protein-protein interactions at G-protein-coupled 
receptors. Trends Pharmacol Sci. 22:513-8. 
Miner, J.H. 2008. Laminins and their roles in mammals. Microsc Res Tech. 71:349-
56. 
Miner, J.H., J. Cunningham, and J.R. Sanes. 1998. Roles for laminin in 
embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking 
the laminin alpha5 chain. J Cell Biol. 143:1713-23. 
Mohler, H., D. Benke, and J.M. Fritschy. 2001. GABA(B)-receptor isoforms 
molecular architecture and distribution. Life Sci. 68:2297-300. 
Mohler, H., and J.M. Fritschy. 1999. GABAB receptors make it to the top--as 
dimers. Trends Pharmacol Sci. 20:87-9. 
Montell, D.J., and C.S. Goodman. 1989. Drosophila laminin: sequence of B2 subunit 
and expression of all three subunits during embryogenesis. J Cell Biol. 
109:2441-53. 
Mukherjee, S., Bal, S., Saha, P. 2001. Protein interaction maps using yeast two-
hybrid assay. Current Science. 81:458-464. 
Nehring, R.B., H.P. Horikawa, O. El Far, M. Kneussel, J.H. Brandstatter, S. Stamm, 
E. Wischmeyer, H. Betz, and A. Karschin. 2000. The metabotropic GABAB 
 231 
receptor directly interacts with the activating transcription factor 4. J Biol 
Chem. 275:35185-91. 
Ng, G.Y., S. Bertrand, R. Sullivan, N. Ethier, J. Wang, J. Yergey, M. Belley, L. 
Trimble, K. Bateman, L. Alder, A. Smith, R. McKernan, K. Metters, G.P. 
O'Neill, J.C. Lacaille, and T.E. Hebert. 2001. Gamma-aminobutyric acid type 
B receptors with specific heterodimer composition and postsynaptic actions 
in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol 
Pharmacol. 59:144-52. 
Ng, G.Y., J. Clark, N. Coulombe, N. Ethier, T.E. Hebert, R. Sullivan, S. Kargman, 
A. Chateauneuf, N. Tsukamoto, T. McDonald, P. Whiting, E. Mezey, M.P. 
Johnson, Q. Liu, L.F. Kolakowski, Jr., J.F. Evans, T.I. Bonner, and G.P. 
O'Neill. 1999. Identification of a GABAB receptor subunit, gb2, required for 
functional GABAB receptor activity. J Biol Chem. 274:7607-10. 
Ngo, S.T., P.G. Noakes, and W.D. Phillips. 2007. Neural agrin: a synaptic stabiliser. 
Int J Biochem Cell Biol. 39:863-7. 
Nitkin, R.M., M.A. Smith, C. Magill, J.R. Fallon, Y.M. Yao, B.G. Wallace, and U.J. 
McMahan. 1987. Identification of agrin, a synaptic organizing protein from 
Torpedo electric organ. J Cell Biol. 105:2471-8. 
O'Brien, R.J., D. Xu, R.S. Petralia, O. Steward, R.L. Huganir, and P. Worley. 1999. 
Synaptic clustering of AMPA receptors by the extracellular immediate-early 
gene product Narp. Neuron. 23:309-23. 
O'Hara, P.J., P.O. Sheppard, H. Thogersen, D. Venezia, B.A. Haldeman, V. 
McGrane, K.M. Houamed, C. Thomsen, T.L. Gilbert, and E.R. Mulvihill. 
1993. The ligand-binding domain in metabotropic glutamate receptors is 
related to bacterial periplasmic binding proteins. Neuron. 11:41-52. 
Oleszewski, M., P. Gutwein, W. von der Lieth, U. Rauch, and P. Altevogt. 2000. 
Characterization of the L1-neurocan-binding site. Implications for L1-L1 
homophilic binding. J Biol Chem. 275:34478-85. 
Ong, J., and D.I. Kerr. 1990. GABA-receptors in peripheral tissues. Life Sci. 
46:1489-501. 
Overall, C.M., G.A. McQuibban, and I. Clark-Lewis. 2002. Discovery of chemokine 
substrates for matrix metalloproteinases by exosite scanning: a new tool for 
degradomics. Biol Chem. 383:1059-66. 
Oxford, J.T., J. DeScala, N. Morris, K. Gregory, R. Medeck, K. Irwin, R. Oxford, R. 
Brown, L. Mercer, and S. Cusack. 2004. Interaction between amino 
propeptides of type XI procollagen alpha1 chains. J Biol Chem. 279:10939-
45. 
Panayotou, G., P. End, M. Aumailley, R. Timpl, and J. Engel. 1989. Domains of 
laminin with growth-factor activity. Cell. 56:93-101. 
Paraoanu, L.E., and P.G. Layer. 2004. Mouse acetylcholinesterase interacts in yeast 
with the extracellular matrix component laminin-1beta. FEBS Lett. 576:161-
4. 
Parent, C.A., and P.N. Devreotes. 1996. Molecular genetics of signal transduction in 
Dictyostelium. Annu Rev Biochem. 65:411-40. 
Parker, D.A., J. Ong, V. Marino, and D.I. Kerr. 2004. Gabapentin activates 
presynaptic GABAB heteroreceptors in rat cortical slices. Eur J Pharmacol. 
495:137-43. 
 232 
Perez-Garci, E., M. Gassmann, B. Bettler, and M.E. Larkum. 2006. The GABAB1b 
isoform mediates long-lasting inhibition of dendritic Ca2+ spikes in layer 5 
somatosensory pyramidal neurons. Neuron. 50:603-16. 
Pfaff, T., B. Malitschek, K. Kaupmann, L. Prezeau, J.P. Pin, B. Bettler, and A. 
Karschin. 1999. Alternative splicing generates a novel isoform of the rat 
metabotropic GABA(B)R1 receptor. Eur J Neurosci. 11:2874-82. 
Pierce, K.L., and R.J. Lefkowitz. 2001. Classical and new roles of beta-arrestins in 
the regulation of G-protein-coupled receptors. Nat Rev Neurosci. 2:727-33. 
Pin, J.P., C. De Colle, A.S. Bessis, and F. Acher. 1999. New perspectives for the 
development of selective metabotropic glutamate receptor ligands. Eur J 
Pharmacol. 375:277-94. 
Pin, J.P., T. Galvez, and L. Prezeau. 2003. Evolution, structure, and activation 
mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther. 
98:325-54. 
Powell, S.K., and H.K. Kleinman. 1997. Neuronal laminins and their cellular 
receptors. Int J Biochem Cell Biol. 29:401-14. 
Quiocho, F.A. 1990. Atomic structures of periplasmic binding proteins and the high-
affinity active transport systems in bacteria. Philos Trans R Soc Lond B Biol 
Sci. 326:341-51; discussion 351-2. 
Reiter, E., and R.J. Lefkowitz. 2006. GRKs and beta-arrestins: roles in receptor 
silencing, trafficking and signaling. Trends Endocrinol Metab. 17:159-65. 
Rich, R.L., and D.G. Myszka. 2008. Survey of the year 2007 commercial optical 
biosensor literature. J Mol Recognit. 21:355-400. 
Robbins, M.J., A.R. Calver, A.K. Filippov, W.D. Hirst, R.B. Russell, M.D. Wood, S. 
Nasir, A. Couve, D.A. Brown, S.J. Moss, and M.N. Pangalos. 2001. 
GABA(B2) is essential for g-protein coupling of the GABA(B) receptor 
heterodimer. J Neurosci. 21:8043-52. 
Ross, R.A. 2007. Allosterism and cannabinoid CB(1) receptors: the shape of things 
to come. Trends Pharmacol Sci. 28:567-72. 
Rual, J.F., K. Venkatesan, T. Hao, T. Hirozane-Kishikawa, A. Dricot, N. Li, G.F. 
Berriz, F.D. Gibbons, M. Dreze, N. Ayivi-Guedehoussou, N. Klitgord, C. 
Simon, M. Boxem, S. Milstein, J. Rosenberg, D.S. Goldberg, L.V. Zhang, 
S.L. Wong, G. Franklin, S. Li, J.S. Albala, J. Lim, C. Fraughton, E. 
Llamosas, S. Cevik, C. Bex, P. Lamesch, R.S. Sikorski, J. Vandenhaute, H.Y. 
Zoghbi, A. Smolyar, S. Bosak, R. Sequerra, L. Doucette-Stamm, M.E. 
Cusick, D.E. Hill, F.P. Roth, and M. Vidal. 2005. Towards a proteome-scale 
map of the human protein-protein interaction network. Nature. 437:1173-8. 
Rubinstein, M., S. Peleg, S. Berlin, D. Brass, T. Keren-Raifman, C.W. Dessauer, T. 
Ivanina, and N. Dascal. 2009. Divergent regulation of GIRK1 and GIRK2 
subunits of the neuronal G protein gated K+ channel by GalphaiGDP and 
Gbetagamma. J Physiol. 587:3473-91. 
Ryan, M.C., R. Tizard, D.R. VanDevanter, and W.G. Carter. 1994. Cloning of the 
LamA3 gene encoding the alpha 3 chain of the adhesive ligand epiligrin. 
Expression in wound repair. J Biol Chem. 269:22779-87. 
Saghatelyan, A.K., S. Gorissen, M. Albert, B. Hertlein, M. Schachner, and A. 
Dityatev. 2000. The extracellular matrix molecule tenascin-R and its HNK-1 
carbohydrate modulate perisomatic inhibition and long-term potentiation in 
the CA1 region of the hippocampus. Eur J Neurosci. 12:3331-42. 
 233 
Saghatelyan, A.K., M. Snapyan, S. Gorissen, I. Meigel, J. Mosbacher, K. Kaupmann, 
B. Bettler, A.V. Kornilov, N.E. Nifantiev, V. Sakanyan, M. Schachner, and 
A. Dityatev. 2003. Recognition molecule associated carbohydrate inhibits 
postsynaptic GABA(B) receptors: a mechanism for homeostatic regulation of 
GABA release in perisomatic synapses. Mol Cell Neurosci. 24:271-82. 
Saglietti, L., C. Dequidt, K. Kamieniarz, M.C. Rousset, P. Valnegri, O. Thoumine, F. 
Beretta, L. Fagni, D. Choquet, C. Sala, M. Sheng, and M. Passafaro. 2007. 
Extracellular interactions between GluR2 and N-cadherin in spine regulation. 
Neuron. 54:461-77. 
Sasaki, M., H.K. Kleinman, H. Huber, R. Deutzmann, and Y. Yamada. 1988. 
Laminin, a multidomain protein. The A chain has a unique globular domain 
and homology with the basement membrane proteoglycan and the laminin B 
chains. J Biol Chem. 263:16536-44. 
Sauter, K., T. Grampp, J.M. Fritschy, K. Kaupmann, B. Bettler, H. Mohler, and D. 
Benke. 2005. Subtype-selective interaction with the transcription factor 
CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) 
regulates cell surface expression of GABA(B) receptors. J Biol Chem. 
280:33566-72. 
Scheele, S., A. Nystrom, M. Durbeej, J.F. Talts, M. Ekblom, and P. Ekblom. 2007. 
Laminin isoforms in development and disease. J Mol Med. 85:825-36. 
Schultz, D.W., M.L. Klein, A.J. Humpert, C.W. Luzier, V. Persun, M. Schain, A. 
Mahan, C. Runckel, M. Cassera, V. Vittal, T.M. Doyle, T.M. Martin, R.G. 
Weleber, P.J. Francis, and T.S. Acott. 2003. Analysis of the ARMD1 locus: 
evidence that a mutation in HEMICENTIN-1 is associated with age-related 
macular degeneration in a large family. Hum Mol Genet. 12:3315-23. 
Schwarz, D.A., G. Barry, S.D. Eliasof, R.E. Petroski, P.J. Conlon, and R.A. Maki. 
2000. Characterization of gamma-aminobutyric acid receptor GABAB(1e), a 
GABAB(1) splice variant encoding a truncated receptor. J Biol Chem. 
275:32174-81. 
Shimizu-Nishikawa, K., K. Kajiwara, and E. Sugaya. 1995. Cloning and 
characterization of seizure-related gene, SEZ-6. Biochem Biophys Res 
Commun. 216:382-9. 
Shimizu, S., M. Honda, M. Tanabe, and H. Ono. 2004. GABAB receptors do not 
mediate the inhibitory actions of gabapentin on the spinal reflex in rats. J 
Pharmacol Sci. 96:444-9. 
Sia, G.M., J.C. Beique, G. Rumbaugh, R. Cho, P.F. Worley, and R.L. Huganir. 2007. 
Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit 
with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. 
Neuron. 55:87-102. 
Stacey, M., H.H. Lin, S. Gordon, and A.J. McKnight. 2000. LNB-TM7, a group of 
seven-transmembrane proteins related to family-B G-protein-coupled 
receptors. Trends Biochem Sci. 25:284-9. 
Steiger, J.L., S. Bandyopadhyay, D.H. Farb, and S.J. Russek. 2004. cAMP response 
element-binding protein, activating transcription factor-4, and upstream 
stimulatory factor differentially control hippocampal GABABR1a and 
GABABR1b subunit gene expression through alternative promoters. J 
Neurosci. 24:6115-26. 
 234 
Stelzl, U., U. Worm, M. Lalowski, C. Haenig, F.H. Brembeck, H. Goehler, M. 
Stroedicke, M. Zenkner, A. Schoenherr, S. Koeppen, J. Timm, S. Mintzlaff, 
C. Abraham, N. Bock, S. Kietzmann, A. Goedde, E. Toksoz, A. Droege, S. 
Krobitsch, B. Korn, W. Birchmeier, H. Lehrach, and E.E. Wanker. 2005. A 
human protein-protein interaction network: a resource for annotating the 
proteome. Cell. 122:957-68. 
Stetefeld, J., U. Mayer, R. Timpl, and R. Huber. 1996. Crystal structure of three 
consecutive laminin-type epidermal growth factor-like (LE) modules of 
laminin gamma1 chain harboring the nidogen binding site. J Mol Biol. 
257:644-57. 
Stokes, P.H., L.S. Thompson, N.J. Marianayagam, and J.M. Matthews. 2007. 
Dimerization of CtIP may stabilize in vivo interactions with the 
Retinoblastoma-pocket domain. Biochem Biophys Res Commun. 354:197-
202. 
Stone, E.M., A.J. Lotery, F.L. Munier, E. Heon, B. Piguet, R.H. Guymer, K. 
Vandenburgh, P. Cousin, D. Nishimura, R.E. Swiderski, G. Silvestri, D.A. 
Mackey, G.S. Hageman, A.C. Bird, V.C. Sheffield, and D.F. Schorderet. 
1999. A single EFEMP1 mutation associated with both Malattia Leventinese 
and Doyne honeycomb retinal dystrophy. Nat Genet. 22:199-202. 
Sugiyama, J.E., D.J. Glass, G.D. Yancopoulos, and Z.W. Hall. 1997. Laminin-
induced acetylcholine receptor clustering: an alternative pathway. J Cell Biol. 
139:181-91. 
Sunada, Y., S.M. Bernier, A. Utani, Y. Yamada, and K.P. Campbell. 1995. 
Identification of a novel mutant transcript of laminin alpha 2 chain gene 
responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum 
Mol Genet. 4:1055-61. 
Tiao, J.Y., A. Bradaia, B. Biermann, K. Kaupmann, M. Metz, C. Haller, A.G. 
Rolink, E. Pless, P.N. Barlow, M. Gassmann, and B. Bettler. 2008. The sushi 
domains of secreted GABA(B1) isoforms selectively impair GABA(B) 
heteroreceptor function. J Biol Chem. 283:31005-11. 
Tilakaratne, N., and P.M. Sexton. 2005. G-Protein-coupled receptor-protein 
interactions: basis for new concepts on receptor structure and function. Clin 
Exp Pharmacol Physiol. 32:979-87. 
Timpl, R., and J.C. Brown. 1996. Supramolecular assembly of basement membranes. 
Bioessays. 18:123-32. 
Timpl, R., H. Rohde, P.G. Robey, S.I. Rennard, J.M. Foidart, and G.R. Martin. 1979. 
Laminin--a glycoprotein from basement membranes. J Biol Chem. 254:9933-
7. 
Timpl, R., T. Sasaki, G. Kostka, and M.L. Chu. 2003. Fibulins: a versatile family of 
extracellular matrix proteins. Nat Rev Mol Cell Biol. 4:479-89. 
Tisi, D., J.F. Talts, R. Timpl, and E. Hohenester. 2000. Structure of the C-terminal 
laminin G-like domain pair of the laminin alpha2 chain harbouring binding 
sites for alpha-dystroglycan and heparin. EMBO J. 19:1432-40. 
Tokmakov, A.A., E. Matsumoto, M. Shirouzu, and S. Yokoyama. 2006. Coupled 
cytoplasmic transcription-and-translation--a method of choice for 
heterologous gene expression in Xenopus oocytes. J Biotechnol. 122:5-15. 
 235 
Trakselis, M.A., S.C. Alley, and F.T. Ishmael. 2005. Identification and mapping of 
protein-protein interactions by a combination of cross-linking, cleavage, and 
proteomics. Bioconjug Chem. 16:741-50. 
Tu, J.C., B. Xiao, J.P. Yuan, A.A. Lanahan, K. Leoffert, M. Li, D.J. Linden, and P.F. 
Worley. 1998. Homer binds a novel proline-rich motif and links group 1 
metabotropic glutamate receptors with IP3 receptors. Neuron. 21:717-26. 
Tzu, J., and M.P. Marinkovich. 2008. Bridging structure with function: structural, 
regulatory, and developmental role of laminins. Int J Biochem Cell Biol. 
40:199-214. 
Uezono, Y., M. Kanaide, M. Kaibara, R. Barzilai, N. Dascal, K. Sumikawa, and K. 
Taniyama. 2006. Coupling of GABAB receptor GABAB2 subunit to G 
proteins: evidence from Xenopus oocyte and baby hamster kidney cell 
expression system. Am J Physiol Cell Physiol. 290:C200-7. 
Uhrinova, S., F. Lin, G. Ball, K. Bromek, D. Uhrin, M.E. Medof, and P.N. Barlow. 
2003. Solution structure of a functionally active fragment of decay-
accelerating factor. Proc Natl Acad Sci U S A. 100:4718-23. 
Vernon, E., G. Meyer, L. Pickard, K. Dev, E. Molnar, G.L. Collingridge, and J.M. 
Henley. 2001. GABA(B) receptors couple directly to the transcription factor 
ATF4. Mol Cell Neurosci. 17:637-45. 
Veroni, C., M. Grasso, G. Macchia, C. Ramoni, M. Ceccarini, T.C. Petrucci, and P. 
Macioce. 2007. beta-dystrobrevin, a kinesin-binding receptor, interacts with 
the extracellular matrix components pancortins. J Neurosci Res. 85:2631-9. 
Veyhl, M., T. Keller, V. Gorboulev, A. Vernaleken, and H. Koepsell. 2006. RS1 
(RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter 
SGLT1. Am J Physiol Renal Physiol. 291:F1213-23. 
Vigot, R., S. Barbieri, H. Brauner-Osborne, R. Turecek, R. Shigemoto, Y.P. Zhang, 
R. Lujan, L.H. Jacobson, B. Biermann, J.M. Fritschy, C.M. Vacher, M. 
Muller, G. Sansig, N. Guetg, J.F. Cryan, K. Kaupmann, M. Gassmann, T.G. 
Oertner, and B. Bettler. 2006. Differential compartmentalization and distinct 
functions of GABAB receptor variants. Neuron. 50:589-601. 
Villmann, C., L. Bull, and M. Hollmann. 1997. Kainate binding proteins possess 
functional ion channel domains. J Neurosci. 17:7634-43. 
Violin, J.D., and R.J. Lefkowitz. 2007. Beta-arrestin-biased ligands at seven-
transmembrane receptors. Trends Pharmacol Sci. 28:416-22. 
Vogel, B.E., and E.M. Hedgecock. 2001. Hemicentin, a conserved extracellular 
member of the immunoglobulin superfamily, organizes epithelial and other 
cell attachments into oriented line-shaped junctions. Development. 128:883-
94. 
Wagner, C.A., B. Friedrich, I. Setiawan, F. Lang, and S. Broer. 2000. The use of 
Xenopus laevis oocytes for the functional characterization of heterologously 
expressed membrane proteins. Cell Physiol Biochem. 10:1-12. 
Wei, H., S. Ahn, S.K. Shenoy, S.S. Karnik, L. Hunyady, L.M. Luttrell, and R.J. 
Lefkowitz. 2003. Independent beta-arrestin 2 and G protein-mediated 
pathways for angiotensin II activation of extracellular signal-regulated 
kinases 1 and 2. Proc Natl Acad Sci U S A. 100:10782-7. 
Wei, K., J.H. Eubanks, J. Francis, Z. Jia, and O.C. Snead, 3rd. 2001. Cloning and 
tissue distribution of a novel isoform of the rat GABA(B)R1 receptor subunit. 
Neuroreport. 12:833-7. 
 236 
Wess, J. 1997. G-protein-coupled receptors: molecular mechanisms involved in 
receptor activation and selectivity of G-protein recognition. FASEB J. 
11:346-54. 
Weston, C.A., G. Teressa, B.S. Weeks, and J. Prives. 2007. Agrin and laminin induce 
acetylcholine receptor clustering by convergent, Rho GTPase-dependent 
signaling pathways. J Cell Sci. 120:868-75. 
White, J.H., R.A. McIllhinney, A. Wise, F. Ciruela, W.Y. Chan, P.C. Emson, A. 
Billinton, and F.H. Marshall. 2000. The GABAB receptor interacts directly 
with the related transcription factors CREB2 and ATFx. Proc Natl Acad Sci 
U S A. 97:13967-72. 
White, J.H., A. Wise, M.J. Main, A. Green, N.J. Fraser, G.H. Disney, A.A. Barnes, 
P. Emson, S.M. Foord, and F.H. Marshall. 1998. Heterodimerization is 
required for the formation of a functional GABA(B) receptor. Nature. 
396:679-82. 
White, J.H., A. Wise, and F.H. Marshall. 2002. Heterodimerization of gamma-
aminobutyric acid B receptor subunits as revealed by the yeast two-hybrid 
system. Methods. 27:301-10. 
Witchel, H.J., J.T. Milnes, J.S. Mitcheson, and J.C. Hancox. 2002. Troubleshooting 
problems with in vitro screening of drugs for QT interval prolongation using 
HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. 
J Pharmacol Toxicol Methods. 48:65-80. 
Yang, M.Y., J.D. Armstrong, I. Vilinsky, N.J. Strausfeld, and K. Kaiser. 1995. 
Subdivision of the Drosophila mushroom bodies by enhancer-trap expression 
patterns. Neuron. 15:45-54. 
 
 
